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ABSTRACT OF DISSERTATION

TARGETING METHYLGLYOXAL AND PPAR GAMMA TO ALLEVIATE NEUROPATHIC
PAIN ASSOCIATED WITH TYPE 2 DIABETES
Neuropathic pain affects up to 50% of the 29 million diabetic patients in the United
States. Neuropathic pain in diabetes manifests as a disease of the peripheral and central
nervous systems. The prevalence of type 2 diabetes is far greater than type 1 (90%), yet
the overwhelming focus on type 1 models this has left the mechanisms of pain in type 2
diabetes largely unknown. Therefore I aimed to improve the current mechanistic
understanding of pain associated with type 2 diabetes using two preclinical rodent
models: Zucker Diabetic Fatty rats and db/db mice. In addition, I highlight the
translational importance of simultaneous measurement of evoked/sensory and nonevoked/affective pain-related behaviors in preclinical models. This work is the first to
show a measure of motivational-affective pain in a model of type 2 diabetes.
I used methodological approaches including: (1) immunohistochemical and calcium
imaging to assess stimulus-evoked sensitization; (2) measurement nociceptive
behaviors and evoked sensory thresholds as well as pain affect using novel mechanical
conflict avoidance and conditioned place preference/aversion assays; (3)
pharmacological and genetic manipulation of methylglyoxal, TRPA1, AC1, and PPARγ.
I hypothesized that the thiazolidinedione class of peroxisome proliferator-activated
receptor gamma (PPARγ) agonists would reduce neuropathic pain-like behavior and
spinal neuron sensitization in traumatic nerve injury and type 2 diabetes. As PPARγ is a
nuclear receptor, and already targeted clinically to promote cellular insulin sensitization
to reduce hyperglycemia, sustained changes in gene expression are widely believed to
be the mechanism of pain reduction. In two separate research aims, I challenged this
view and tested whether the PPARγ agonist pioglitazone would (1) rapidly alleviate
neuropathic pain through a non-genomic mechanism and (2) reduce painful sensitization
in nociceptive and neuropathic pain models independent from lowering blood glucose.
I aimed to investigate the contribution of the glucose metabolite methylglyoxal to
painful type 2 diabetes. I tested the hypothesis that methylglyoxal produces nociceptive,
evoked, and affective pain that is dependent on activation of the sensory neuron cation
channel TRPA1 and the secondary messenger enzyme AC1. I also tested whether
pioglitazone or the novel methylglyoxal scavenging peptide GERP10 could alleviate
painful type 2 diabetes.

KEYWORDS: painful type 2 diabetes, pioglitazone, chronic neuropathic pain,
methylglyoxal, TRPA1, PPAR gamma
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CHAPTER 1: Background

1.1 Hypothesis and specific aims
My overall hypothesis is that type 2 diabetic neuropathic pain is alleviated by either
administration of thiazolidinedione PPARγ agonists or inhibition of the methylglyoxalTRPA1-AC1 pathway. To test this hypothesis I designed and performed many
experiments to investigate the following specific aims:
1) Determine whether the known analgesic gabapentin alleviates motivationalaffective pain in the spared nerve injury model of neuropathic pain. The purpose
of this aim was to validate the use of conditioned place preference testing to
assess a preclinical measure of affective pain.
2) Test whether the rapid antihyperalgesic action of TZDs is dependent on a nongenomic mechanism.
3) Determine whether astrocyte mechanism are involved in rapid pioglitazone
antihyperalgesia.
4) Characterize the neuropathic pain phenotype of the Zucker Diabetic Fatty rat
model of type 2 diabetes and determine whether spinal nociresponsive neuron
sensitization is associated with pain-like behavior in this model.
5) Determine whether pioglitazone alleviates pain and spinal sensitization in type 2
diabetes independent from its reduction of hyperglycemia.
6) Test whether methylglyoxal is sufficient to produce nociceptive, evoked, and
affective pain-like behavior and determine whether the methylglyoxal scavenging
peptide GERP10 alleviates type 2 diabetic hyperalgesia.
7) Determine the contribution of TRPA1 and AC1 to methylglyoxal-mediated pain in
type 2 diabetes.

1

1.2 Overview of Pain Physiology and Psychology
The phenomenon of pain is a complex physiological and psychological experience
defined by the International Association for the Study of Pain (IASP) as “An unpleasant
sensory and emotional experience associated with actual or potential tissue damage, or
described in terms of such damage.” Importantly, pain can exist in the absence of any
noticeable injury and as such, current medical practice treats a patient’s pain, even when
there is no obvious injury. This fact alone makes the treatment of pain in humans very
difficult, because in many cases physiological symptoms of pain may not exist or are not
detectable and caregivers must rely on subjective reports only. In this line of thinking, the
ability of preclinical researchers to utilize animal (non-human) models to develop
treatments (i.e. drugs, or pharmacological agents that act on one or multiple biological
targets to effect physiological change) for psychological pain is virtually impossible
because animals lack the ability to verbally self-report. However, I argue that there are
very similar ways for both patients and preclinical rodent models (it should be recognized
that there are other animal models used in pain research such as dogs, rabbits, and
non-human primates) to self-report the presence or absence of the sensorydiscriminative and affective-motivational dimensions of pain (see 1.7.2 and Chapter 2: ).

1.2.1 Terminology, or notes on the words and terms used to describe pain
It is difficult to rationalize using the term pain to apply to an unpleasant experience in
rodent models used in pain research, as only an inference can be made whether or not
the animal is experiencing unpleasantness. I should note that many times I ascribe pain
to conclusions that I make from this research in discussion; but, the use of the term pain
in this case is simply an inference. To avoid confusion, and to help delineate discussion
of human patients and rodent models, several terms defined by IASP exist to define the
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phenomena we can measure and study in rodents. These terms can be found in the
Appendix.
Several terms defined by IASP are inherently flawed if used to describe rodent
research because they include the word “pain”. However, if “pain” is replaced with
“response” then terms such as allodynia, hyperalgesia, and neuropathic pain can be
reasonably applied to describe a pain-like experience in rodents. We have used the
words allodynia, hyperalgesia, and hypersensitivity almost interchangeably, but it is
important to note that each term describes a slightly different aspect of somatosensation.
Here, allodynia refers to when an animal responds to a stimulus (e.g. von Frey filaments
or acetone) that does not produce a response prior to injury in that animal or in control
animals. Hyperalgesia is used to describe either a decrease in the response threshold or
an increase in the magnitude of a response to a given stimulus. Hypersensitivity is a
term that encompasses both allodynia and hyperalgesia while escaping the inherent
flaws in the definitions ascribing pain to preclinical models.

1.2.2 The dimensions of pain
The emotional and unpleasant experience of pain begins with the sensorydiscriminative, or the ability to sense a potentially tissue damaging stimulus and to
discriminate its location on the body. The somatosensory system has the ability to
distinguish both the quality (e.g. chemical, thermal, mechanical) and quantity (e.g. nonnoxious versus noxious) of the stimulus. Several types of primary afferents containing
nerve endings innervate the skin, viscera, internal organs, and blood vessels to function
in a sensory-discriminative capacity. These include C, Aδ, and Aβ fibers that are
distinguished by their neurophysiological properties including conduction velocity,
degree of myelination, size (cross sectional area), length, action potential threshold, and
expression of receptors. Reception is the process of detecting an exogenous (such as
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mechanical touch or thermal changes) or endogenous (such as cytokines, chemokines,
or lipid metabolites) stimulus. This typically occurs via protein receptors expressed on
the plasma membrane of afferents with free nerve endings or by larger, more
complicated structures such as Merkel discs, Meissner’, or Pacinian corpuscles.
Transduction is the process of converting that extracellular stimulus to an intracellular
message, which typically occurs by depolarization of the neuron. A stimulus that is great
enough to overcome the activation threshold of the neuron results in the initiation of an
action potential. Transmission is the process by which the neuron propagates the action
potential along its axon toward the first synapse at the junction between the primary
afferent and the second order neuron in the central nervous system. Second order
neurons for the limbs in humans and rodents are located in the spinal cord, which is the
focus of most of the work herein, because typical behavioral tests in rodents involve
measuring the sensitivity of hindpaws to mechanical, chemical, and thermal stimuli.
Integration is the process by which CNS neurons compile signals from one or many
primary afferents and relay this information to third and fourth order neurons that
transmit signals through spinal and brainstem pathways to the thalamic integration
center and cortical areas involved in the motivational-affective and cognitive-evaluative
dimensions of pain. It should be noted that the stimulus-evoked signals can be
modulated at several locations of the transmission process by inhibitory neurons, other
excitatory neurons, neurons integrating other simultaneous stimuli, and descending
modulation that is regulated by specific areas of the brain. These will not be investigated
in the current work.
Motivational-affective describes the unpleasantness (affect) and the inherent drive to
avoid pain (motivation). Motivational-affective pain can be independent from a sensory
experience. This is evident by the fact that even the threat of pain can be perceived as
painful and produce negative affect and avoidance. Conversely, the negative
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reinforcement of ongoing pain is rewarding and therefore subjects will seek this pleasant
experience. This extension of the pain experience beyond its sensory component
increases the complexity of studying pain, as objective research is attempted to define a
subjective experience. We and others report that some therapies may benefit the
sensory aspect of pain (i.e. evoked hypersensitivity) without reducing the subjective
affective component in preclinical models. This is highlighted by the small number of
effective therapies developed by preclinical research, beyond the repurposing (e.g.
gabapentin) or refinement (e.g. opioids) of “old” drugs. Here we describe and validate
conditioned place preference, a preclinical assay used as a tool to assess the
motivational-affective dimension of pain in rodents (1.8 ) and apply this tool to assessing
affective pain in diabetes (section 5.4.1 ). For review of these dimensions of pain see
(Auvray et al, 2010).

1.3 Painful diabetic neuropathy (aka painful diabetes)
1.3.1 The burden of chronic diabetic pain
According to the World Health Organization, almost 350 million people or ~5% of the
population worldwide have diabetes. In the U.S. the prevalence is a bit greater at 9%
(Center for Disease Control), or 29 million people. The cost of diabetes in the U.S. in
2012 was estimated to be $245 billion, with $176 billion in direct costs and $69 billion in
lost productivity. Type 2 diabetes accounts for the majority of diabetes cases at 90%.
This is shocking given the fact that the gold standard for type 2 diabetes prevention and
treatment is diet and exercise.
Approximately 50% of diabetics will experience peripheral neuropathy at some point
during the disease natural history (Vincent et al, 2011). Peripheral neuropathy is likely
due to microvascular complications associated with the metabolic deficits and
inflammation that result in insulin insensitivity, hyperglycemia, decreased motor and
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sensory nerve conduction velocities, macrophage infiltration, loss of intraepidermal
nerve fibers, and altered somatosensation, including painful hyperalgesia/allodynia as
well as painless or insensate neuropathy. Here we focus on the neuropathic pain that
occurs in approximately one-third of diabetic patients (Davies et al, 2006; Abbott et al,
2011; Lee-Kubli et al, 2014), a condition commonly referred to as painful diabetic
neuropathy (PDN) (Vincent et al, 2011). As the current work focuses only on the painrelated behaviors associated with type 2 diabetes and not necessarily the overt
dysfunction of sensory and motor neurons that is neuropathy, we suggest that the term
painful diabetes is a suitable substitute for painful diabetic neuropathy. The
pathogenesis of pain in rodent models of diabetic neuropathy is reviewed by several
groups (Kapur, 2003; Tirabassi et al, 2004; Calcutt and Backonja, 2007; Obrosova,
2009).
The majority of preclinical painful diabetes studies focus on the streptozotocin (STZ)
model of type 1 diabetes (Calcutt et al, 2009). However, as we further discuss below,
STZ is an inappropriate model to study PDN because it produces a natural history of
diabetes that does not model the human condition (Fox et al, 1999). Instead, we use two
genetic models of type 2 diabetes: Zucker Diabetic Fatty rats (ZDF) and db/db mice
(db/db). Figure 1-1A illustrates the dearth of pain publications in these two models of
type 2 diabetes, compared to the explosion of STZ pain publications within the past
couple decades. Figure 1-1B further illustrates the disparity between the very few
numbers of preclinical studies investigating painful type 2 diabetes compared to
exponential increases in publications on type 2 diabetes pain in patients. Figure 1-1C
shows that the prevalence of diabetes in the United States has quadrupled in the past 15
years. Clearly more work is needed to benefit the growing problem of type 2 diabetes
and associated pain.
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Figure 1-1. Publications and prevalence of diabetes.
I performed a Pubmed (http://www.ncbi.nlm.nih.gov/pubmed) search on September
22, 2015 and quantified the number of publications per year from 1973-2015. The
number of publications are shown using the following search terms. (A) Preclinical
models of type 1 diabetes pain (“streptozotocin pain”) and type 2 diabetes pain
(combined publications from “zucker diabetic fatty rat pain” and “db/db pain”
searches). (B) Clinical condition descriptors of “type 1 diabetes pain” and “type 2
diabetes pain”. (C) The number of diagnosed diabetes (type 1 and type 2 combined)
cases per year from 1980-2012.
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1.3.2 Current treatments available for painful diabetes
Analgesic treatments are only effective in a small subset of PDN patients (Smith and
Argoff, 2011). Maintaining blood glucose in the normal range is the first line of defense
against PDN (Veves et al, 2008), and this can be accomplished with a lifestyle change to
incorporate diet and exercise. However, in late-stage type 2 diabetes obesity and pain
may prevent adequate management by diet and exercise. Therefore adjuvant
pharmacotherapies may be needed to manage painful diabetes. Only duloxetine, a
selective

serotonin

and

norepinephrine reuptake

inhibitor,

and pregabalin,

a

gabapentinoid anxiolytic, are approved by the Food & Drug Administration for diabetic
pain treatment (Smith and Argoff, 2011), but are only moderately effective in a subset of
diabetic patients. PDN treatment is complicated by the fact that diabetes decreases the
efficacy of opioid analgesics. The function and antinociceptive effects of opioids are
diminished in both db/db mice (Kamei et al, 1997; Takeshita and Yamaguchi, 1998) and
ZDF rats (Otto et al, 2011) as well as in STZ (Shaqura et al, 2013).
Ongoing

clinical

trials

are

testing

the

efficacy

and

safety

of

new

pharmacotherapeutics but treatment options for PDN are still lacking (Javed et al, 2015).
A non-exhaustive list of potential therapies for PDN include: the lipophilin ligand FK1706
(Yamazaki et al, 2012), taurine (Li et al, 2006), aldose reductase inhibitors (Schemmel et
al, 2010), Poly-ADP-ribose inhibition (Drel et al, 2010), and TRPA1 antagonists (Wei et
al, 2009; Wei et al, 2010; Barrière et al, 2012; Eberhardt et al, 2012; Koivisto et al, 2012;
Andersson et al, 2013). One potential problem with the future success of these therapies
for the treatment of painful type 2 diabetes is that they were developed using the
preclinical STZ model. Here we use mouse and rat models to investigate both the
mechanisms of and potential treatments for painful type 2 diabetes to combat the
growing problem of diabetic neuropathic pain.
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1.4 Neuropathic pain sensitization
Sensitization is defined as the increased responsiveness and/or decreased threshold
of activation of peripheral or central neurons. Peripheral and central sensitization in
rodents and humans is a major contributor to the transition from normal, protective,
evolutionarily advantageous pain to pathological pain that hinders function and quality of
life. It is the prevailing belief that peripheral sensitization mechanisms contribute to
central sensitization (Baron et al, 2013) and mediate the shift between acute pain, which
typically has a distinguishable stimulus (e.g. tissue or nerve injury, exogenous stimulus),
and chronic pain, which may or may not have a recognizable cause. Our goal is not to
re-review or redefine the mechanisms on central sensitization, but only to provide a brief
overview as rationale for investigating the spinal mechanisms of painful diabetes and
PPARγ-directed therapies for neuropathic pain.
Central sensitization is characterized by both functional studies and changes in the
expression of sensitization markers. One prevailing theory is that peripheral injury leads
to central sensitization in the form of long term potentiation (LTP) in the spinal cord
dorsal horn (Sandkuhler and Gruber-Schoffnegger, 2012). A recent study showed that
this plasticity that contributes to chronic pain could be reduced by reconsolidating the
nociceptive event, effectively erasing the pain memory (Bonin and De Koninck, 2014). In
addition, neuropathic pain models result in increased responses to peripheral input in
dorsal horn neurons (Ji et al, 2003; Doolen et al, 2012), increases in the expression of
astrocyte (Svensson and Brodin, 2010) and microglial (Beggs and Salter, 2007; Zhuo et
al, 2011) markers, and exaggerated phosphorylation of extracellular signal-regulated
kinase (pERK) and Fos (Gao and Ji, 2009), which acts as a marker for neuronal
activation. Indeed, the above mechanisms are shown to contribute to spinal sensitization
in models of type 2 diabetes (Cheng et al, 2010; Liao et al, 2011; Dauch et al, 2012; Xu
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et al, 2014; Schuelert et al, 2015). For further review of painful central sensitization
generalized to many types of pain see (Ji et al, 2003; Woolf, 2011; Baron et al, 2013).
Stimulus evoked phosphorylation of extracellular signal-regulated kinase (pERK) is a
marker of central sensitization (Ji et al, 1999). Activation of peripheral nociceptors
increases pERK in the spinal cord dorsal horn (Ji et al, 1999). Light-touch stimulation of
the hindpaw in a traumatic nerve injury model of neuropathic pain leads to increased
pERK in the dorsal horn of injured subjects (Zhuang et al, 2005; Morgenweck et al,
2013). Noxious hindpaw stimulation also induces pERK in spinal neurons (Ji et al, 2002).
In injured animals, ERK is activated (i.e. phosphorylated) within ten to thirty minutes,
indicating a relatively rapid increase in the responsivity of spinal neurons in response to
peripheral stimulation, making pERK is a suitable marker for central sensitization (Gao
and Ji, 2009). Further supporting the role of spinal ERK activation in neuropathic pain,
intrathecal delivery of pERK inhibitors such as U0126 reduces hypersensitivity in
diabetic pain models (Daulhac et al, 2006; Tsuda et al, 2008; Daulhac et al, 2011; Xu et
al, 2014).
The mechanisms of central sensitization in painful type 2 diabetes are not well
known, as only a few preclinical studies have investigated central sensitization in painful
type 2 diabetes. Type 2 diabetic subjects exhibit increased expression of markers of
central sensitization, including pERK (Daulhac et al, 2011; Dauch et al, 2012; Xu et al,
2014) and the astrocyte marker GFAP (Liao et al, 2011; Ren et al, 2012). To our
knowledge, Schuelert et al were the first to show functional electrophysiological
evidence of central sensitization in type 2 diabetes, indicating that spinal neuron
responses to peripheral non-noxious mechanical stimulation were increased (Schuelert
et al, 2015). Here we evaluate stimulus-dependent pERK in type 2 diabetic rats and
mice to investigate the role of spinal nociresponsive neurons in type 2 diabetes. We also
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test the hypothesis that sensitization of these neurons contributes to the pathogenesis of
PDN.

1.5 Specific mediators involved in the regulation of pain
1.5.1 Peroxisome proliferator-activated receptor gamma (PPARγ)
Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor
that regulates the gene expression related to insulin signaling, glucose and fatty acid
metabolism, adipogenesis, neurological disease, and pain (Feinstein, 2003; Evans et al,
2004; Kota et al, 2005; van Neerven and Mey, 2007; Maeda and Kishioka, 2009;
Ahmadian et al, 2013; Yonutas and Sullivan, 2013). The endogenous ligands for PPARγ
include 15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2), poly-unsaturated fatty acids
(PUFA), and arachidonic acid and some of its metabolites. The exogenous ligands for
PPARγ include thiazolidinedione (TZD), non-TZD molecules, and natural derivatives.
TZDs include older molecules such as ciglitazone and troglitazone and newer molecules
such as rosiglitazone and pioglitazone, in addition to some TZD-derivatives under
development. Non-TZD PPARγ agonists include MDG548 (Lecca et al, 2015), PAM1616 (Kim et al, 2010), MBX-102 (Gregoire et al, 2009), FK614 (Minoura, 2007), and
other partial agonists such as PEA (Costa et al, 2008). Ligands are also derived from
natural sources such as the compound monascin (Hsu et al, 2013). Studies using
antagonists

of

PPARγ

such

as

T007,

BADGE,

and

GW9662

(2-chloro-5-

nitrobenzanilide) suggest PPARγ-dependent effects of agonists. However, the excellent
review from Luconi et al indicate a multitude of ways PPARγ agonists could exert their
effects, including both PPARγ-dependent and independent pathways (Luconi et al,
2010). Germline PPARγ knockout is embryonic lethal but several conditional or tissue
specific transgenic mutations have been reported in mice (Sarruf et al, 2009; Wu et al,
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2009; Lu et al, 2011), including a nestin-Cre neuronal knockout (de Guglielmo et al,
2014) that could prove very useful in future studies investigating PPARγ analgesia.
The FDA has approved rosiglitazone (Avandia®) and pioglitazone (Actos®) for the
treatment of type 2 diabetes. These TZDs act as insulin sensitizers to lower blood
glucose. It should be noted that their safety in humans has come under scrutiny. For
example, pioglitazone may contribute to the development of bladder cancer following
long-term administration (Lewis et al, 2011). The FDA has released safety precaution
warnings for both TZDs with regard to cardiovascular risks; however, both drugs are still
used in mono and combination therapy for the treatment of type 2 diabetes.
Over the past thirteen years, a growing body of preclinical evidence indicates that the
PPARγ agonists 15d-PGJ2, rosiglitazone, and pioglitazone reduce central (Park et al,
2007), inflammatory (Taylor et al, 2002; Morgenweck et al, 2010; Hasegawa-Moriyama
et al, 2013), nociceptive (Oliveira et al, 2007; Napimoga et al, 2008; Pena-Dos-Santos et
al, 2009; Griggs et al, 2015), and neuropathic (Churi et al, 2008; Costa et al, 2008; Iwai
et al, 2008; Maeda et al, 2008; Fehrenbacher et al, 2009; Jain et al, 2009; Jia et al,
2010; Takahashi et al, 2011; Hasegawa-Moriyama et al, 2012; Jain et al, 2013; Jain et
al, 2013; Jia et al, 2013; Morgenweck et al, 2013; Paragomi et al, 2014; Zanardelli et al,
2014; Griggs et al, 2015) pain. PPARγ is expressed in key areas of pain processing
including the brain (Cullingford et al, 1998; Cristiano et al, 2001; Zander et al, 2002;
Dello Russo et al, 2003; Moreno et al, 2004; Park et al, 2004; Victor et al, 2006; Sarruf et
al, 2009), spinal cord (Diab et al, 2002; Moreno et al, 2004; Churi et al, 2008; Maeda et
al, 2008; Shibata et al, 2008), and peripheral nerves (Yamagishi et al, 2008). PPARγ
agonists reduce many factors associated with behavioral hypersensitivity including: (1)
proinflammatory TNFα, IL-1β, and NF-κB in the spinal cord and peripheral nerve (Park et
al, 2007; Maeda et al, 2008; Jia et al, 2010; Jain et al, 2013; Jia et al, 2013); (2) M1
macrophage polarization with simultaneous promotion of M2 in peripheral nerve (Park et
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al, 2007; Takahashi et al, 2011; Hasegawa-Moriyama et al, 2012; Hasegawa-Moriyama
et al, 2013); (3) microglial (Park et al, 2007; Iwai et al, 2008; Takahashi et al, 2011;
Morgenweck et al, 2013) and astrocyte (Park et al, 2007; Jia et al, 2013; Morgenweck et
al, 2013; Griggs et al, 2015) activation in the spinal cord; and (4) Fos and pERK markers
of neuron activation in the spinal cord and brain (Morgenweck et al, 2010; Morgenweck
et al, 2013; Griggs et al, 2015). Here we investigate the mechanism of action of
pioglitazone in both nerve injury and type 2 diabetic pain models.

1.5.2 Transient receptor potential cation channel A1 (TRPA1)
Subtypes of the transient receptor potential (TRP) superfamily of cation channels
include ankyrin (A), vanilloid (V), melastatin (M), and canonical (C). TRP receptors are
can be polymodal, responding to chemicals found in food as well as hot, cold, and
mechanical stimulation. Here we use capsaicin, a compound found in chili peppers, to
activate TRPV1 in order to model nociception in the rodent primary afferent. In addition,
we investigate the activation of TRPA1 by the glucose metabolite methylglyoxal. See
review on TRP channels in pain for more information on these well-studied receptors
(Julius, 2013).
TRPA1 is activated by cold (Story et al, 2003) and mechanical (Kwan et al, 2009)
stimuli, as well as chemicals (Bautista et al, 2005; McNamara et al, 2007; Trevisani et al,
2007; Eberhardt et al, 2012; Gregus et al, 2012) such as methylglyoxal (MG).
Sensitization of TRPA1 in peripheral neurons is suggested to fine tune mechanical
sensitivity (Kwan et al, 2009; Brierley et al, 2011). In mice, TRPA1 is expressed in small,
unmyelinated, peptidergic peripheral DRG neurons (C-fibers) and predominantly
colocalizes with TRPV1 (Story et al, 2003; Bautista et al, 2005; Kobayashi et al, 2005;
Garcia-Anoveros and Duggan, 2007). The proportion of DRG neurons that express
TRPA1 varies depending on the species used (rat or mouse) and between publications,
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with a range of 20-40% in rat and 3-56% in mouse (Kobayashi et al, 2005). Functional
studies indicated that MG produces a calcium response in 72% of capsaicin (prototypical
TRPV1 agonist) responsive DRG neurons (Andersson et al, 2013), suggesting that 72%
of TRPV1 fibers also express TRPA1. This expressional and functional evidence
suggests that TRPA1 may play a role in mediating diverse stimulus modalities, and
supports our investigation of spontaneous nociceptive as well as both mechanical- and
heat-evoked hypersensitivity by the novel agonist methylglyoxal (Eberhardt et al, 2012).
Important to note, there is little evidence to support the expression of TRPA1 on
postsynaptic neurons in the dorsal horn, suggesting that presynaptic TRPA1 contributes
to the activation of these nociresponsive neurons in the spinal cord.
TRPA1 is implicated in several pain conditions. The TRPA1 antagonist A-967079
reduces nociresponsive behavior after administration of mustard oil (TRPA1 agonist) as
well as attenuating cold allodynia in the monoiodoacetate model of osteoarthritis.
Inhibition of TRPA1 may reduce pain-related behaviors by blocking CGRP release in the
DRG (Chen et al, 2011). Interestingly, A-967079 did not inhibit mechanical
hypersensitivity in nerve injury (CCI/SNI) or inflammatory (CFA) pain models (Chen et al,
2011). However, an alternative TRPA1 antagonist (which we have used in the current
studies) HC-030031 attenuated nociresponsive behavior after AITC administration
(TRPA1 agonist) as well as mechanical hypersensitivity in both nerve injury (SNL) and
inflammatory (CFA) pain models (Eid et al, 2008). Neither of these antagonists affected
locomotor coordination, body temperature, heart rate, or naïve heat sensitivity (Eid et al,
2008; Chen et al, 2011). A third antagonist, Chembridge-5861528, reduces mechanical
hypersensitivity after peripheral administration of TRPA1 agonists, in models of
neuropathic pain such as STZ-induced type 1 diabetes or SNI, and in a post-operative
pain model (Wei et al, 2009; Wei et al, 2010; Wei et al, 2012; Wei et al, 2013).
Antagonist studies further implicate the contribution of spinal TRPA1 to peripheral
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hypersensitivity in various pain models (Wei et al, 2011). Here we investigate the role of
spinal and/or peripheral TRPA1 in the maintenance of pain in type 2 diabetes.
The structural-functional relationships (Paulsen et al, 2015) of the TRPA1 channel as
well as the new development of selective antagonists (Preti et al, 2015) provide valuable
information as to the mechanism of TRPA1 activation by endogenous and exogenous
agonists. The mode of activation of TRPA1 by putative (functional) agonists may be due
to covalent modification of specific, thermodynamically available, reactive protein
residues such as cysteines (Macpherson et al, 2007). In various pain models,
endogenous TRPA1 agonists are produced (Stucky et al, 2009) and this may mediate
ongoing

hypersensitivity

associated

with

these

models.

Indeed,

functional

characterization of TRPA1 in DRG neurons indicated that an endogenous agonist
activates TRPA1 via modification of cysteines (Takahashi et al, 2008). The release of
endogenous TRPA1 agonists in a pathological pain condition (i.e. injury) or after
peripheral stimulation (such as by mechanical stimulation of the hindpaw (McGaraughty
et al, 2010) helps to explain the putative contribution of spinal TRPA1 to pain-related
behaviors. In other words, our current results and other studies indicate that spinal
administration of a TRPA1 antagonist blocks peripherally evoked hypersensitivity;
therefore, either the pain model or the stimulation itself must result in the release of
TRPA1 activators at the first synapse in the dorsal horn. This is explored in section
5.4.3.

1.5.3 Adenylyl cyclase, isoform 1 (AC1)
Calcium activated adenylyl cyclase 1 (AC1) (Xia and Storm, 1997) is a key signal
transduction protein and modulator of pain plasticity in the central nervous system
(Zhuo, 2012). AC1 (and AC8 to some extent) acts to facilitate N-methyl-D-aspartate
receptor (NMDAR) mediated nociceptive transmission in the spinal cord dorsal horn, an
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effect that is modulated by both 5-HT activity and forskolin-stimulated cAMP production
(Wang and Zhuo, 2002). AC1 knockout and systemic administration of the AC1 inhibitor
NB001 inhibited the late acute response and chronic hypersensitivity associated with
administration of intramuscular formalin, while the immediate nociresponsive effects
were unchanged by modulation of AC1. Similarly, knockout of AC1 does not reduce ERK
activation in spinal neurons evoked by glutamate, capsaicin, or formalin in naïve
animals, but does reduce persistent spinal long term potentiation (LTP) (Wei et al, 2006).
These results suggest that AC1 mediates central sensitization of spinal nociceptive
neurons but not rapid/acute responses to noxious stimulation in a naïve state.
Supporting an AC1 role in central sensitization, a potentiated AC1 system in the spinal
cord is revealed by the reinstatement of pain after recovery from an inflammatory injury
(Corder et al, 2013). We hypothesized that AC1 mediates persistent hyperalgesia in type
2 diabetes that is dependent upon activation of TRPA1.

1.5.4 Methylglyoxal and glyoxalase 1
Methylglyoxal is a highly reactive cellular metabolite of glycolysis that accumulates in
type 2 diabetic hyperglycemia (Bierhaus et al, 2012; Kender et al, 2014; Kong et al,
2014; Allaman et al, 2015; Dornadula et al, 2015). Figure 1-2 illustrates the biosynthetic
and biodegradation pathways of methylglyoxal. Methylglyoxal contains both aldehyde
and ketone moieties that result in protein modification at lysine/arginine residues and
facilitates

cysteine-cysteine

disulfide

bonds

(Rabbani

and

Thornalley,

2012).

Methylglyoxal forms other protein adducts such as advanced glycation end-products
(AGEs) (Shipanova et al, 1997; Oya et al, 1999; Berner et al, 2012), which result in
diabetic complications (Westwood and Thornalley, 1995; Desai and Wu, 2007; Matsui et
al, 2010; Sohn et al, 2011). Figure 1-3 illustrates two methods of measuring
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methylglyoxal-derived AGEs or free methylglyoxal in biological samples and depicts the
structure of methylglyoxal.
Methylglyoxal is metabolized by the glyoxalase (GLO) system involving both GLO1
and GLO2 enzymes and requiring reduced glutathione (GSH) as an oxidizing agent. An
excellent review of the history of discoveries related to MG and GLO1 is available
(Rabbani and Thornalley, 2014). Potential polymorphisms in GLO1 can affect enzyme
function (Peculis et al, 2013), thereby rendering an organism more susceptible to
changes in glucose metabolism. This is exemplified in different mouse strains, where
BALB/cByJ mice are protected from STZ-induced diabetic neuropathy compared to
BALB/cJ mice, in which GLO1 expression is decreased tenfold (Jack et al, 2012). Both
aging (Fleming et al, 2013) and diabetes (Jack et al, 2011; 2012; Skapare et al, 2013)
are associated with reduced GLO1 activity thereby rendering greater risk for the
detrimental effects of MG. Studies overexpressing GLO1 implicate methylglyoxal in: the
production of anxiety-related behavior (Distler et al, 2012), reduction of seizures after
administration of epileptic seizure agents (Distler et al, 2013), and inducing hyperalgesia
in type 1 diabetes (Bierhaus et al, 2012). Conversely, chronic inhibition of GLO1 by Sr-pBromobenzylglutathionecyclopentyl

diester

(BrBz)

produces

evoked

behavioral

hypersensitivity (Andersson et al, 2013). This indicates that the endogenous levels of
MG, which are inversely correlated with GLO1 activity (Thornalley, 1996), regulate pain
sensitivity. We propose that overexpression of GLO1 activity in type 2 diabetes could
reduce PDN as a future study (section 6.3.2 ).
Methylglyoxal is implicated in the pathogenesis of several neurological disease
conditions. Methylglyoxal induces the release of glutamate in human neuroblastoma SHSY5Y cells that is dependent on NMDA-R activation and results in the depolarization of
neocortical pyramidal cells producing neurotoxicity through necrotic and reactive oxygen
species mechanisms (de Arriba et al, 2006). Both calcium imaging and patch clamp
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electrophysiology experiments indicate that DRG neurons are activated by methylglyoxal
(300 μM), suggesting methylglyoxal might modulate peripheral nociceptor sensitivity to
produce pain (Koivisto et al, 2012). Methylglyoxal generates anxiogenesis (Hovatta et al,
2005; Distler et al, 2012) and epileptic seizure activity that is regulated by GLO1 activity
(Distler et al, 2013). Furthermore, methylglyoxal may be the common factor linking
associations between Parkinson’s and type 2 diabetes (R. Hipkiss, 2012) and GLO1
variations are loosely associated with autism spectrum disorder (Kovac et al, 2014).
Methylglyoxal is reported to activate ion channels involved in pain processing such as
GABAA (Distler et al, 2012), Nav1.8 (Bierhaus et al, 2012), and TRPA1 (Eberhardt et al,
2012; Koivisto et al, 2012; Ohkawara et al, 2012; Andersson et al, 2013; Koivisto et al,
2013). Here we investigate the activity of MG at TRPA1 receptors to produce painful
type 2 diabetes.
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Figure 1-2. Biochemical pathways of methylglyoxal production and
degradation.
Adapted from (Allaman et al, 2015).
Methylglyoxal is produced from (A) glycolysis and (B) lipid and protein metabolism
and is (C) detoxified (i.e. metabolized) by the glyoxalase system using glutathione
(GSH) redox cycling coupled to (D) NADPH production from pentose phosphate.
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Figure 1-3. Methods to measure MG-related entities.
(A) Methylglyoxal-derived advanced glycation end-products (AGEs) can be
measured using a competitive ELISA that recognizes hydroimidazolone MG-H1
protein residues where methylglyoxal covalently modifies arginine residues. (B) Free
methylglyoxal (chemical structure is shown) circulating through the blood or within
tissues can be measured by high-pressure liquid chromatography followed by
tandem mass spectrometry. A representative mass spectrometry trace is shown for
vehicle or methylglyoxal (MG) infusion. Mass spectrometry data courtesy of Dustin
Carroll.

1.6 Modeling pain conditions in rodents
In order to study the human condition of pain we need preclinical models. Bioethical
and practical considerations preclude the ability of the researcher to perform
experimental manipulations on humans. For example, it is not feasible or reasonable to
expect a patient to allow a researcher to transect a piece of their sciatic nerve in order to
study the pain of traumatic nerve injury. However, as described later in section 1.6.2.1
we have used this technique to investigate neuropathic pain mechanisms in rats.
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Animal models are important because they can be readily manipulated by the
experimenter and constant variables (e.g. genetics, environment, time, location, etc.)
can be well-controlled. In addition, reproducibility of results can be tested across
experiments, labs, and institutions. Common animal models in the field of research are
mice and rats, of which there are thousands of different strains and genetic backgrounds
available through commercial vendors. The past twenty years of research has advanced
biotechnology and genetic engineering so that specific pieces of DNA can be
manipulated to create transgenic or knockout mice or rats. In this work we have utilized
germline knockout mice to investigate the role of specific proteins involved in painful
diabetes.
Manipulations other than genetic changes are also useful in pain research. The
following sections describe two categories of animal pain models utilized in this
research: Nociceptive, which we define as chemical activation of primary afferent
nociceptors to produce immediate pain-like behavior that lasts only about one hour; and
Neuropathic, which we define as a direct lesion to the peripheral (and to some extent,
central) nervous system that results in pain-like behavior that lasts days to weeks to
even an indefinite duration.

1.6.1 Nociceptive
1.6.1.1 Capsaicin
The prototypical agonist of TRPV1 is capsaicin, a compound found in chili
peppers that contributes to the taste of spicy foods (Caterina et al, 1997). Intraplantar
injection of capsaicin activates TRPV1-positive primary afferents (i.e. nociceptors) that
are mostly small, unmyelinated C-fibers. These C-fibers typically respond to chemical
(e.g. capsaicin) or thermal (e.g. heat) stimuli. TRPV1 is a cation channel whose open
probability increases when a ligand such as capsaicin is bound. Increased open
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probability allows a greater number of cations, such as sodium and calcium, to enter the
neuron (as compared to the resting state with no ligand) resulting in depolarization of the
neuron. When the stimulus is great enough, as is the case with injection of even low
doses of the potent capsaicin agonist, the action potential threshold is reached and the
nociceptor begins to relay “pain” information to the first synapse within the spinal cord
dorsal horn. This activation of nociceptors by the capsaicin chemical stimulus leads to
nociceptive responses in the form of paw licking, flinching, and lifting.
Intraplantar capsaicin injection has been used as a model of nociceptor activation.
For example, capsaicin activates nociceptive neurons in the spinal cord dorsal horn as
evidenced by both superfusion in physiological slice studies (Wei et al, 2006) and
immunohistochemical analysis of the dorsal horn after peripheral administration (Griggs
et al, 2015). As such, it is convenient to label these dorsal horn neurons as
nociresponsive, since they respond to the stimulation of nociceptors. In addition,
capsaicin also induces expression of both Fos and pERK in the dorsal horn, which
provides for a relatively simple quantifiable measurement of nociresponsive neuron
activation after peripheral nociceptor stimulation (Griggs et al, 2015).

Figure 1-4. Intraplantar capsaicin evokes pERK in the spinal cord dorsal horn.
Intraplantar capsaicin (50 μg in 50 μl) was injected beneath the plantar skin of the
left hindpaw in Sprague-Dawley rats. Animals were perfusion-fixed 10 min following
intraplantar injection and spinal cords were harvested for immunohistochemical
analysis. Representative images of the ipsilateral lumbar dorsal horn after (A)
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vehicle or (B) capsaicin administration. (C) Quantification of the number of cell
profiles positive for pERK (n=3-4).  p<0.05 vs. VEH.

1.6.1.2 Methylglyoxal (acute administration)
Akin to activation of TRPV1, evidence is building that methylglyoxal (MG) activates
TRPA1-positive nociceptors to produce spontaneous nociceptive behavior (Eberhardt et
al, 2012; Koivisto et al, 2012; Andersson et al, 2013; Koivisto et al, 2013; Oguri et al,
2014). Similar to activation of TRPA1 afferents by formalin (McNamara et al, 2007) or
15d-PGJ2 (Cruz-Orengo et al, 2008), we tested the hypothesis that intraplantar
administration of MG would induce nociception and activation of spinal neurons (see
Figure 5-2). This model of chemical induced nociception allowed us to further investigate
the role of TRPA1 and spinal sensitization in MG-mediated nociceptive pain.

1.6.2 Neuropathic
The IASP defines neuropathic pain as “pain caused by a lesion or disease of the
somatosensory nervous system”. We distinguish the difference between nociceptive and
neuropathic pain in that neuropathic pain becomes pathological even in the absence of
an obvious exogenous stimulus (such as capsaicin or methylglyoxal administration).
Much work has been completed to elucidate the mechanisms of neuropathic pain after
traumatic nerve injury, post-herpetic neuralgia, chemotherapeutic neuropathy, trigeminal
neuralgia, or diabetes. Here we used three different models of neuropathic pain to
investigate the mechanisms of PPARγ analgesia as well as the contribution of
methylglyoxal to diabetic neuropathic pain. For reviews of neuropathic pain mechanism
see the following references (Campbell and Meyer, 2006; Scholz and Woolf, 2007;
Sandkühler, 2009; Jensen and Finnerup, 2014).
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1.6.2.1 Traumatic (Spared) Nerve Injury
There are several models of traumatic nerve injury utilized in rodents. Most
involve either ligation, by tying sutures around a nerve to induce neuroinflammation and
associated sensitization, or ligation followed by transection, where a piece of the nerve is
removed. There are two major nerves utilized in these types of studies: trigeminal and
sciatic. Here we focus on manipulation of the sciatic nerve to induce neuropathic pain.
Spared nerve injury (SNI) is a method by which the branches of the sciatic nerve
trifurcation (tibial, common peroneal, sural) are differentially ligated and/or transected.
Transection of one or more of these branches results in hypersensitivity and
sensitization of the intact, or spared, nerve. In our studies, we transect the tibial and
common peroneal branches of the sciatic nerve and spare the sural nerve. The
procedure (Decosterd and Woolf, 2000) and innervation territories of these nerves in the
spinal cord dorsal horn (Corder et al, 2010) are described previously and elaborated
upon in section 3.3.2

1.6.2.2 Diabetic neuropathic pain
Models of both type 1 and type 2 diabetes exist in the pain research community.
The most common model of diabetes and associated pain-like behavior is induced by
streptozotocin (STZ), a glucose analog and pancreatic beta cell toxin. STZ induces beta
cell destruction resulting in the loss of insulin production and hyperglycemia. STZ
models a type 1 diabetic-like phenotype. Here we focus on models of type 2 diabetic
pain for reasons described in section 4.2 We use both rat (Zucker Diabetic Fatty; ZDF)
and mouse (Leprdb/db; db/db) genetic models of type 2 diabetes. These rodents develop
a type 2 diabetic phenotype because of an inbred genetic mutation that produces a nonfunctional leptin receptor. At early stages of diabetes, ZDF and db/db exhibit behavioral
hypersensitivity to noxious mechanical and heat stimuli. However, as diabetes
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progresses the animals become hyposensitive. This allows for investigating the
mechanisms of both painful and insensate neuropathy in diabetes. Here we focus on the
period of hypersensitivity in order to study painful diabetic neuropathy (PDN), or the
neuropathic pain associated with type 2 diabetes.
The Zucker Diabetic Fatty (ZDF) rat originated from a colony harboring a mutation in
their leptin receptor causing a truncated, non-functional protein product. Inbreeding of
ZDF rats resulted in a reliable model of genetically induced spontaneous type 2
diabetes. ZDFs develop type 2 diabetes by age 2-3 months (Pickavance et al, 1998;
Shibata et al, 2000; Li et al, 2006; Brussee et al, 2008; Sugimoto et al, 2008). Control
Zucker Lean (ZL) rats are heterozygous for the leptin receptor mutation and are not
diabetic. Thermal hyperalgesia in ZDF rats is present from age 14 weeks (Li et al, 2006;
Donahue et al, 2012) and can last up to age 28 weeks (Oltman et al, 2008). Mechanical
hyperalgesia occurs as early as age 14 weeks (Zhuang et al, 1997; Li et al, 2006;
Romanovsky et al, 2008; Sugimoto et al, 2008) while mechanical allodynia develops at
age 25 weeks and can last up to age 29 weeks (Otto et al, 2011). Our lab was unable to
see evidence of tactile allodynia in ZDF rats up to age 24 weeks (Donahue et al, 2012).
ZDF rats develop motor and sensory nerve conduction velocity deficits by age 16 weeks
(Brussee et al, 2008; Oltman et al, 2008). Hypoalgesia is a common symptom of
diabetics in later stages of disease progression and this condition also has been shown
in ZDF rats (Oltman et al, 2008); however, this proposal aims to characterize the
hypersensitivity seen after diabetes develops but before progression to hypoalgesia.

1.6.2.2.1 Methylglyoxal (chronic administration)
Several studies suggest that chronic administration of methylglyoxal (MG) may be a
suitable model of diabetic complications (Dhar et al, 2011; Dornadula et al, 2015; IllienJunger et al, 2015). These groups showed that chronic MG administration in the drinking
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water, via repeated systemic injection, or minipump induces mild hyperglycemia,
mitochondrial dysfunction, and neuroinflammation. However, pain-like behavior in a
chronic MG model has not been investigated. Here we show that acute administration of
MG produces pain-like behavior. We attempted to induce chronic neuropathic pain by
using minipumps to administer MG in naïve, wild-type mice. However, experimental
complications limited our conclusions from this study (see Figure 6-5). Therefore a future
aim of this work is to develop a chronic neuropathic pain model induced by long-term
administration of MG in mice and/or rats (see 6.3.1 ).

1.7 Measuring preclinical “pain” in rodents
It is virtually impossible to measure pain in rodents when considering the true
definition of pain, which includes the words unpleasant and emotional. We simply cannot
ask the rodent subject whether they hurt, or whether a particular stimulus is unpleasant
or induces negative emotion. We can only observe behavior and make inferences based
upon these observations. Instead of ascribing the word pain to behavioral observations
that may or may not be unpleasant or emotional, we can refer to these behaviors as
pain-like. A majority of pain research has used stimulus-evoked measures of pain-like
behavioral hypersensitivity. New assays, or the repurposing of previously described
behavioral assays from the fields of psychology and addiction, are now available to go
beyond assessment of the sensory-discriminative dimension of pain.

1.7.1 Stimulus-evoked measures
Sensory organs and receptors in the skin allow animals to discern both quality and
quantity of a potentially painful stimulus. Stimulus modalities include mechanical,
thermal, and chemical. Primary afferents that innervate the skin and sensory organs
express various proteins that each contribute to sensing stimuli in different modalities.
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Here we investigate two such receptors: TRPV1, the primary heat receptor that is
activated by capsaicin; and TRPA1, primarily a cooling receptor that is activated by
methylglyoxal. Both TRPV1 and TRPA1 can contribute to mechanosensation in naïve
and pathological pain conditions.
Stimulation of primary afferent terminals in the periphery can result in activation of
nociceptive neurons in the spinal cord dorsal horn. These spinal neurons act as relay
neurons that transmit pain information to circuits within the spinal cord as well as to third
and fourth order neurons in the brainstem, thalamus, and cortex. This first (and
potentially second) synapse in the spinal cord can be modulated by inhibitory and/or
excitatory interneurons in the spinal cord or by descending projections from structures
within the brainstem. However, a growing body of evidence suggests that the sensory
aspects of stimulus-evoked pain-like behaviors are predominantly spinally mediated
reflexes, and therefore do not reflect the affective-motivational or cognitive-evaluative
aspects of pain. Nonetheless, the methods of assessing stimulus-evoked pain-like
behavior in rodents are often quite similar to those used in humans, and therefore may
still have translatable value. However, we argue that simultaneous assessment of both
stimulus-evoked and non-evoked measures of pain in rodents is necessary in studies
aiming to evaluate the clinical utility of drugs that may potentially relieve pain.
Assessment of stimulus-evoked pain-like behavior is accomplished by measuring the
threshold of stimulation at which the animals responds, or withdraws from the given
stimulus. Conversely, the magnitude of the response, as is the case for chemicalinduced nociception by capsaicin or methylglyoxal, can be measured. Here we use von
Frey filaments and a modified Randall-Selitto pressure method to determine the force at
which animals withdraw/respond to non-noxious or noxious stimulation, respectively.
Similarly, we use a hotplate to subject animals to a heat stimulus and measure the
latency, or the duration of time until the animal withdraws/responds. For mechanical or
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heat stimulation, a decrease in the withdraw threshold or latency indicates
hypersensitivity. To measure cold sensitivity we either evaluate the duration of withdraw
response after stimulation with acetone (presumably evaporation results in a cooling
sensation) or quantify the number of responses in animals subjected to a coldplate.

1.7.2 Stimulus-independent measures
1.7.2.1 Chemical-induced nociception
Activation of primary afferent nociceptors by endogenous and exogenous moieties
produces pain-related behaviors. Compounds (e.g. capsaicin, formalin, carrageenan,
methylglyoxal) are administered subcutaneously beneath the epidermis (intradermal).
We refer to this as an intraplantar injection (i.pl.) because compounds are given into the
ventral plantar surface of the hindpaw. Chemical activation of receptors on the free
nerve endings of nociceptors results in spinally mediated reflex withdraw behaviors
including licking, lifting, and/or flinching of the affected limb. We deem these
spontaneous measures of nociception or nociresponsive behaviors because the effect is
immediate, typically short-lived on the order of minutes, and does not require repeated
stimulation (i.e. administration of the compound of interest) as is the case for stimulusevoked mechanical or thermal hyperalgesia. Quantification of the pain-related behaviors
allows us to test how various manipulations (e.g. a receptor antagonist) affect the
specific peripheral nociceptive pathway and/or how modulation of the spinal neuron
reflex system changes nociception.

1.7.2.2 Mechanical conflict avoidance
A novel Mechanical Conflict Avoidance System (MCS) was recently developed by
our colleagues (Lau et al, 2012) to incorporate cognitive processing in the measurement
of preclinical motivational-affective pain in rodents. MCS gives the subjects a choice to
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remain in an environment containing an aversive light stimulus or to enter an
environment that contains an aversive mechanical stimulus in the form of heightadjustable, blunted metal probes. By navigating through the mechanical stimulus
environment the subjects are rewarded with access to a darkened environment without
probes. If animals chose to leave the light chamber and cross the probes in the stimulus
chamber, they then had the option to enter a darkened reward chamber. This method is
described in detail in section 4.3.4 and used to test the hypothesis that type 2 diabetes
is associated with affective pain in ZDF rats (section 4.4.1 ).

1.7.2.3 Conditioned Place Preference/Avoidance
Assessment of clinical and preclinical pain is not always performed using the same
assays, which contributes to the lack of clinical efficacy of drugs that reverse reflexive
pain in rodents (Vierck et al, 2008). Alternatively, Bennett suggests that the lack of
success in clinical trials is not due to measuring the wrong outcome in animals (i.e.
evoked sensitivity), but that clinicians are evaluating imprecise endpoints in patients
(Bennett, 2012). Therefore, assays that go beyond evoked measures and that can be
performed using similar experimental designs in both rodents and humans are needed.
Conditioned place preference (CPP) is used to measure the rewarding (Bardo and
Bevins, 2000) and pain relieving (Sufka, 1994; King et al, 2009) effects of experimental
drugs in rodents and humans. CPP has gained attention as an approach to unmask the
affective dimension of pain in preclinical rat (King et al, 2011) and mouse (He et al,
2012) models of peripheral nerve injury. The CPP approach harnesses the fact that an
animal presumably in pain will be motivated to seek out an environment previously
associated with pain relief. Since pain is aversive, negative reinforcement of the aversive
stimulus is rewarding. Animals are trained by the unconditioned stimulus (i.e. the
behavioral effects of analgesic drug administration) in an environment with distinctive

29

sensory cues that serves as the conditioned stimulus. After conditioning animals are
allowed to choose whether or not they prefer to spend more time in the drug-paired
environment in the absence of any drug administration. Pairing the affective
consequences of analgesic drug administration takes into consideration the motivational
aspects of pain and allows for measurement of preclinical analgesia in the absence of an
exogenous stimulus (Tzschentke, 2007). One caveat to CPP/CPA is that diseases that
affect memory may confound results from this assay, as memory is needed to recognize
the environment where pain relief was received. We validate the method of CPP in a
model of nerve injury (see 1.8 ) and use this assay to determine the effect of
methylglyoxal on motivational-affective pain.
Several reports indicate dissociation between decreased evoked hypersensitivity and
negative reinforcement of pain (i.e. CPP) after analgesic drug administration. After injury,
rodents exhibit CPP to inhibition of spinal or peripheral nerve transmission by local
injection of lidocaine (King et al, 2009; King et al, 2011). This suggests that ongoing
activity from peripheral neurons in the pain pathway contributes to aversive aspects of
supposed pain after injury. However, pharmacological inhibition of TRPV1 (Okun et al,
2011), COX2, or TRPA1 (Okun et al, 2012) does not reverse ongoing pain (i.e. eliminate
a preference for peripheral nerve block after injury) but alleviates evoked
hypersensitivity. In the streptozotocin model of painful diabetic neuropathy, inhibition of
TRPA1 reversed mechanical hypersensitivity, but not spontaneous pain as assessed
using the CPP paradigm (Wei et al, 2013). The failure of TRPA1 and TRPV1 inhibitors in
producing CPP preclinically is mimicked by the limited ability of TRPA1 or TRPV1
antagonists to reduce pain in humans (Brederson et al, 2013). These studies highlight
the importance of measuring both sensory/discriminative and affective/motivational
outcomes in preclinical models in order to better predict clinical utility of analgesic drugs.
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1.8 Preface
My current results reflect six years of work investigating chronic neuropathic pain
using preclinical rodent models. I began this work by validating models for nociceptive
pain (e.g. capsaicin and methylglyoxal), traumatic nerve injury (e.g. spared nerve injury),
and painful type 2 diabetes (e.g. db/db mice and Zucker Diabetic Fatty rats). I used
various methods to characterize and evaluate pain-related behaviors in rodents,
including validating the use of conditioned place preference testing to assess the
motivational-affective component of pain in Chapter 2: . In Chapter 3: I elucidated the
rapid antihyperalgesic effect of PPARγ agonists and determined that the inhibition of
spinal sensitization by pioglitazone is mediated through a non-genomic, anisomycininsensitive, astrocyte-related mechanism. Next in Chapter 4: and Section 6.4.2 I
simultaneously characterized models of painful diabetic neuropathy (i.e. ZDF and db/db)
and determined that pioglitazone, a drug approved by the FDA for treating type 2
diabetes, inhibits painful type 2 diabetes independent from its effect on decreasing blood
glucose. I also validated a second method for measuring pain-like negative affect using
a novel mechanical conflict avoidance, showing that diabetic ZDF rats exhibit
motivational-affective pain-like behavior. Finally, in Chapter 5: I extended findings from
the overgeneralized streptozotocin model of painful diabetes, providing strong evidence
implicating TRPA1 in sustained diabetic hypersensitivity in a superior model, type 2
diabetic db/db mice. Using this model along with exogenous administration of the
glucose metabolite methylglyoxal, I will show that MG is sufficient to produce behavioral
hypersensitivity and affective pain (i.e. conditioned place aversion) through activation of
peripheral TRPA1 and subsequent sensitization of spinal neurons through a TRPA1AC1 mechanism. Furthermore, I investigate the inhibition of methylglyoxal-induced pain
by the methylglyoxal scavenging peptide GERP10 and pioglitazone.
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My results are the first to report evidence of affective pain in a model of type 2
diabetes as well as the reduction of painful type 2 diabetes GERP10 and pioglitazone.
My long-term goal for this work is to inform the initiation of future clinical studies
investigating the analgesic properties of pioglitazone and/or GERP10. In Chapter 6: I
evaluate my results alongside the available literature to synthesize new insights into the
mechanism(s) by which PPARγ mediates its antihyperalgesic effects in neuropathic pain
conditions. I also discuss evidence suggesting that targeting TRPA1, AC1, or GLO1 may
alleviate painful type 2 diabetes. Future studies discussed in the following content
chapters and the overall discussion in Chapter 6: are proposed to extend our knowledge
of the involvement of MG, GLO1, TRPA1, AC1, and PPARγ in mediating and inhibiting
chronic neuropathic pain associated with type 2 diabetes.
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CHAPTER 2: Gabapentin alleviates affective pain after traumatic nerve injury
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2.1 Abstract
Gabapentin reduces behavioral signs of stimulus-evoked allodynia and hyperalgesia
in preclinical studies of traumatic nerve injury, but its effects on more clinically-relevant
measures of stimulus-independent pain are unclear. To address this gap, we determined
whether gabapentin would relieve affective pain after spared nerve injury (SNI). Twelve
days after sham or SNI surgery, we administered gabapentin over three consecutive
conditioning days and then evaluated conditioned place preference (CPP). Gabapentin
produced CPP and reversed mechanical hypersensitivity in SNI but not sham rats at a
dose (100 mg/kg) that did not change open field activity. These results show for the first
time that gabapentin provides relief from affective pain without producing locomotor
sedation, and adds to a limited clinical literature suggesting that its use can be extended
to treat pain arising from traumatic nerve injury.
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2.2 Introduction
Preclinical research targeting discovery of novel treatments for neuropathic pain
primarily rely on mechanical or thermal stimulus-evoked behavioral outcomes. However,
this approach fails to mimic the affective and spontaneous aspects of chronic pain that
are most relevant to pharmacotherapy in humans, as indicated by the high failure rate of
analgesic drug candidates in clinical trials. The use of conditioned place preference
(CPP) to assess non-evoked pain, originally described two decades ago (Sufka, 1994),
has re-emerged as a leading measure of affective neuropathic pain (King et al, 2009)
and has the potential to address the disconnect between preclinical and clinical efficacy
(King and Porreca, 2014). The use of CPP to measure preclinical pain relief is
advantageous because the test is performed in the absence of an exogenous stimulus
(Tzschentke, 2007), incorporates the motivation to seek reward (Bardo and Bevins,
2000), and evaluates the affective (King et al, 2009) pain relieving effects of analgesic
drug administration (King and Porreca, 2014).
Gabapentin (Neurontin®) is a primary treatment for neuropathic pain (Attal et al,
2010) in patients with trigeminal neuralgia (Lemos et al, 2011), post-herpetic neuralgia
(Rowbotham et al, 1998), painful chemoneuropathy (Caraceni et al, 2004), and painful
diabetic neuropathy (Backonja et al, 1998; Vincent et al, 2011). Reverse translation
studies in rodents indicate that gabapentin attenuates affective pain produced by
cisplatin (Park et al, 2013) or streptozotocin (Wagner et al, 2014), as well as the evoked
hypersensitivity associated with traumatic nerve injury (Xie et al, 2014). However, no
study has evaluated whether gabapentin reduces affective pain after traumatic nerve
injury. To address this question, we performed gabapentin CPP in rats with spared nerve
injury (SNI), a widely used preclinical model of traumatic nerve injury (Decosterd and
Woolf, 2000).
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2.3 Methods
2.3.1 Animals
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing
200-250 g at the time of surgery and 300-350 g at the time of behavioral procedures
were housed 2 per cage on a 12-hour light/dark cycle (7am lights on / 7pm lights off) in a
temperature (68-72º F) and humidity controlled room with food and water provided ad
libitum. All efforts were made to minimize animal suffering, to reduce the number of
animals used, and to utilize alternatives to in vivo techniques, in accordance with the
International Association for the Study of Pain and the National Institutes of Health Office
of Laboratory Animal Welfare Guide for the Care and Use of Laboratory Animals. All
behavioral procedures were carried out between 8am-6pm and approved by the
Institutional Animal Care and Use Committee (IACUC) at University of Kentucky.
Behavioral measurements were performed by an observer blinded to experimental
treatments.

2.3.2 Spared Nerve Injury (SNI) surgery
Sham and SNI surgeries were performed as previously described (Decosterd and
Woolf, 2000). To generate surgical sham control subjects, all steps were performed
except ligation and transection of the common peroneal and tibial nerves. The day of
sham or SNI surgery is referred to as day 0.

2.3.3 Measurement of pain-like behavior and open field activity
Animals were acclimated in individual Plexiglas boxes (4” x 8” x 4”) on top of a raised
stainless steel mesh grid for 1 h. Mechanical hypersensitivity was assessed using von
Frey filaments (Stoelting, Inc., Wood Dale, IL) using a modified up-down method (Dixon,
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1980; Chaplan et al, 1994) as previously described (Morgenweck et al, 2013). The
calculated 50% withdraw threshold is reported.
A photobeam activity system (PAS; 16 x 16 array; San Diego Instruments, San
Diego, CA) was used to measure exploratory locomotion in a clear, square box
surrounded by the photobeam array. Saline or gabapentin (100 mg/kg) was
administered i.p. prior to placing the rat into the open field chamber. The total number of
photobeam breaks was automatically quantified by the PAS software for 30 min in 5 min
bins in the absence of any observer.

2.3.4 Conditioned Place Preference
The use of conditioned place preference (CPP) as a tool to measure the ongoing
aversiveness (i.e. affective pain) after injury or preference for rewards has been well
established (Sufka, 1994; Bardo and Bevins, 2000; King et al, 2009; Wei et al, 2013).
Eight rat CPP boxes (Med Associates, St Albans, VT) were used to assess chamber
preference before and after the drug conditioning phase. The experimental timeline and
details of the CPP apparatus are illustrated in Figure 1. Rats were able to discriminate
the drug- versus vehicle-paired chamber using visual (wall color), tactile (flooring), and
olfactory (Lipsmackers Chapstick, Bonne Bell, Westlake, OH) cues. Preliminary
experiments indicated no preference for vanilla (white chamber) or kiwi (black chamber)
chapstick olfactory cues in sham or SNI rats. To reduce time spent in the gray chamber
lighting in the white and black chambers was adjusted to 25% of that in the grey
chamber. Manual guillotine doors were used to isolate the white and black pairing
chambers from the grey chamber during conditioning. Each individual CPP box was fully
contained in a sound and light attenuating enclosure. Time of testing, animal handling
method, and cleaning of the CPP boxes were held constant.
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Preconditioning. The CPP procedure spanned six consecutive days. On Day 1,
subjects were acclimated to the CPP boxes for 30 min, with open access to each of the
three chambers. On Day 2 (preconditioning), animals were placed in the grey middle
chamber, and then we determined time spent in the white or black pairing chambers for
15 min. Animals that spent <20% or >80% time in the black and/or white chamber (i.e.
showing an apparatus bias or initial, unconditioned preference) during preconditioning
were removed from the experiment (King et al, 2009). By these criteria, ten animals were
removed from von Frey and CPP analyses.
Conditioning. On Days 3, 4 and 5 (conditioning), we used a biased assignment
approach to drug pairing: saline was paired with the preferred chamber in the morning,
and gabapentin was paired with the non-preferred chamber in the afternoon. Our biased
approach was chosen for five reasons: 1) increases assay sensitivity; 2) allows for a
within subjects design and statistical analysis (Cunningham et al, 2003; Tzschentke,
2007); 3) of all CPP studies in 2001, 30% used a biased approach and 42% analyzed
results using a difference score (postconditioning minus preconditioning) (Cunningham
et al, 2003); 4) a biased approach was very recently used to assess gabapentin CPP in
the streptozotocin model of painful diabetic neuropathy (Wagner et al, 2014); 5)
Cunningham et al demonstrated that if the CPP apparatus is not biased (time spent in
the white chamber = time spend in black chamber when average across all subjects, as
in the current study) , then the use of either a biased or unbiased chamber-assignment
approach does not affect the ability to produce CPP (Cunningham et al, 2003).
Conditioning consisted of the following sequential steps: i.p. injection, return of the
animal to its home cage for 5 min, and then placement within the white or black chamber
for 30 min (injections were never paired with the grey, middle chamber). We used a 30
min conditioning time based on reports that gabapentin maximally reduced mechanical
hypersensitivity at 30-60 min after injection (Park et al, 2013; Wagner et al, 2014). We
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chose 3 d of gabapentin conditioning because 1 d was not sufficient to produce CPP in a
mouse model of chemoneuropathy (Park et al, 2013).
Postconditioning and analysis. On Day 6 (postconditioning), animals were placed
into the grey chamber and we evaluated time spent in either the white or black chamber.
The difference score for each subject was calculated by subtracting the time spent in the
saline- or gabapentin paired chamber before pairing (during preconditioning) from the
time spent in each chamber after pairing (postconditioning), and then averaged within
each group.

Figure 2-1. Experimental timeline and diagram of the conditioning place
preference (CPP) apparatus.
(Top) Baseline von Frey thresholds were measured on d -1 prior to Sham or Spared
Nerve Injury (SNI) surgery on d 0. Mechanical hypersensitivity (von Frey) was
measured on d 9 (pre CPP) and d 16 (post CPP). The Conditioned Place Preference
(CPP) assay was performed on d 10 – 15 (open arrows) and consisted of
acclimation, preconditioning, conditioning, and postconditioning. Open field activity
was determined on d 17. (Bottom) The CPP apparatus consisted of: (left) a white
chamber with grid flooring, vanilla chapstick, and 25% light intensity; (middle) a grey
chamber with solid flooring, no olfactory cue, and 100% light intensity; (right) a black
chamber with bar flooring, kiwi chapstick, and 25% light intensity.
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2.3.5 Experimental Design
Evoked mechanical sensitivity was measured prior to sham or SNI surgery (day 0), 9
d after surgery (pre CPP), and after completion of the CPP procedure on d 15 (post
CPP). The CPP assay was performed on days 10 – 15. Following post CPP
measurement of von Frey withdraw thresholds to confirm the sustained presence of
mechanical hypersensitivity, saline or gabapentin (100 mg/kg) was injected i.p. and von
Frey thresholds were recorded 15, 30, and 60 min later. A 24 h timepoint was taken to
determine whether the anti-hypersensitivity effects of gabapentin endured from one
conditioning day to the next. Open field activity after i.p. saline or gabapentin
administration was performed at the conclusion of von Frey and CPP experiments on d
17.

2.3.6 Drugs
Gabapentin (Spectrum Chemical, Gardena, CA) was dissolved in 0.9% saline
immediately prior to injections and administered i.p. in a volume of 0.5-1.0 ml (final dose
= 100 mg / kg body weight).

2.3.7 Statistical Analysis
A paired t-test was used to compare the effect of sham or SNI surgery on
mechanical sensitivity prior to CPP, preconditioning versus postconditioning time spent
in CPP chambers, and CPP difference scores. Gabapentin effect on behavior in the von
Frey assay was compared for significant differences over time using repeated measures
two-way ANOVA followed by Holm-Sidak multiple comparison correction. An alpha value
of α = 0.05 was used to determine statistical significance. All data were analyzed and
graphed using Prism 6.0 (GraphPad, La Jolla, CA) and are presented as mean ± SEM.
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2.4 Results
2.4.1 SNI produces evoked mechanical hypersensitivity
Spared nerve injury (SNI) evokes mechanical hypersensitivity that begins a few days
after surgery and lasts for at least 6 months (Decosterd and Woolf, 2000). To compare
evoked mechanical hypersensitivity and affective pain, we performed von Frey testing
prior to surgery (baseline), before CPP (pre), after CPP (post), and for 60 min following
i.p. gabapentin administration in sham and SNI rats. CPP conditioning occurred at day
12-14 during established mechanical hypersensitivity. As illustrated in Fig 2A, SNI
produced hypersensitivity to von Frey mechanical stimulation at the pre CPP timepoint [p
< 0.0001]. There was no change in mechanical thresholds in sham animals [p > 0.05].

2.4.2 Gabapentin reverses SNI-induced evoked mechanical hypersensitivity
After CPP testing, we assessed inhibition of SNI-induced mechanical hypersensitivity
by measuring von Frey withdraw thresholds after systemic administration of gabapentin
at the same dose used during CPP conditioning (100 mg/kg). Fig 2B illustrates that
gabapentin significantly attenuated evoked mechanical hypersensitivity in rats with SNI
at 30 [p < 0.05] and 60 [p < 0.05] min after i.p. injection [drug x time; F (3, 36) = 17.5; P <
0.0001]. Mechanical withdraw thresholds were slightly, but insignificantly, increased at
15 min. Sham animals did not exhibit evoked mechanical hypersensitivity (compared to
baseline) [p > 0.05] and von Frey withdraw thresholds were unaltered by gabapentin
[drug x time; F (3, 18) = 0.015; P > 0.05].
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Figure 2-2. Gabapentin reverses evoked mechanical hypersensitivity
associated with nerve injury.
(A) Mechanical thresholds are shown at baseline (before surgery) and d 9 (pre CPP)
after sham or spared nerve injury (SNI) surgery prior to conditioned place
preference testing. SNI (n=17) decreased mechanical thresholds relative to sham
(n=8) controls. (B) On d 16 (post CPP), mechanical thresholds remain decreased in
SNI but not sham animals. Gabapentin (100 mg/kg; i.p.) increased mechanical
thresholds in SNI (n=11) but not sham (n=5) animals. Saline did not change
mechanical thresholds in sham (n=3) or SNI (6) animals. (A),  “SNI” at the pre
CPP timepoint significantly different from all other groups. (B),  “SNI –
Gabapentin” significantly different from “SNI – Saline”.

2.4.3 Gabapentin produces CPP in rats with SNI but not sham surgery
To confirm that animals do not prefer one chamber over another, we assessed time
spent in each. This was done prior to drug-pairing during conditioning. In sham rats, time
spent in the white [355.1 ± 16.0 s] and black [363.2 ± 18.8 s] chambers was similar [p =
0.37]. In SNI rats, time spent in the white [336.2 ± 15.6 s] and black [346.1 ± 18.6 s]
chambers was also similar [p = 0.34]. These data indicate that there is no initial bias for
the CPP apparatus and that injury did not alter preconditioning preferences.
To determine whether gabapentin alleviates affective pain after traumatic nerve
injury, we assessed CPP in sham and SNI rats. Fig 3A illustrates our biased conditioning
approach: preconditioning time spent in the saline-paired chamber was greater than time
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spent in the gabapentin-paired chamber in both sham [p < 0.05] and SNI [p < 0.0001]
rats. Biased drug pairing remained counterbalanced, where half the animals received
gabapentin in the white chamber and half in the black chamber. Conditioning to
gabapentin produced an increase in time spent in the gabapentin-paired chamber in SNI
[p = 0.0043] but not sham rats [p = 0.2]. When compared to saline difference scores, Fig
3B illustrates a significantly higher gabapentin difference score in SNI [p < 0.0001] but
not sham [p = 0.70] rats. These results indicate that gabapentin produces CPP in SNI
but not sham rats at 2 wks after injury. A previous study indicates that the
antihyperalgesic effect of gabapentin varies over time after nerve injury (Hama and
Borsook, 2005). Future studies could investigate the ability of gabapentin to produce
CPP at later timepoints.
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Figure 2-3. Gabapentin attenuates affective pain associated with traumatic
nerve injury.
To determine affective pain relief we performed CPP with three days of conditioning
(saline or gabapentin; 100 mg/kg; i.p.). (A) Time spent in the saline-paired chamber
during preconditioning was greater than time spent in the gabapentin-paired
chamber as a result of our biased drug-pairing approach. In sham rats (n=8), there
was no change in preference during postconditioning (“Post”) when compared to
preconditioning baselines (“Pre”). In SNI rats (n=17), gabapentin produced an
increase in time spent in the gabapentin-paired chamber when compared to
preconditioning baseline. (B) Saline and gabapentin difference scores were
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significantly different in SNI but not sham rats. These results taken together indicate
gabapentin induces CPP thereby relieving affective pain in rats with traumatic nerve
injury. # Significantly different from preconditioning saline-paired in SNI. $
Significantly different from preconditioning gabapentin-paired in SNI.  Significant
difference between indicated groups.

2.4.4 Gabapentin did not change locomotor activity in sham or SNI rats
Gabapentin produces adverse effects in humans including somnolence, dizziness,
peripheral edema, infection, and ataxia (Rowbotham et al, 1998). To address the
potential effect of gabapentin on exploratory or somatomotor activity, resulting in
confounding alterations in mechanical thresholds or CPP, we assessed open field
activity. Fig 4A indicates that gabapentin did not change locomotor activity in sham
[drug; F (1, 6) = 0.18; P > 0.05] or SNI [drug; F (1, 8) = 0.005; P > 0.05] rats.
Furthermore, there was no difference in activity between sham and SNI animals treated
with saline [injury; F (1, 8) = 0.02; P = 0.89] indicating that SNI did not change locomotor
function.
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Figure 2-4. Gabapentin does not alter locomotor activity.
(A) The number of beam breaks in sham or SNI animals treated with saline or
gabapentin (100 mg/kg; i.p.) was not different in an open field photobeam activity
assay (n=5-6).
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2.5 Discussion
Here we present the first data indicating that gabapentin relieves affective pain (i.e.
produces CPP) associated with traumatic nerve injury in a preclinical model. Our current
results are consistent with recent findings in other rodent models of neuropathic pain.
For example, gabapentin produces CPP in mice following chronic cisplatin treatment
(Park et al, 2013) or in the streptozotocin model of type I painful diabetic neuropathy
(Wagner et al, 2014). Xie et al reported that gabapentin reversed mechanical
hyperalgesia associated with spinal nerve ligation (SNL), without measuring its effect on
affective pain using CPP (Xie et al, 2014). Repetition of our study in an alternative model
of traumatic nerve injury such as SNL or using a dose response could provide additional
support for our conclusion that gabapentin alleviates affective pain generalized to
multiple types of neuropathic conditions.
The current study shares important experimental design characteristics with Park et
al and Wagner et al (Park et al, 2013; Wagner et al, 2014), but in the setting of traumatic
nerve injury. First, a systemic dose of 100 mg/kg was administered over three
conditioning days. Second, gabapentin produced CPP rapidly, within 30 min of
administration. Third, gabapentin did not produce CPP in control animals, ruling out the
possibility that gabapentin is intrinsically rewarding. This is in contrast to rewarding
analgesic drugs such as morphine, which produce CPP in naïve or uninjured subjects,
thus complicating interpretation of effects on affective pain (Sufka, 1994; Tzschentke,
2007). Fourth, gabapentin reduced both evoked and affective measures of pain. This is
striking in light of recent reports indicating that other analgesic drugs such as TRP
antagonists (Brederson et al, 2013) inhibit evoked but not affective pain in preclinical
models of inflammation (Okun et al, 2011), osteoarthritis (Okun et al, 2012), type I
diabetes (Wei et al, 2013), and SNI (Wei et al, 2013).
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We conclude that gabapentin alleviates affective pain after SNI in rodents, and
suggest further studies to determine the clinical efficacy of gabapentin for the treatment
of chronic pain associated with traumatic nerve injury. Indeed, a randomized, doubleblind, placebo-controlled, cross-over, multicenter clinical trial involving patients with
peripheral nerve injury due to trauma or surgery reported that, compared to placebo,
gabapentin provided better pain relief and increased the number of subjects with a pain
reduction of at least 30% (Gordh et al, 2008). In addition, our results highlight the
importance of measuring the affective component of pain in preclinical studies to better
predict clinical efficacy of pain-relieving drugs.

2.6 Supplemental Discussion
2.6.1 Gabapentin reduction of neuropathic pain in humans and rodents
Gabapentin (Neurontin®) is an anticonvulsant drug that is a primary treatment (Attal
et al, 2010) for neuropathic pain in patients with diabetes (Vincent et al, 2011), trigeminal
neuralgia (Lemos et al, 2011), cancer (Caraceni et al, 2004), traumatic nerve injury
(Gordh et al, 2008), and post-herpetic neuralgia (Kukkar et al, 2013). Gabapentin also
decreases evoked measures of pain-like hypersensitivity in rodent models of painful
diabetic neuropathy (Field et al, 1999; Zhang et al, 2013), orofacial nerve injury (Nakai et
al, 2014), spinal cord injury (Kitzman et al, 2007; Rabchevsky et al, 2011), hindlimb
nerve injury (Luo et al, 2002; Yezierski et al, 2013), and chemoneuropathy (Park et al,
2013). Gabapentin likely produces analgesia by reducing neuronal excitability through
inhibition of α2δ1 subunits presynaptic calcium channels (Brown et al, 1998; Kukkar et
al, 2013). Relief from pain-like hypersensitivity is associated with decreased Fos
expression in the spinal cord and PAG after nerve injury (Morgado et al, 2010),
attenuation of fMRI BOLD signals in the cortical pain matrix in nerve injured mice
(Takemura et al, 2011), and attenuated overexpression of Nav1.7 and pERK in
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streptozotocin-treated rats (Zhang et al, 2013). Because gabapentin is currently
recommended for the treatment of neuropathic pain patients (Attal et al, 2010), and it is
unknown whether gabapentin attenuates preclinical spontaneous pain, we performed a
reverse translation study to assess gabapentin induced CPP. Our finding that
gabapentin decreases affective pain in rodents with traumatic nerve injury highlights the
ability of the CPP approach to predict clinical efficacy. Future reverse translation studies
could investigate whether gabapentin relieves affective pain in a preclinical model of
painful type 2 diabetes, such as db/db or ZDF.
Evoked mechanical hypersensitivity in SNI, but not sham, animals begins to subside
at 15 min, is significantly reduced at 30 min, and is maximally reversed at 60 min after
systemic administration of gabapentin. This efficacy time course is similar to that of Park
et al, where mechanical hypersensitivity alleviation and production of CPP occurs within
30 min of gabapentin administration in cisplatin-treated mice (Park et al, 2013).
Rapid attenuation of both evoked and spontaneous pain-like behavior after injury is
likely due to gabapentin acting on α2δ calcium channel subunits to reduce neuronal
excitability (Kukkar et al, 2013). Our results suggest that 30 min is enough time for
gabapentin to affect α2δ channels at presynaptic terminals. The finding that gabapentin
does not produce CPP or change mechanical thresholds in sham animals may be due to
the finding that expression of α2δ subunits is increased after peripheral nerve injury (Luo
et al, 2002; Nieto-Rostro et al, 2014). Furthermore, we found no effect of gabapentin on
locomotor activity suggesting that adverse effects related to motor and exploratory
activity are not present at the current dose. Effects on exploratory behavior would
confound our conclusion that production of CPP indicates alleviation of spontaneous
pain-like behavior after SNI. This is an important measure that is easily obtained by
monitoring activity during CPP conditioning.
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2.6.2 Methodological considerations in CPP
2.6.2.1 Production of CPP to systemic gabapentin after injury
To our knowledge, Park et al (2013) were the first to investigate CPP to gabapentin
with the notable difference that the neuropathic pain-like model was generated by
administration of the chemotherapeutic cisplatin. Additionally, the authors report that two
but not one day of gabapentin pairing was necessary to produce a preference in cisplatin
but not control mice. Gabapentin was administered systemically (i.p.) at the same dose
used in the current study. They achieved CPP only after two days of conditioning with
vehicle pairing in the morning and drug pairing in the afternoon. In another very recent
study, gabapentin produced CPP in streptozotocin (STZ) diabetic but not naïve mice
indicating, contrary to other reports, that STZ induction of type 1 diabetes produces a
state of ongoing pain (Wagner et al, 2014). Production of CPP to gabapentin in STZ
mice required three conditioning sessions and the authors used a biased approach (i.e.
pairing gabapentin to the least-preferred chamber) because the CPP apparatus showed
initial bias after the preconditioning test. We also used a biased approach while Park et
al counterbalanced their pairings.
It should be noted that even though we used a biased approach, pairings were
indeed counterbalanced because half of the rats received gabapentin in the white
chamber while half were paired with the black, an approach also used by Wagner et al.
Cunningham et al demonstrated that when there is no apparatus bias (i.e. on average,
animals spend equal time in the black and white pairing chambers as in the current
study), then the use of a biased or unbiased chamber-assignment approach does not
affect the ability to produce CPP (Cunningham et al, 2003). Furthermore, the lack of
gabapentin CPP in sham rats (current results) or vehicle-treated mice (Park et al, 2013)
indicates that gabapentin is not intrinsically rewarding. This is important given the abuse
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potential of analgesic drugs such as morphine that produce CPP in naïve, uninjured
animals (Sufka, 1994; Tzschentke, 2007) and Figure 2-5.
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Figure 2-5. Morphine produces conditioned place preference in rats.
Difference scores (postconditioning minus preconditioning time spent in chamber)
for animals that were conditioned with saline vehicle in both chambers (left) or
vehicle in one chamber and morphine in the other (right). Systemic administration of
morphine induced a significant place preference in rats.

2.6.2.2 Constant experimental conditions are critical to yield consistent CPP results
Neither SNI nor sham surgery altered baseline initial preference indicating that our
CPP apparatus is unbiased, which is an important methodological consideration to
eliminate experimental confounds. We were able to replicate very similar baseline values
in SNI animals between Experiment 1 and Experiment 2 even though these studies were
performed six months apart. Our CPP setup includes different tactile cues in the white
and black pairing chambers; therefore, it is important to note that injury alone did not
produce a preference to either tactile cue (grating versus bars) as evidenced by equal
baseline preferences for the white and black chambers. Additionally, preference for a
vanilla (white chamber) or kiwi (black chamber) chapstick olfactory cue was equal in
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sham and SNI rats in both experiments (see Figure 2-6). We were extremely careful to
handle the animals in the same manner within and between experiments and in the
different injury groups. We used eight different CPP boxes and were able to achieve
consistent average baselines between experiments. Although not directly tested, we
should stress that experimental variables such as time of day of testing, handling
method, the way animals are placed into the neutral grey chamber, cleaning boxes
before and after each CPP session, etc. should be highly controlled to achieve
consistent baselines as reported here. Carefully controlled variables will allow easier
replication and increase the predictive value (i.e. sensitivity) of the CPP approach.
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Figure 2-6. Baseline preferences with the addition of a chapstick olfactory cue.
Counterbalanced addition of vanilla and kiwi chapstick to the pairing chambers in
the conditioned place apparatus did not introduce a scent bias, as evidenced by
equal time spent in each vanilla- or kiwi-scented chamber.

2.6.2.3 Minimization of time spent outside the pairing chambers
We cannot ignore the fact that, for whatever reason, conditioning the animals in both
experiments resulted in an increase in time spent in the grey neutral chamber. It is
possible that the stress of vehicle or gabapentin pairing (e.g. i.p. injections, handling,
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cage manipulations) resulted in a slight aversion to the black and white chambers after
conditioning, resulting in increased grey time in postconditioning. However, the negative
reinforcement of pain by the gabapentin unconditioned stimulus was great enough to
overcome any positive associations made to the grey chamber as evidenced by a
significant difference score between saline and gabapentin and no differences between
saline and grey or gabapentin and grey. If anything, part of the gabapentin reward is
masked by the slight increase in grey chamber times indicating that we are
underestimating the magnitude of the effects on motivation to seek pain relief. Another
perspective is that since animals were never placed into the grey chamber after i.p.
injection, this area was less aversive than the white or black chambers, which were
paired with three i.p. injections each during conditioning. A third explanation is that after
three days of conditioning in only the white and black chambers novelty of the grey
chamber was reintroduced during postconditioning. A recent report indicates that
injection of i.p. saline during habituation or preconditioning does not alter production of
CPP and may even increase avoidance of the grey chamber after conditioning (Zhang et
al, 2014). The use of a two chamber apparatus may also overcome this limitation, but
also introduces additional methodological considerations beyond the scope of this
discussion.

2.6.2.4 Expression of CPP after systemic drug administration
The technical challenge to expression of CPP is that the desired effect of the
analgesic drug (i.e. unconditioned stimulus) needs to be rapid so that the animals
associate analgesia with chamber contextual cues (i.e. conditioned stimulus).
Furthermore, differential effects of drugs on evoked versus ongoing pain may contribute
to the failure of injured animals from exhibiting CPP. A negative result (i.e. no expression
of CPP to analgesic drug pairing) indicates that the experiment should be repeated in
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the presence of a positive control (e.g. morphine production of CPP in naïve animals,
clonidine in SNI animals, others).

2.6.3 Conclusions when experiments fail to produce CPP
Several recent studies highlight the differences of analgesic drugs on evoked and
spontaneous pain as assessed by CPP testing. Wei et al (2013) found that the TRPA1
antagonist Chembridge-5861528 alleviates mechanical hypersensitivity but does not
produce CPP in streptozotocin (STZ) treated rats, a model of diabetic neuropathy.
However, the authors were able to produce CPP in SNI animals with intrathecal
clonidine indicating that the CPP method was appropriate. The authors suggest that 15
min of conditioning may not be enough time for drug effects on spontaneous pain (Wei
et al, 2013). In another STZ study, systemic administration of the gabapentin analog
pregabalin alleviated evoked mechanical hypersensitivity but not spontaneous pain as
evidenced by the lack of expression of CPP (Rutten et al, 2011). The authors suggested
that CPP is not suitable for measurement of spontaneous pain in the STZ model.
However, due to the lack of a positive control for the CPP assay, an alternative
explanation is that CPP was not expressed due to methodological concerns, or that STZ
does not invoke a state of ongoing aversiveness in rodents.
Our results suggest that CPP is indeed a predictive tool of the clinical efficacy of
analgesic drugs such as gabapentin for the treatment of spontaneous neuropathic pain.
However, enthusiasm may be diminished by the notion that normal ambulatory behavior
produces a pain-like stimulus evoked by the tactile environment (Bennett, 2012). In other
words, exploratory behavior in the CPP apparatus induces an evoked pain-like state.
This concern is mitigated by the findings of Qu et al, who found that analgesic drugs
produced CPP in axotomized, but not sham, animals. The authors conclude that “these
observations in animals with complete denervation of the hind paw also provide an
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important control, eliminating concerns for pain resulting from tactile stimulation
potentially arising from ambulation within the testing apparatus” (Qu et al, 2011). In
addition, it is unlikely that the low threshold, innocuous stimulation of normal ambulatory,
exploratory movement in the CPP chamber is sufficient to produce ongoing affective
pain.
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CHAPTER 3: Pioglitazone rapidly reduces neuropathic pain through astrocyte
and non-genomic PPARγ mechanisms
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3.1 Abstract
Repeated administration of peroxisome proliferator-activated receptor gamma
(PPARγ) agonists reduces neuropathic pain-like behavior and associated changes in
glial activation in the spinal cord dorsal horn. As PPARγ is a nuclear receptor, sustained
changes in gene expression are widely believed to be the mechanism of pain reduction.
However, we recently reported that a single intrathecal injection of pioglitazone, a
PPARγ agonist, reduced hyperalgesia within 30 minutes, a time frame that is typically
less than that required for genomic mechanisms. To determine the very rapid antihyperalgesic actions of PPARγ activation we administered pioglitazone to rats with
spared nerve injury (SNI) and evaluated hyperalgesia. Pioglitazone inhibited
hyperalgesia within 5 min of injection, consistent with a non-genomic mechanism.
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Systemic or intrathecal administration of GW9662, a PPARγ antagonist, inhibited the
anti-hyperalgesic actions of intraperitoneal or intrathecal pioglitazone, suggesting a
spinal PPARγ-dependent mechanism. To further address the contribution of nongenomic mechanisms, we blocked new protein synthesis in the spinal cord with
anisomycin. When co-administered intrathecally, anisomycin did not change pioglitazone
anti-hyperalgesia at an early 7.5 min timepoint, further supporting a rapid non-genomic
mechanism. At later timepoints anisomycin reduced pioglitazone anti-hyperalgesia,
suggesting a delayed recruitment of genomic mechanisms. Pioglitazone reduction of
SNI-induced increases in GFAP expression occurred more rapidly than expected, within
60 min. We are the first to show that activation of spinal PPARγ rapidly reduces
neuropathic pain independent from canonical genomic activity. We conclude that acute
pioglitazone inhibits neuropathic pain in part by reducing astrocyte activation, and via
both genomic and non-genomic PPARγ mechanisms.

3.2 Introduction
Peroxisome proliferator-activated receptor gamma (PPARγ) is activated by
thiazolidinedione (TZD) drugs such as pioglitazone (Saltiel and Olefsky, 1996) that cross
the blood brain barrier (Maeshiba et al, 1997). TZDs reduce molecular and behavioral
sequelae of many neurological diseases [see (Feinstein, 2003; Kapadia et al, 2008;
Maeda and Kishioka, 2009; Yonutas and Sullivan, 2013)]. It is widely assumed that
genomic PPARγ activity mediates reduction of inflammatory (Oliveira et al, 2007;
Morgenweck et al, 2010) and neuropathic (Maeda et al, 2008; Morgenweck et al, 2013)
pain after repeated TZD dosing. However, agonists for PPARγ and other nuclear
receptors (e.g. estrogen, glucocorticoid, PPARα) can modulate neuronal excitability
(Filardo et al, 2002; Levin, 2008; Joels et al, 2012) and pain (LoVerme et al, 2006; Churi
et al, 2008; Fehrenbacher et al, 2009; Zhang et al, 2012) within minutes. Thus, the anti-
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hyperalgesic effects of nuclear receptor agonists may occur through multiple
mechanisms including: 1) genomic, receptor-dependent transcription/translation, 2) nongenomic, receptor-dependent activation of membrane-bound receptors (Luconi et al,
2010; Rowan et al, 2010; Joels et al, 2012), 3) receptor-independent “off-target” effects
at GPCRs (Maggiolini and Picard, 2010; Nakamoto et al, 2012; Nakamoto et al, 2013).
Traumatic nerve injury produces changes in the spinal cord such as astrocyte
activation (Zhang and De Koninck, 2006; Vega-Avelaira et al, 2007), increased postsynaptic responses to glutamate (Wei et al, 2008), and long-term potentiation (GruberSchoffnegger et al, 2013) resulting in central sensitization (Scholz and Woolf, 2007).
During chronic pain states, activated spinal astrocytes release pro-nociceptive mediators
(Watkins et al, 2001; Ohtori et al, 2004) such as TNFα that facilitate pain sensitization
[for review see (Grace et al, 2014)]; therefore, pharmacotherapeutic approaches that
decrease astrocyte activation may reduce chronic pain. TZDs agonize PPARγ
expressed in spinal cord (Moreno et al, 2004) and brain (Cristiano et al, 2001) astrocytes
to reduce activation (Bernardo and Minghetti, 2008) and GFAP upregulation (Heneka et
al, 2005). Dosing over several weeks produced anti-hyperalgesia that was associated
with reductions in spinal GFAP (Maeda et al, 2008; Jia et al, 2013; Morgenweck et al,
2013), injury-induced pro-inflammatory cytokine expression (Jia et al, 2010), and in vitro
astrocyte TNFα release (Storer et al, 2005; Gurley et al, 2008). A single injection of
PPARγ agonist reduces neuropathic pain (Churi et al, 2008); however, an important gap
is whether there are acute effects on spinal astrocytes.
Here, we characterized the effects of PPARγ activation in neuropathic (spared nerve
injury; SNI) and acute nociceptive (capsaicin) conditions after acute drug administration.
We hypothesized that rapid inhibition of pain by PPARγ agonists is mediated by
receptor-dependent, spinal mechanisms and is independent of translation (i.e. nongenomic). We used systemic and spinal agonist/antagonist administration to determine
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the site of PPARγ anti-hyperalgesia. We investigated pain-like hypersensitivity as early
as 5 min after intrathecal injection of pioglitazone in the presence or absence of
anisomycin, an inhibitor of protein synthesis (Grollman and Walsh, 1967; Frey et al,
1988; Schafe and LeDoux, 2000). Finally, we tested whether a single pioglitazone
injection, as opposed to repeated administration (Morgenweck et al, 2013), would
reduce astrocyte activation in the form of GFAP overexpression after SNI.

3.3 Materials & Methods
3.3.1 Animals
Male Sprague-Dawley rats (CD-IGS, Charles River Laboratories, Inc., Wilmington, MA)
weighing 300-450g at the time of behavioral procedures were housed 2 per cage on a
12-hour light/dark cycle (7am lights on / 7pm lights off) in a temperature (68-72 ºF) and
humidity controlled room with food and water provided ad libitum. All efforts were made
to minimize animal suffering, to reduce the number of animals used, and to utilize
alternatives to in vivo techniques, in accordance with the International Association for the
Study of Pain and the National Institutes of Health Office of Laboratory Animal Welfare
Guide for the Care and Use of Laboratory Animals. All behavioral procedures were
performed between 8am-6pm (lights on) and approved by an Institutional Animal Care
and

Use

Committee

(IACUC)

protocol.

Behavioral

measurements

and

immunohistochemistry quantification were performed by an observer blinded to
experimental treatments (e.g. injury and/or drug).

3.3.2 Spared Nerve Injury (SNI) surgery
Surgical anesthesia was achieved with isoflurane (5% induction and 1.5%
maintenance diluted in oxygen). As previously described (Decosterd and Woolf, 2000;
Taylor et al, 2007), the skin was incised on the left hindlimb over the sciatic nerve
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trifurcation. The overlying muscles were retracted to expose the common peroneal,
tibial, and sural nerves. The common peroneal and tibial nerves were ligated with 6-0
silk (Ethicon, Somerville, NJ) and transected 1mm proximal and 1mm distal to the
ligation. The ligation knot and adjacent nerve were removed. Sural nerve perturbations
were avoided. The muscle and skin were closed with loosely tied 5-0 absorbable sutures
(Ethicon) and 9mm stainless steel wound clips, respectively. During sham surgeries, all
steps were performed except ligation and transection of the common peroneal and tibial
nerves. SNI or sham surgery day is referred to as day 0.

3.3.3 Pain-like behavior.
Animals were acclimated in individual Plexiglas boxes (4” x 8” x 4”) on top of a raised
stainless steel mesh grid (mechanical and cold) or Plexiglas floor (Hargreaves) for 1 h.
Fluctuations in noise, vibrations, temperature, and other distractors in the behavioral
testing room were avoided to optimize reliable measurements between cohorts of
animals tested on different days.
Mechanical hypersensitivity was assessed using von Frey filaments (Stoelting, Inc.,
Wooddale, IL). The lateral aspect of the hindpaw plantar surface (sural receptive field)
was stimulated with an incremental series of 8 monofilaments of logarithmic stiffness
using a modified up-down method (Dixon, 1980; Chaplan et al, 1994). Each filament was
applied to the sural receptive field three times at proximal, intermediate, and distal
locations with respect to the heel. Testing began by applying an intermediate von Frey
monofilament (number 4.31, exerts 2.0 g of force) perpendicular to the glabrous skin,
causing a slight bending. In the case of a positive response (withdraw of the paw) a
filament exerting less force was applied. In the case of a negative response, a filament
exerting greater force was applied. The calculated 50% withdraw threshold is reported.
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Cold hypersensitivity was assessed after application of a drop of acetone to the sural
receptive field. We used a 3 mL syringe attached to an 8 cm length of PE-10 tubing
flared to a diameter of 3.5 mm at the distal end. Surface tension maintained the volume
of the drop to 10-12 μl. The amount of time the animal lifted, shook, or licked the affected
hindpaw was recorded with a cutoff of 30 s after each acetone application. The average
of three trials per subject at each timepoint is reported.
Heat hypersensitivity was assessed by recording paw withdraw latencies using the
Hargreaves method and apparatus (Hargreaves et al, 1988). An adjustable infrared heat
source (8 V, 50 W lamp, Ugo Basile, Italy) was positioned under the Plexiglas floor
directly beneath the uninjured hindpaw. Prior to each behavioral testing session,
intensity was adjusted so that the average latency to paw withdraw was 9 ± 2 s. If an
animal did not respond within 20 s, the radiant beam was shut off to avoid tissue
damage. The average of three trials per subject at each timepoint is reported.

3.3.4 Motor coordination.
Motor coordination was assessed by placing the animals on an accelerating rotarod
(Stoelting, Wood Dale, IL). Beginning at 2 revolutions per minute (rpm), the rotarod
machine was programed to accelerate 0.5 rpm every 5 s until reaching 60 rpm. Animals
were acclimated to the rotarod and subjected to one training session per d for 2
consecutive d prior to drug administration. During training and testing, the rats were
placed on the rotating bar at 2 rpm, the acceleration program was started, and the time
spent on the rotarod prior to fall was recorded. During the first training session, the
animals were repeatedly placed on the rotarod until they performed 3 consecutive trials
≥ 150 s or reached a predetermined cutoff of 20 trials, whichever occurred first. By the
second day of training, all rats successfully completed 3 consecutive trials ≥ 150 s prior
to reaching 20 trials. Baseline measurement of time spent on the rotarod was recorded 7
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d after SNI followed by reassessment at 1, 2, and 3 h after i.p. or i.t. drug administration.
Three trials per timepoint were averaged.

3.3.5 Intracerebroventricular cannulation.
Surgery was performed one week before injury to allow for 5 μl of drug or vehicle
injection directly into the ventricle. Surgical anesthesia was achieved with isoflurane (5%
for induction, 1.5% for maintenance in oxygen). Rats were placed in a stereotaxic
apparatus fitted with blunt ear bars (Stoelting, Kiel, WI). After an incision to expose the
cranium, the dorsal surface of the skull was leveled by zeroing the dorsoventral
coordinate at lambda and bregma. A 26Ga stainless steel guide cannula (Plastics One,
Roanoke, VA) was lowered to the right lateral brain ventricle using the following
stereotaxic coordinates: 0.7 mm posterior to bregma, 1.5 mm lateral from midline and
3.3-4.0 mm below the skull surface (Paxinos and Watson, 1997). Correct placement was
indicated by the observation of the movement of 1µl sterile saline from a piece of PE-10
tubing attached to the cannula into the ventricle (Taylor et al, 1994). The cannula was
fixed to the skull with 3 small screws and dental cement and after suturing the incision a
30 Ga stylet (Plastics One) was secured within the guide cannula.

3.3.6 Drugs
Pioglitazone potassium salt (10028, Cayman Chemical, Ann Arbor, MI) was
dissolved in a 0.9 % saline slurry. GW9662 (70785, Cayman Chemical) was dissolved in
a mixture of ethanol, ethoxylated castor oil, and saline (2:2:6) for i.t. administration and
50% DMSO in saline for i.p. administration. Neither vehicle solution altered pain-like
behavior (see Fig 2). Anisomycin (A9789, Sigma-Aldrich, St. Louis, MO) was first
dissolved in a small volume of 1 M HCl and then an equal volume of 0.9% saline was
added. Next, the solution was titrated with NaOH to obtain a physiological pH of 7.0-7.4.
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Finally, the anisomycin solution was further diluted in saline to a final concentration of 20
mg/ml. Capsaicin (M2028, Sigma-Aldrich) was first dissolved in 100% ethanol (5% final
v/v) followed by addition of a Tween 80 (P1754, Sigma-Aldrich) in saline (8% v/v)
solution to a final capsaicin concentration of 50 mg/ml (w/v). Capsaicin (50 μl) was
injected into the subdermal space between the 2nd and 3rd digits on the ventral plantar
surface using a 30 Ga ½” needle.

3.3.7 Drug Injections
Rats were anesthetized with isoflurane. Vehicle or drug solution (10-20 μl) was
injected into the subarachnoid space using a 27 Ga 1” needle inserted into a stretch of
PE-20 tubing and attached to a Hamilton micro syringe (Mestre et al, 1994). We
confirmed needle placement by both visualization of cerebrospinal fluid aspiration within
the tubing and/or a reflexive tail/hindpaw flick. For systemic pioglitazone studies, i.p. (2
or 10 mg/kg) or i.t. GW9662 (300 µg) was administered 15 min prior to pioglitazone. For
intrathecal pioglitazone studies, GW9662 (300 µg) or anisomycin (0-200 μg) was coadministered with pioglitazone to avoid multiple i.t. injections.

3.3.8 Capsaicin-induced nociception.
Intrathecal vehicle (saline), pioglitazone (0-300 μg), or anisomycin (0-200 μg) were
injected 20 min before intraplantar (i.pl.) capsaicin (50 μg in 50 μl). Behavior was
recorded for 0-2 min following i.pl. capsaicin. The number of flinches and the time spent
licking or lifting (s) the affected hindpaw were combined and reported as the number of
nociceptive responses, where 1 s of licking/lifting is equal to one flinch response
(Seabrook et al, 2002; Lu et al, 2009; Andersson et al, 2013). Sham injections consisted
of capsaicin vehicle as a control. Rats were perfused 60 min following i.pl. capsaicin for
Fos immunohistochemistry.
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3.3.9 Immunohistochemical quantification of Fos and GFAP in the dorsal horn.
Rats were anesthetized with pentobarbital (Fatal Plus, Med-Vet International,
Mettawa, IL) and perfused through the left ventricle with 250 ml of room temperature 0.1
M phosphate buffered saline (PBS) with heparin (10,000 USP units/L) followed by 250
ml of ice-cold fixative (10% phosphate buffered formalin). The lumbar spinal cord was
removed and post-fixed overnight in 10% phosphate buffered formalin and then
cryoprotected in 30% sucrose in 0.1 M PBS for several days. Transverse sections (30
μm) from L4-L5 were cut on a freezing microtome and collected in 0.1 M PBS. The
sections were washed three times in 0.1 M PBS and then pretreated with blocking
solution (3% normal goat serum and 0.3% Triton X-100 in 0.1 M PBS) for 1 h. Sections
were incubated overnight at room temperature in blocking solution containing either
rabbit anti-Fos (1:500, SC-52, Santa Cruz Biotechnology, Santa Cruz, CA) for capsaicin
studies or anti-GFAP (1:1000, ab7779, Abcam, Cambridge, MA) for SNI studies. The
slices were washed three times in 0.1 M PBS, incubated in goat anti-rabbit (1:800, Alexa
488 or 568, Molecular Probes, Grand Island, NY) for 90 min, washed in 0.1 M PBS then
0.01 M PB, mounted onto Superfrost Plus slides, air dried, and cover-slipped using
Prolong Gold with DAPI mounting medium (Molecular Probes, Grand Island, NY).
All images were captured and analyzed on a Nikon Eclipse TE2000-E microscope
using 4x or 10x objectives using NIS-Elements Advanced Research software. In
capsaicin studies we quantified the number of Fos+ cell profiles in lamina I-V of the
dorsal horn. In SNI studies the dorsal horn was separated into lamina I-II, lamina III-IV,
and lamina V as well as medial, central, and lateral regions of interest (ROI). Mediallateral ROI correspond to afferent input from the tibial (medial), common peroneal
(central), and sural (lateral) receptive fields as previously described (Corder et al, 2010).
Each of the six ROI were quantified and analyzed separately. For GFAP, pixel intensity
values were summed, normalized to ROI area, and background subtracted. Background
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intensity was determined by selecting a ROI in the devoid of GFAP+ cells. This method
accounts for changes in both the number and the fluorescence intensity of GFAP+ cells.
Slices were analyzed by an observer blinded to treatment. Quantification of 4-6 slices
per subject was averaged for each ROI and n=3-4 rats per group are reported.

3.3.10 Western blotting of lumbar spinal GFAP.
Western blot analyses were performed on lumbar spinal cord quadrants that were
sonicated on ice in 50 mM Tris buffer containing 100 mM 6-amino-n-caproic acid, 1 mM
EDTA, 5 mM benzamidine, 0.2 mM phenylmethyl sulfonyl fluoride (in 100% ethanol),
and protease inhibitors. After extraction, proteins were subjected to NuPAGE Bis–Tris
(4-12%) gel electrophoresis under reducing conditions (Invitrogen, Carlsbad, CA) and
then transferred to nitrocellulose membranes electrophoretically (Invitrogen, Carlsbad,
CA). Nonspecific binding sites on the membrane were blocked with Odyssey Blocking
Buffer (50%; LI-COR Biosciences, Lincoln, NE) in TBS containing 0.1% Tween-20,
0.05% Tris-Chloride, and 0.03% 5 M NaCl for 1 h at 22-24°C. Membranes were
subsequently incubated with primary antibodies in Odyssey Blocking buffer containing
0.1% Tween-20 overnight at 4°C. The membranes were then washed with PBS
containing 0.1% Tween-20, and probed with appropriate IRDye secondary antibodies
(LI-COR Biosciences) in Odyssey Blocking buffer containing 0.1% Tween-20 for 1 h at
22-24°C, protected from light. Following washing with PBS containing 0.1% Tween-20,
membranes were scanned on an Odyssey Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE). Primary antibodies and dilution ratios used were rabbit GFAP
(1:1000, z0334, Dako, Carpinteria, CA), and mouse β actin (1:100,000, A5316, SigmaAldrich, St. Loius, MO). Secondary antibodies used were goat anti-mouse IRDye 680RD
(1:15,000, LI-COR Biosciences), goat anti-rabbit IRDye 800CW (1:15,000, LI-COR
Biosciences). Bands were quantified using Image Studio (LI-COR Biosciences).
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3.3.11 Statistical analysis.
For analysis of behavioral data and westerns, multiple groups were compared for
significant differences over time using repeated measures two-way ANOVA or between
groups using a standard two-way ANOVA followed by Holm-Sidak multiple comparison
correction. Area-under-the-curve (AUC) was calculated using the trapezoidal method
and analyzed using a one-way ANOVA with Holm-Sidak multiple comparison correction
or an unpaired, two-tailed t-test. Ipsilateral versus contralateral (paired) or pioglitazone
versus saline (unpaired) comparisons of GFAP immunohistochemistry ROIs (6 total
analyses) or GFAP western quadrants were analyzed using a two-tailed t-test. An alpha
value of α=0.05 was used to determine statistical significance. All data were analyzed
and graphed using Prism 6.0 (GraphPad, La Jolla, CA) and are presented as mean ±
SEM.

3.4 Results
3.4.1 Systemic pioglitazone reduces mechanical and cold hypersensitivity
To determine whether PPARγ activation reduces hyperalgesia, we evaluated
behavioral indices of neuropathic pain after a single i.p. injection of pioglitazone. Spared
nerve injury (SNI) decreased mechanical [time; F (1, 37) = 1453; P < 0.0001] and cold
[time; F (1, 37) = 86; P < 0.0001] sensitivities at 14 d after injury. As illustrated in Fig 1AB, systemic pioglitazone attenuated mechanical [dose x time; F (21, 259) = 5.756; P <
0.0001] and cold hypersensitivity [F (21, 259) = 3.485; P < 0.0001]. Area under the curve
(AUC) analyses in Fig 1C-D indicate that pioglitazone dose-dependently attenuated
mechanical [dose; F (3, 37) = 6.747; P = 0.001] and cold hypersensitivity [F (3, 37) =
3.575; P = 0.023].
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3.4.2 PPARγ in the spinal cord mediates the anti-hyperalgesic actions of systemic
pioglitazone
Churi et al. reported that a single intrathecal injection of the PPARγ agonist
rosiglitazone produced anti-hyperalgesia within one hour (Churi et al, 2008). However,
the authors did not test for PPARγ-dependency. To address this gap and test the
hypothesis that PPARγ mediates the acute anti-hyperalgesic effects of i.p. pioglitazone,
we pretreated SNI rats with GW9662, an irreversible PPARγ antagonist (Leesnitzer et al,
2002; Chen et al, 2004). As illustrated in Fig 2A-D, systemic GW9662 (i.p.) prevented
pioglitazone reductions in mechanical [AUC; F (2, 25) = 13.14; P = 0.0001] and cold
[AUC; F (2, 27) = 3.992; P = 0.03] hypersensitivity.
Next we sought to determine whether the anti-hyperalgesic effects of systemic
pioglitazone are mediated through activation of spinal PPARγ. As illustrated in Fig 2E-H,
intrathecal (i.t.) GW9662 attenuated pioglitazone reduction of mechanical [AUC; F (3,
23) = 18.55; P < 0.0001] and cold [AUC; F (3, 23) =12.85; P < 0.0001] hypersensitivity.
Both systemic and spinal administration of GW9226 attenuated the reduction of
mechanical and cold hypersensitivity by administration of systemic pioglitazone.
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Figure 3-1. A single systemic injection of pioglitazone (Pio) dose-dependently
reduced behavioral signs of neuropathic pain.
Spared nerve injury (SNI, arrow) resulted in pain-like hypersensitivity.
Intraperitoneal (i.p.) pioglitazone dose-dependently reversed (A) mechanical and (B)
cold hypersensitivity 14d after SNI. Pain-related behavioral responses to plantar
application of von Frey and acetone stimuli were measured before (0d) and after
(14d) SNI and at 15, 30, 60, 90, 120, 180, and 240 min after intraperitoneal (i.p.)
injection of pioglitazone (0, 10, 30, 100 mg/kg) in saline vehicle. Area under the
curve (AUC) is shown for (C) von Frey and (D) acetone pain-related behaviors. 
“i.p. Pio 100 mg/kg” significantly different from “i.p. Saline”. † “i.p. Pio 30 mg/kg” and
“i.p. Pio 100 mg/kg” significantly different from “i.p. Saline”. “n” are shown in
parentheses.
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180

Figure 3-2. Anti-hyperalgesic actions of systemic pioglitazone are mediated by
spinal PPARγ.
Systemic GW9662 (GW), a PPARγ antagonist, blocked pioglitazone (Pio) reduction
of (A-B) mechanical and (C-D) cold hypersensitivity 14d after SNI. (E-F) Spinal GW
completely abolished pioglitazone reduction of mechanical hyperalgesia and (G-H)
partially blocked pioglitazone alleviation of cold hypersensitivity. GW was
administered i.p. or i.t. 15 min prior to i.p. pioglitazone.  significantly different from
“i.p. GW 10 mg/kg” or “i.p. Pio 100 mg/kg + i.t. GW 300μg”. † significantly different
from “i.p. GW 2 mg/kg” and “i.p. GW 10 mg/kg”. # significantly different from “i.p.
Saline + i.t. Vehicle”. ‘n’ are shown in parentheses.

3.4.3 PPARγ in the spinal cord mediates the anti-hyperalgesic actions of intrathecal
pioglitazone
To support the PPARγ antagonist experiment above in identifying the spinal cord as
a key site of PPARγ anti-hyperalgesic action, we administered pioglitazone and/or
GW9662 by the intrathecal or intracerebroventricular route. Fig 3A demonstrates that i.t.
pioglitazone attenuated mechanical hyperalgesia [dose x time; F (18, 162) = 2.951; P =
0.0001] as rapid as 30 min after injection in a dose-dependent manner. To account for
possible supraspinal activation of PPARγ after i.t. pioglitazone via the cerebrospinal fluid
circulation, we injected the same doses via the intracerebroventricular (i.c.v.) route. We
found no anti-hyperalgesic effect of pioglitazone at these doses [F (3, 21) = 1.959; P =
0.15]. Fig 3B illustrates that co-administration of the PPARγ antagonist GW9662
completely blocked the anti-hyperalgesic actions of i.t. pioglitazone [drug x time; F (18,
198) = 16.26; P < 0.0001].
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Figure 3-3. Spinal PPARγ mediates pioglitazone anti-hyperalgesia.
(A) Intrathecal (i.t.) pioglitazone (Pio) dose-dependently reduced mechanical
hyperalgesia at doses that have no effect when administered by the
intracerebroventricular (i.c.v.) route. (B) Intrathecal co-administration of the PPARγ
antagonist GW9662 (GW) completely reversed pioglitazone anti-hyperalgesia. †
high and medium ‡ high, medium, low dose Pio significantly different from “i.t.
Saline”.  significantly different from “i.t. Saline + i.t. Vehicle”. ‘n’ are shown in
parentheses.

3.4.4 PPARγ activation does not produce motor deficits or analgesia
We determined whether the anti-hyperalgesic actions of pioglitazone might be
confounded by off-target effects on motor systems or transient reflexive pain (Taylor,
2001). Fig 4A-B illustrates that a relatively high dose of pioglitazone did not change
rotarod performance after i.p. [p = 0.81] or i.t. [p = 0.35] injection. Because von Frey

68

mechanical withdraw thresholds are maximal in uninjured rats (e.g. 15 g), we assessed
response latencies to noxious heat to determine if pioglitazone altered acute nociception
in sham rats. Intrathecal pioglitazone did not change heat response latencies [p = 0.5]
suggesting that the effects of PPARγ activation are not analgesic. Together with our
previous reports (Churi et al, 2008; Morgenweck et al, 2010; Morgenweck et al, 2013),
we conclude that reduction of mechanical hyperalgesia by PPARγ agonists is not
secondary to adverse effects on motor coordination or normal sensory thresholds.
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Figure 3-4. Pioglitazone did not produce ataxia or changes in transient
nociception.
Motor coordination was assessed on an accelerating rotarod before and at 1, 2, and
3 h after high dose pioglitazone (Pio) administration by (A) systemic (i.p. 100 mg/kg)
or (B) spinal (i.t. 1000 μg) routes. Pioglitazone did not change time spent on the
accelerating rotarod. (C) The analgesic effects of pioglitazone were tested using the

70

Hargreaves assay before and after intrathecal saline or pioglitazone administration
in sham rats. Pioglitazone did not change paw withdraw latencies to noxious heat. n
= 8-10 per group.

3.4.5 PPARγ agonists rapidly reduce nociceptive and neuropathic pain-like behavior
The above studies illustrate that i.t. administration of pioglitazone reduces tactile
hypersensitivity within 30 min of administration in SNI rats. Consistent with this finding,
intrathecal pioglitazone, compared to saline, reduced nociceptive behavior when given
20 min prior to intraplantar capsaicin (nociceptive responses; 16.3 ± 2.3 vs. 62.2 ± 16.1;
n = 5-6) [p = 0.013]. To test the hypothesis that PPARγ anti-hyperalgesic mechanisms
occur rapidly after traumatic nerve injury, we extended our temporal analysis of pain-like
behavior in the SNI model to earlier time points. Fig 5A-B demonstrates that the PPARγ
agonists rosiglitazone [F (1, 9) = 5.942; P = 0.0375] and pioglitazone [F (1, 8) = 28.24; P
= 0.0007] attenuated SNI-associated mechanical hypersensitivity within 5 min of
injection. We repeated the study with 7.5 min as the first behavioral timepoint to allow full
recovery from isoflurane anesthesia, as evidenced by the slight increase in von Frey
thresholds in the saline control group in Fig 5B. Fig 5C illustrates a robust antihyperalgesic effect of pioglitazone [F (1, 14) =26.62; P = 0.0001] and at the 7.5 minute
timepoint [p < 0.0001] in the absence of a residual anesthetic effect [p = 0.9998]. Our
findings that rosiglitazone and pioglitazone produce anti-hyperalgesia and antinociception within 5-20 min of administration suggest that non-genomic PPARγ
mechanisms mediate rapid reduction of pain-like behavior.
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Figure 3-5. PPARγ agonists rapidly reduce mechanical hyperalgesia.
Intrathecal injection of the PPARγ ligands (A) rosiglitazone (Rosi) or (B) pioglitazone
(Pio) rapidly (within 5 min) reduced mechanical hypersensitivity 14d after SNI.
Intrathecal injections were performed under isoflurane anesthesia, which resulted in
a small anti-hyperalgesic effect at 5 min. Therefore, we repeated the experiment
with 7.5 min the earliest timepoint tested. (C) Pioglitazone rapidly attenuated
mechanical hypersensitivity that lasted from 7.5 to 90 min with no anesthesia effect
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in the saline group.  significantly different from “i.t. Saline”. ‘n’ are shown in
parentheses.

3.4.6 In vivo blockade of protein translation in the dorsal horn by intrathecal anisomycin
To examine whether a translation-independent (i.e. non-genomic) mechanism
mediates the rapid anti-hyperalgesic effects of PPARγ, we administered intrathecal
anisomycin to block protein synthesis in the dorsal horn in vivo at a dose that did not
produce confounding alterations in nociception (Kim et al, 1998). To achieve this, we
evaluated the effect of multiple doses of anisomycin, based on previously used doses of
25 to 125 µg (Schafe and LeDoux, 2000; Parsons et al, 2006; Asiedu et al, 2011; Bonin
and De Koninck, 2014), on capsaicin-induced protein (i.e. Fos) expression. Capsaicin
activates TRPV1-positive primary afferent nociceptors (Brederson et al, 2013) resulting
in spontaneous, dose-dependent pain in humans (Simone et al, 1989). Intraplantar
injection of capsaicin in rodents elicits spontaneous nociceptive behavior (Simone et al,
1987) and induces Fos expression in the superficial dorsal horn within 30 to 90 min
(Hossaini et al, 2010; Beaudry et al, 2011), providing a suitable tool for evaluating effects
of anisomycin on new protein synthesis.
As depicted in Fig 6A, we administered intrathecal pioglitazone and/or anisomycin
twenty minutes prior to evaluation of capsaicin-evoked nociceptive behavior. Sixty
minutes after capsaicin injection, we euthanized animals for quantification of Fos
expression in the L4-L5 dorsal horn. As illustrated in Fig 6B, combinations of capsaicin,
pioglitazone, and anisomycin administration significantly altered Fos expression in
laminae I-V [group; F (7, 17) = 9.38; P < 0.0001]. Compared to vehicle injection,
intraplantar capsaicin increased Fos expression [p = 0.007], an effect that was dosedependently inhibited by pretreatment with 100-200 μg doses of anisomycin [p < 0.05]
but not 50 μg [p = 0.064]. Anisomycin (200 µg) also reduced Fos expression when co-

73

administered with pioglitazone [p = 0.0006]. Pioglitazone did not alter capsaicin-evoked
Fos [p = 0.74] when administered alone.
We offer two explanations for the lack of effect of pioglitazone on spinal Fos
expression even though nociceptive behavior was reduced after intraplantar capsaicin
injection. First, Fos and behavior do not always positively correlate: drug-induced
reduction of pain-like behavior can occur in the absence of (Harris, 1998; Coggeshall,
2005; Gao and Ji, 2009) or with increases in (Orii et al, 2002) Fos expression. Second,
the target of pioglitazone, PPARγ, directly activates c-fos transcription (Rogue et al,
2010). If pioglitazone directly increases Fos expression in inhibitory interneurons, which
can account for a significant population of total cells expressing Fos (Todd et al, 1994),
then this would confound the ability of our Fos method to reflect noxious stimulusevoked spinal neuron activation.

3.4.7 Anisomycin does not alter the anti-nociceptive effects of intrathecal pioglitazone
Having validated that anisomycin reduces protein translation (i.e. Fos) in the dorsal
horn, we used this method to explore the anti-nociceptive and translation-independent
actions of PPARγ activation in the capsaicin model. As illustrated in Fig 6C,
combinations of capsaicin, pioglitazone, and anisomycin administration significantly
altered nociceptive behavior [group; F (7, 35) = 5.476; P = 0.0003]. Intraplantar
capsaicin markedly increased nociceptive behavior when compared to vehicle injection
[p = 0.0055]. Anisomycin alone (50-200 μg) did not alter capsaicin-evoked nociceptive
behavior [p > 0.05]. Pioglitazone reduced nociceptive behavior when administered alone
[p = 0.0029] or in combination with the 200 µg dose of anisomycin [p = 0.0029]. These
results indicate that anisomycin blocks genomic activity (i.e. Fos expression) in the
dorsal horn without altering nociceptive behavior or pioglitazone anti-nociception,
providing proof of principle for this method.
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Figure 3-6. Anisomycin reduces translation of capsaicin-evoked Fos without
blocking the rapid anti-nociceptive actions of pioglitazone.
(A) Experimental timeline to test the hypothesis that capsaicin evoked Fos
translation is inhibited by intrathecal anisomycin pretreatment. (B) Vehicle (0μg
Cap), pioglitazone (Pio), and/or anisomycin (Ani) were co-administered i.t. 20 min
prior to i.pl. capsaicin (50μg). Capsaicin-induced spontaneous licking, lifting, and
flinching nociceptive responses from 0-2 min after injection were almost completely
abolished by pioglitazone (300μg) alone or in combination with anisomycin (200μg)
pretreatment. Anisomycin (50-200μg) alone did not alter capsaicin nociception. (C)
Capsaicin-evoked Fos expression was dose-dependently inhibited by anisomycin
and unaltered by pioglitazone. (D) Sham injection of vehicle produced moderate Fos
expression when compared to (E) i.t. vehicle injections followed by i.pl. capsaicin.
(F) 50μg, (G) 100μg, (H) 150μg, and (I) 200μg anisomycin dose-dependently
reduced Fos. (J) Pioglitazone alone had no effect on Fos expression while (K)
anisomycin completely abolished Fos when co-administered with pioglitazone. 
significantly different from capsaicin only (black bars). n = 3-9 for behavioral and n =
3-4 for Fos analyses.
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3.4.8 Spinal anisomycin does not change the rapid anti-hyperalgesic effects of
pioglitazone
Next we extended spinal anisomycin blockade of translation in the dorsal horn to the
SNI model of neuropathic pain. We began with a dose of anisomycin that, when
administered into the brain, inhibits conditioned taste aversion (Rosenblum et al, 1993),
auditory fear conditioning (Schafe and LeDoux, 2000; Parsons et al, 2006; Parsons et al,
2006), and incorporation of radioactive methionine into nascent proteins (Rosenblum et
al, 1993; Parsons et al, 2006). We found that the 200 µg dose of anisomycin abolished
capsaicin-evoked Fos, but also produced a confounding attenuation of SNI-induced
mechanical hypersensitivity. By lowering the anisomycin dose to 100 µg, we obtained a
significant reduction in Fos without altering SNI-induced hypersensitivity. As illustrated in
Fig 7A, combinations of intrathecal vehicle, pioglitazone, or anisomycin changed
mechanical sensitivity in SNI rats when analyzed across the entire 240 min time course
[drug x time; F (24, 168) = 3.416; P < 0.0001]. Further analysis of the 7.5 - 120 min
timepoints revealed that pioglitazone attenuated mechanical hypersensitivity when
injected alone [vs. Vehicle + Saline; F (1, 9) = 29.41; P = 0.004] or with 100 µg
anisomycin [vs. Vehicle + Saline; F (1, 11) = 5.098; P = 0.045]. At this dose, anisomycin
alone did not inhibit mechanical hypersensitivity [p = 0.54]. To compare the effect of
anisomycin on pioglitazone anti-hyperalgesia at early versus delayed timepoints, we
analyzed the data at each of four timepoints (Fig 7B): before intrathecal injections (predrug), during early pioglitazone anti-hyperalgesia (7.5 min), during late pioglitazone antihyperalgesia (60 min), and after anti-hyperalgesia resolved (180 min). Compared to
intrathecal vehicle, pioglitazone [p = 0.013] and pioglitazone plus anisomycin [p = 0.026]
attenuated hypersensitivity at 7.5 min when compared to intrathecal vehicle only [drug; F
(3, 20) = 5.173; P = 0.008]. By contrast, the delayed anti-hyperalgesic actions of
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pioglitazone at 60 min [p = 0.003 vs. Vehicle + Saline] were significantly reduced by
anisomycin [p = 0.021 vs. Vehicle + Pio].
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Figure 3-7. Early but not late pioglitazone anti-hyperalgesia is independent of
translation.
To test whether immediate PPARγ anti-hyperalgesia is dependent on canonical
genomic activity, we co-administered pioglitazone with an anisomycin dose that
blocks translation but not nociception (100μg; see discussion for details). (A)
Timecourse of mechanical thresholds after i.t. injection of pioglitazone (Pio) or
anisomycin (Ani). (B) Analysis of mechanical thresholds at 7.5, 60 and 180 min
timepoints. Anisomycin did not change the anti-hyperalgesic effects of pioglitazone
at the early 7.5 min period, but reduced pioglitazone anti-hyperalgesia at 60 min.
These results suggest that pioglitazone produces its anti-hyperalgesic effects by
both translation-independent (7.5 min) and translational-dependent (60 min)
mechanisms.  significantly different. ‘n’ are shown in parentheses.
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3.4.9 Acute pioglitazone reduces expression of GFAP after nerve injury
Neuropathic pain is associated with astrocyte activation after nerve injury (Zhang and
De Koninck, 2006). We previously reported that repeated administration of pioglitazone
reduced not only established neuropathic pain, but also astrocyte activation in the dorsal
horn of SNI rats (Morgenweck et al, 2013). To determine whether a single administration
of pioglitazone also reduces astrocyte activation after SNI, we evaluated the protein
expression of GFAP in the lumbar dorsal horn using both immunohistochemistry and
western blot as soon as 60 min.
Similar to previous reports (Zhang and De Koninck, 2006), Fig 8A-B illustrates that
SNI produced a unilateral increase in GFAP expression in the ipsilateral dorsal horn 14d
after injury [ipsi vs. contra; F (1, 12) = 8.55; P = 0.0127]. This occurred in both injured
(tibial and common peroneal) and uninjured (sural) innervation territories [t-test; p <
0.05]. Fig 8C-D illustrates that pioglitazone reduced GFAP expression in the
contralateral and ipsilateral dorsal horn within 60 min of injection [drug; F (1, 8) = 74.93;
P < 0.0001].
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Figure 3-8. Acute PPARγ activation reduces GFAP expression.
(A) Spared nerve injury produced an increase in GFAP expression on the injured
(ipsilateral) side when compared to the uninjured (contralateral) side of the lumbar
dorsal horn. (B) SNI-induced a GFAP increase in injured (tibial and common
peroneal) and uninjured (sural) innervation territories. (C-D) Pioglitazone (100 mg/kg
i.p.; 1 h prior to perfusion) reduced GFAP expression on both the contralateral and
ipsilateral dorsal horn. Each region of interest was analyzed separately using a twotailed t-test. # significantly different from “contralateral” in the “Saline” group
(paired).  significantly different from “Saline” (unpaired). n = 3 per group.

To confirm that the acute reduction of GFAP expression elicited by pioglitazone (Fig
8) did not result from structural changes that mask the GFAP antibody epitope in fixed
tissue, we performed denaturing western blots. At 14 d after sham or SNI surgery, we
administered i.p. pioglitazone, measured behavioral anti-hyperalgesia, and harvested
L4-5 spinal cord quadrants 90 min later. As illustrated in Fig 9A, pioglitazone but not
saline reduced mechanical hyperalgesia in SNI animals [drug; F (1, 10) = 11.17; P =
0.0075] at 60 [p = 0.023] and 90 [p < 0.0001] min after administration. Western blot
analysis of the four lumbar quadrants is reported in Fig 9B (dorsal) and Fig 9C (ventral).
Neither injury [p = 0.58] nor drug [p = 0.33] treatment changed GFAP expression in the
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contralateral dorsal horn. By contrast, we found a significant injury x drug interaction in
the ipsilateral dorsal horn [F (1, 20) = 11.39; P = 0.003]. Post-hoc tests revealed that SNI
increased GFAP expression when compared to sham animals treated with saline [p =
0.0014]. This increase was reduced by pioglitazone in the ipsilateral [p = 0.0026] but not
contralateral [p = 0.54] dorsal horn of SNI animals (Fig 9B). In the contralateral ventral
horn, neither injury [p = 0.14] nor pioglitazone [p = 0.40] changed GFAP expression.
Injury [p = 0.41] or pioglitazone [p = 0.84] did not change GFAP expression in the
ipsilateral ventral horn.

Figure 3-9. SNI is required for pioglitazone reduction of pain and astrocyte
activation.
To determine whether pioglitazone is toxic to astrocytes and to rule out
conformational changes in the GFAP antibody epitope during immunohistochemical
analysis we performed a denaturing western blot. Spinal cord quadrants (L4-5) were
harvested 90 min after i.p. pioglitazone administration at d14 after sham or spared
nerve injury (SNI) surgery. (A) Pioglitazone attenuated mechanical hypersensitivity
in SNI, but not sham, animals. (B) Dorsal and (C) Ventral integrated densities
normalized to Sham + Saline are shown. There was no effect of injury or drug
treatment in the ventral horn or in the contralateral dorsal horn segments. GFAP
expression was increased in the ipsilateral dorsal horn of SNI + Saline animals
when compared to all other groups. Pioglitazone significantly reduced ipsilateral
dorsal horn GFAP expression in SNI, but not sham, animals. This suggests that the
anti-hyperalgesic effects of pioglitazone are associated with decreased astrocyte
activation after nerve injury.  significantly different from “SNI + Saline”. n=6-7 per
group.
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3.5 Discussion
3.5.1 Anisomycin to assess translation-independent activity of nuclear receptors in the
spinal cord
Here we used in vivo administration of anisomycin to dissect genomic versus nongenomic mechanisms of a nuclear receptor in the spinal cord. Previous studies using
anisomycin suggested that protein translation is necessary for late phase LTP in the
brain (Krug et al, 1984; Frey et al, 1988), hyperalgesic priming in the peripheral nervous
system (Asiedu et al, 2011), ongoing pain transmission in the spinal cord (Kim et al,
1998), and reduction of established hyperalgesia during pain memory reconsolidation in
the spinal cord (Bonin and De Koninck, 2014). As these studies did not confirm inhibition
of translation, we found it important to demonstrate that intrathecal anisomycin inhibits
spinal protein expression. We found that anisomycin, at a dose of 100 µg, decreased
expression of capsaicin-evoked Fos without changing SNI-induced hyperalgesia. This
provides proof of principle for using this approach to determine the contribution of nongenomic PPARγ mechanisms to the rapid and delayed phases of pioglitazone antihyperalgesia.

3.5.2 Non-genomic PPARγ activity mediates the early anti-hyperalgesic effect of
pioglitazone
Based on our finding that the anti-hyperalgesic effect of pioglitazone occurred very
rapidly (7.5 min) and this was maintained in the presence of 100 μg anisomycin, we
suggest the involvement of a non-genomic PPARγ mechanism. Non-genomic
mechanisms in the dorsal horn might also explain the rapid anti-hyperalgesic effects
observed after interruption of other nuclear receptors including estrogen and PPARα
receptors. For example, in vivo administration of 17β-estradiol rapidly (within 15 min)
enhanced bradykinin-induced hyperalgesia (Rowan et al, 2010) and inhibited opioid
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receptor-like 1 anti-nociception (Small et al, 2013): these were unaffected by
pretreatment with anisomycin or conjugation of 17β-estradiol to membrane-impermeable
BSA (Rowan et al, 2010; Small et al, 2013) suggesting that membrane estrogen
receptors contribute to rapid pain modulation. Also, the inhibition of neuropathic pain
(within 30 min) by the PPARα agonists PEA and GW7647 (Costa et al, 2008) was
abrogated in PPARα knockout mice or by pharmacological blockade of calcium-activated
potassium channels (Lo Verme et al, 2005; LoVerme et al, 2006; Costa et al, 2008)
suggesting both rapid and PPARα-dependent analgesic actions. We speculate that, in a
similar manner, the rapid anti-hyperalgesic effect of pioglitazone is mediated by
membrane PPARγ that is linked to ion channel activity, neuronal excitability, and/or
central sensitization mechanisms.

3.5.3 Genomic PPARγ activity mediates the late anti-hyperalgesic effects of
pioglitazone
We found that anisomycin significantly reduced the anti-hyperalgesic effects of
pioglitazone at later time points (60 minutes), supporting a contribution of classical
genomic mechanisms involving transcription and translation. This is consistent with
several reports indicating that repeated pioglitazone administration produced sustained
anti-hyperalgesic actions persisting for days to weeks after cessation of drug
administration (Takahashi et al, 2011; Morgenweck et al, 2013), beyond the time
necessary for drug clearance (Maeshiba et al, 1997). Similarly, our current results and
previous studies (Park et al, 2007; Churi et al, 2008; Morgenweck et al, 2010) indicate
that a single TZD injection produces anti-hyperalgesia lasting for several hours, much
longer than the half-life of pioglitazone (Maeshiba et al, 1997). In summary, our results
suggest pioglitazone anti-hyperalgesia transitions from a rapid, anisomycin–resistant
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mechanism to a delayed, anisomycin-sensitive mechanism within approximately 60
minutes.

3.5.4 The anti-hyperalgesic effect of pioglitazone is mediated by spinal PPARγ
PPARγ agonists reduce tactile hypersensitivity after nerve injury, but the site(s) of
action and selectivity of these agents remain elusive. Here, systemic or spinal
pioglitazone decreased nerve injury-induced tactile hypersensitivity, and this effect was
lost when given in the presence of intrathecal GW9662. We conclude that PPARγ in the
dorsal horn of the spinal cord contributes to the anti-hyperalgesic effects of pioglitazone.
This is consistent with previous studies showing that: 1) PPARγ is expressed in the
lumbar spinal cord (Churi et al, 2008; Maeda et al, 2008); 2) hyperalgesia after SNI was
exacerbated

by

intrathecal

administration

of

the

PPARγ

antagonist

BADGE

(Fehrenbacher et al, 2009); and 3) intrathecal GW9662 inhibited the anti-hyperalgesic
effect of both repeated systemic or single intrathecal administration of rosiglitazone or
15d-PGJ2 (Churi et al, 2008; Morgenweck et al, 2013). It is unlikely that brain PPARγ
mediates anti-hyperalgesia after intrathecal pioglitazone, because i.c.v. administration of
comparable doses had no effect; this is consistent with previous results showing that low
i.c.v. doses of rosiglitazone or 15d-PGJ2 (Churi et al, 2008) did not change tactile
hypersensitivity.
Our studies do not rule out “off-target” effects that might contribute to rapid
pioglitazone anti-hyperalgesia. Gras et al (2009) reported that rosiglitazone-stimulated
calcium mobilization was lost after GPR40 siRNA knockdown, suggesting that TZDs (i.e.
PPARγ agonists) may activate GPR40 (Gras et al, 2009). Activation of GPR40, which is
expressed in brain (Ma et al, 2007; Ma et al, 2008) and spinal cord neurons (Nakamoto
et al, 2012), by endogenous (DHA) and exogenous (GW9508) ligands reduced
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inflammatory pain (Nakamoto et al, 2012; Nakamoto et al, 2013). Thus GPR40 is an
intriguing target for future studies.

3.5.5 Pioglitazone acutely inhibits astrocyte activation
We previously reported that repeated pioglitazone administration spanning several
weeks reduced GFAP in the dorsal horn (Morgenweck et al, 2013). Here we observed
the same result in a timeframe of just 60 minutes following a single dose of pioglitazone,
leading us to speculate that astrocytes contribute to rapid anti-hyperalgesia
mechanisms. This might be PPARγ-dependent, since markers of astrocyte activation are
reduced by other PPARγ agonists (Storer et al, 2005; Gurley et al, 2008).
Our results are not the first to describe that an acute intervention (i.e. pioglitazone)
can alter astrocyte function. For example, increases in GFAP expression occur as soon
as 30 min after electrical stimulation of primary afferents (Wang et al, 2010) or
intraplantar injection of CFA (Wang et al, 2010) or snake venom toxin sPLA2-Asp49
(Chacur et al, 2004). Second, the astrocyte toxins l-α-aminoadipate and fluorocitrate
reduced neuropathic pain and GFAP expression within 30 to 60 min of administration
(Zhuang et al, 2006; Wei et al, 2008). Third, fluorocitrate prevented the early phase of
TNFα-induced long term potentiation (LTP) in the ex vivo spinal cord (GruberSchoffnegger et al, 2013). Therefore, based on the current finding that pioglitazone
reduced GFAP in the dorsal horn, we propose that pioglitazone inhibits the astrocytic
release of neuron-sensitizing molecules that contribute to LTP and, ultimately, the
maintenance of chronic neuropathic pain. Indeed, pioglitazone reduced the release of
TNFα from astrocytes in culture (Storer et al, 2005).
Our results do not rule out a supraspinal component to the anti-hyperalgesic actions
of systemically-administered pioglitazone. This hypothesis is suggested by the findings
that: 1) in models of CNS injury, pioglitazone reduced mitochondrial dysfunction (Hunter
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and Bing, 2007; Hunter et al, 2008; Sauerbeck et al, 2011; Yonutas and Sullivan, 2013)
and promoted glucose metabolism in astrocytes (Dello Russo et al, 2003; Pancani et al,
2011); 2) pioglitazone reduced Aβ-induced astrocyte activation in the hippocampus
(Heneka et al, 2005); 3) PPARγ is expressed in cortical astrocytes (Cristiano et al, 2001;
Moreno et al, 2004); 4) astrocytes in the anterior cingulate cortex facilitate pain
sensitization and inhibition (Chen et al, 2012; Ikeda et al, 2013; Grace et al, 2014;
Yamashita et al, 2014). This provides for the possibility that systemic pioglitazone
administration produces anti-hyperalgesia through cortical, in addition to spinal,
astrocytic mechanisms.
Investigations of nerve injury-induced activation of astrocytes in areas of the dorsal
horn innervated by injured versus uninjured afferents are sparse (Zhang and De
Koninck,

2006;

Beggs

and

Salter,

2007;

Corder

et

al,

2010).

Here,

our

immunohistochemical quantification method (Corder et al, 2010) revealed that nerve
injury increased GFAP expression in regions of the ipsilateral dorsal horn innervated by
both injured tibial afferents (medial) and uninjured sural afferents (lateral). This is
consistent with qualitative studies showing that astrocyte activation extends beyond
injured territories (Beggs and Salter, 2007), and suggests that astrocytes induce
hyperalgesia by sensitizing intact nociceptive pathways.
Validation of immunohistochemical results with a complementary approach is
essential because IHC assays can be misinterpreted due to drug or injury-induced
cytotoxic changes in the conformation and/or the formalin sensitivity of the GFAP
epitope (i.e. epitope masking) (Bell et al, 1987; Eng et al, 2000). We chose an approach
involving a denaturing western blot, and the results indicate that pioglitazone does not
change GFAP expression in sham animals, nor on the contralateral side in SNI animals,
nor in the ventral horn in sham or SNI animals. This not only suggests that astrocyte
viability is preserved after pioglitazone injection, but also that epitope masking does not
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confound our conclusion that a single injection of pioglitazone exerts anti-hyperalgesic
actions in part by reducing astrocyte activation.

3.5.6 Conclusions
Our results indicate that pioglitazone acts at spinal PPARγ to inhibit astrocyte
activation and to produce fast-acting, dose-dependent, and translation-independent
inhibition of pain-like hypersensitivity after traumatic nerve injury. The specific
mechanisms of rapid pain reduction by PPARγ and the involvement of astrocytes
warrant further investigation. Our studies do not rule out actions of PPARγ agonists in
the peripheral nervous system (Maeda et al, 2008; Takahashi et al, 2011) that would
reduce spinal sensitization, but do illustrate an important behavioral and neurobiological
role for non-genomic inhibition of pain in the spinal cord by a nuclear receptor.

86

CHAPTER 4: Pioglitazone inhibits the development of hyperalgesia and
sensitization of spinal nociresponsive neurons in type 2 diabetes
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4.1 Abstract
Thiazolidinedione drugs (TZDs) such as pioglitazone are FDA-approved for the
treatment of insulin resistance in type 2 diabetes. However, whether TZDs reduce
painful diabetic neuropathy (PDN) remains unknown. Therefore we tested the
hypothesis that chronic administration of pioglitazone would reduce PDN in Zucker
Diabetic Fatty (ZDFfa/fa) rats. Compared to Zucker Lean (ZLfa/+) controls, ZDF developed:
(1) elevated blood glucose, HbA1c, methylglyoxal and insulin; (2) mechanical and
thermal hyperalgesia at the hindpaw; (3) increased avoidance of noxious mechanical
probes in a mechanical conflict avoidance behavioral assay, the first report of a measure
of affective-motivational pain-like behavior in ZDF; and (4) exaggerated lumbar dorsal
horn immunohistochemical expression of pressure-evoked phosphorylated extracellular
signal-regulated kinase (pERK). Seven weeks of pioglitazone (30 mg · kg-1 · d-1 in food)
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reduced blood glucose, HbA1c, hyperalgesia, and pERK in ZDF. This is the first report to
reveal hyperalgesia and spinal sensitization in the same ZDF animals, both evoked by a
noxious mechanical stimulus that reflects pressure pain frequently associated with
clinical PDN. As pioglitazone provides the combined benefit of reducing hyperglycemia,
hyperalgesia, and central sensitization, we suggest that TZDs represent an attractive
pharmacotherapy in patients with type 2 diabetes-associated pain.

4.2 Introduction
Approximately one-third of patients with diabetes experience pain (Davies et al,
2006; Abbott et al, 2011; Lee-Kubli et al, 2014), commonly referred to as painful diabetic
neuropathy (PDN) (Vincent et al, 2011). A majority of preclinical PDN studies focus on
the streptozotocin (STZ) model of type 1 diabetes (Calcutt et al, 2009). However, 90% of
diabetic patients are type 2 (World Health Organization), the prevalence of PDN is
greater in patients with type 2 (Van Acker et al, 2009; Abbott et al, 2011), and pain
mechanisms in type 1 versus type 2 likely differ (Schmidt et al, 2003; Schmidt et al,
2004; Kamiya et al, 2005; Schuelert et al, 2015). Therefore we chose to study a genetic
model of type 2 PDN, the Zucker Diabetic Fatty (ZDFfa/fa) rat (Clark et al, 1983).
Hyperglycemia develops within 6-10 wks of age (Clark et al, 1983; Li et al, 2006;
Brussee et al, 2008; Sugimoto et al, 2008) in ZDF but not Zucker Lean (ZLfa/+) controls,
and is followed by behavioral correlates of PDN, including hypersensitivity to mechanical
(Roane and Porter, 1986; Zhuang et al, 1997; Brussee et al, 2008; Sugimoto et al, 2008;
Otto et al, 2011; Vera et al, 2012; Galloway and Chattopadhyay, 2013) and thermal
(Roane and Porter, 1986; Li et al, 2006; Rong and Ma, 2011; Galloway and
Chattopadhyay, 2013) somatosensory stimulation. However, conflicting studies report
either hypoalgesia (Sugimoto et al, 2008; Shevalye et al, 2012) or hyperalgesia (Roane
and Porter, 1986; Zhuang et al, 1997) in similarly aged ZDF. This raises concerns
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regarding examination of sensory thresholds at just a single age without regard to the
developmental stage of diabetes (Roane and Porter, 1986; Zhuang et al, 1997; Li et al,
2006; Brussee et al, 2008; Shevalye et al, 2012), or omission of ZL controls when
multiple ages are assessed (Otto et al, 2011). These deficiencies in the literature led us
to rigorously evaluate multiple pain-like behaviors in ZDF and ZL at various ages in a
well-controlled study.
We hypothesized that spinal cord plasticity contributes to pain in type 2 diabetes
because: (1) hyperalgesic db/db mice exhibit dorsal horn increases in both
phosphorylated extracellular signal-regulated kinase (pERK) (Dauch et al, 2012; Xu et
al, 2014), a marker of nociresponsive neuron activation (Gao and Ji, 2009) in the spinal
dorsal horn (Ji et al, 1999; Zhuang et al, 2005; Morgenweck et al, 2013), and the
astrocyte activation marker GFAP (Liao et al, 2011; Dauch et al, 2012; Ren et al, 2012;
Xu et al, 2014); (2) intrathecal injection of either the ERK phosphorylation inhibitor
U0216 (Xu et al, 2014) or the astrocyte toxin L-α-aminoadipate (Liao et al, 2011)
reverses hyperalgesia; and (3) augmented NMDA and AMPA receptor expression and
function in the spinal cord (Li et al, 1999) may contribute to hyperalgesia in ob/ob mice
(Latham et al, 2009). A recent report indicated that spinal neurons in ZDF exhibit central
sensitization in response to non-noxious hindpaw stimulation (Schuelert et al, 2015).
However, concurrent evaluation of pain-like behavior was not performed. We go beyond
these studies by evaluating spinal plasticity in PDN using a clinically relevant noxious
pressure stimulus to evoke not only pERK in the spinal dorsal horn but also behavioral
hyperalgesia in the same subjects.
Thiazolidinedione drugs (TZDs) such as pioglitazone (Actos®) are approved by the
U.S. Food and Drug Administration for the treatment of type 2 diabetes. TZDs also
reduce the molecular and behavioral sequelae of neurological disease (Feinstein, 2003;
Kapadia et al, 2008), as well as neuropathic pain associated with brain (Sauerbeck et al,
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2011; Yonutas and Sullivan, 2013), spinal cord (Park et al, 2007; McTigue, 2008) or
nerve (Churi et al, 2008; Maeda et al, 2008; Takahashi et al, 2011; Morgenweck et al,
2013; Griggs et al, 2015) injury. For example, we recently reported that pioglitazone
reduced hypersensitivity to non-noxious mechanical stimulation in rats with traumatic
nerve injury (Morgenweck et al, 2013). However, it still remains unclear whether TZDs
reduce the neuropathic pain associated with type 2 diabetes (Taylor, 2015). In addition,
behavioral signs of PDN in rodents are more frequently associated with hypersensitivity
to noxious, rather than non-noxious stimulation. To address these gaps, we tested the
hypothesis that chronic administration of Actos® would prevent the development of
noxious pressure-evoked hyperalgesia and spinal central sensitization in ZDF rats.

4.3 Materials and Methods
4.3.1 Subjects
Experiments were carried out in accordance with the Institutional Animal Care and
Use Committee at the University of Kentucky (Approved Protocol # 2009-0429). All
efforts were made to minimize animal suffering, to reduce the number of animals used,
and to utilize alternatives to in vivo techniques, in accordance with the International
Association for the Study of Pain (Zimmermann, 1983) and the National Institutes of
Health Office of Laboratory Animal Welfare Guide for the Care and Use of Laboratory
Animals.
Male ZL and ZDF rats (http://www.criver.com/products-services/basic-research/finda-model/zucker-diabetic-fatty-(zdf)-rat, Charles River, Wilmington, MA) aged 4-19 weeks
were used for all experiments. “Obese” ZDF rats are homozygous for the loss-of-function
“fatty” mutation in the leptin receptor (fa/fa) that results in the development of type 2
diabetes (Clark et al, 1983). “Lean” ZL rats are heterozygous (fa/+), do not develop a
diabetic phenotype, and are genetic controls for ZDF. All rats were housed in a
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temperature- and humidity-controlled room on a 12 hour light – 12 hour dark cycle with
lights on from 7:00am to 7:00pm. Prior to any behavioral or dietary manipulations, all
rats were provided water and Formulab 5008 (TestDiets, Purina Mills, Richmond, IN)
chow ad libitum. Formulab 5008 (formerly Purina 5008) food yields reliable diabetic
symptoms including hyperglycemia, hyperlipidemia, impaired glucose tolerance and
insulin insensitivity as reported by Charles River.

4.3.2 Measurement of Blood Glucose & HbA1c
Blood was collected at sacrifice for the measurement of MG-AGE and insulin at 19
wks of age in the Characterization of PDN study, and for the measurement HbA1c both
before (12 wks) and after (19 wks) drug treatment in the Pioglitazone Administration
study. Blood glucose was measured at weekly intervals in both studies. The
experimental designs for these studies are described below.
Rats were lightly restrained in a towel and the distal tail wiped with an alcohol swab.
A small nick was made at the distal tip of the tail using a #11 scalpel blade. Initial
bleeding was wiped clean with gauze and subsequent drops of blood were either loaded
into a room temperature HbA1c cartridge and analyzed using a DCA Vantage Analyzer
(Siemens, Munich, Germany), or placed on a glucose test strip in triplicate and inserted
into a glucose monitor (TrueTrack, Walgreens, Deerfield, IL). To avoid perturbations in
pain-like behavior elicited by fasting or exogenous glucose administration in a tolerance
test (Dobretsov et al, 2001; Dobretsov et al, 2003), non-fasted blood glucose was
measured. A random blood glucose level greater than 200 mg/dL (11.1 mmol/L) was
defined as hyperglycemia (Sacks, 2011). We measured blood glucose at the same time
each week to minimize circadian-induced fluctuations.
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4.3.3 Pain-Like Behavior: Stimulus-Evoked
Fluctuations in noise, vibrations, temperature, and other distractors in the behavioral
testing room were minimized to optimize reliable measurements between cohorts of
animals tested during different behavioral sessions. To further reduce variability and
acclimate animals to the different testing apparatuses, two weeks of training were
performed prior to behavioral measures reported at 8 weeks of age.
Heat hyperalgesia was assessed by placing the animals on a heated surface (52.5 ±
1 °C) within an acrylic enclosure (Hotplate; Columbus Instruments, Columbus, OH). The
time until a hindpaw withdraw response (e.g. jumping, licking, flicking) occurred was
recorded. The animal was immediately removed after the withdraw response or at a
cutoff of 30 s to avoid tissue injury. Three trials, with an inter-trial interval of at least 5
min, were averaged for each time point.
Mechanical hyperalgesia was measured using the Randall Selitto method (Randall et
al, 1957) with slight modification to accommodate an electronic device with a force
transducer (IITC Life Science Inc., Woodland Hills, CA). The thoracic body and head
were lightly restrained in a towel with both hindpaws exposed. To start, one hindpaw
was placed into the calipers with the blunted-point of the force transducer placed on the
plantar surface between the 2nd and 3rd digits. The force exerted on the surface of the
hindpaw by the blunted-point was gradually and uniformly increased until a withdraw
reflex occurred. Animals were not required to vocalize. The gram force required to elicit
a withdraw response was recorded. Because patients report increased responsiveness
to repeated mechanical stimuli (Otto et al, 2003), we used multiple trials per time point to
assess pressure hyperalgesia. The force until paw withdraw was measured three times
for each hindpaw and then averaged together, as there was no significant difference in
left versus right withdraw thresholds. The combined average of hindpaw withdraw
thresholds is reported at each timepoint.
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Cold hyperalgesia was assessed by placing the animal on a cooled surface (4ºC ±
0.5ºC) within an acrylic enclosure (Coldplate; IITC Life Science Inc., Woodland Hills, CA)
for five minutes. The combined number of nociceptive responses (e.g. jumping, licking,
flicking) for both hindpaws during the 5 min period is reported (Jasmin et al, 1998).

4.3.4 Pain-Like Behavior: Affective-Motivational
To assess the affective-motivational component of pain, we utilized a novel
Mechanical Conflict Avoidance System (MCS) (Lau et al, 2012). MCS gives animals the
option to remain in a start chamber containing an aversive light stimulus or choose to
cross a chamber containing an aversive mechanical stimulus in the form of heightadjustable, blunted probes. If animals chose to leave the light chamber and cross the
probes in the stimulus chamber, they then had the option to enter a darkened reward
chamber. MCS behavioral testing began at 17 wks of age and consisted of three stages:
familiarization, training, and testing. The latency to exit the light chamber was used as a
measure of avoidance of the mechanical stimulus, and therefore a measure of affectivemotivational pain-like behavior.
Familiarization – 1 day. Animals were placed in the light chamber with the light off;
access to the stimulus chamber was restricted by a closed guillotine door. After 15 s of
darkness, the light was turned on. After 20 s of light exposure, the guillotine door was
raised and the animal was free to explore the entire apparatus, including the dark
chamber, for 5 min. The animal was then returned to the homecage.
Training – 4 days. Animals were trained to move from the light chamber, through the
stimulus chamber at a probe height of 0 mm (i.e. no probes), and into the dark chamber.
Animals were placed in the light chamber with the light off; access to the stimulus
chamber was restricted by a closed guillotine door. After 15 s of darkness, the light was
turned on. After 20 s of light exposure, the guillotine door was raised and a timer started
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to measure the latency to exit the light chamber. If the animal did not exit the light
chamber within 30 s, the guillotine door was closed and the animal was returned to its
homecage. Upon entering the dark chamber, a second guillotine door was closed to
restrict the animal to the dark chamber. Animals remained in the dark chamber for 45 s
to reinforce the crossing of the stimulus chamber and then were returned to the
homecage. Each animal underwent four training trials on each of the four training days.
Testing – 3 days. Assessment of the latency to exit in the presence of varying
degrees of mechanical stimulus (1, 3, 4 mm) was initiated at 18 wks of age. Each testing
day began with 1 trial in the absence of a stimulus (0 mm) followed by 3 trials with the
probes raised to a predetermined height: 1 mm (d 1), 3 mm (d 2), 4 mm (d 3). The
training procedure described above was also used for testing in either the absence (trial
1) or presence (trials 2-4) of mechanical probes in the stimulus chamber. Only one probe
height was tested per day. Assessment at the 0 mm probe height was used to confirm
that animals were still trained to cross the stimulus chamber.
Animals remained in their home cage for at least 10 min between training and testing
trials. All four paws were required to leave the light chamber to determine the latency to
exit. The average of 4 trials for each training day or 3 trials for each testing probe height
is reported for each animal.

4.3.5 pERK Quantification via Immunohistochemistry
Upon general anesthesia with isoflurane (5% induction, 1.5% maintenance), the
plantar surface between the 2nd and 3rd digits of the left hindpaw was stimulated with 110
g of constant force for 30 s per minute over a 5 min period. These stimulus parameters
were chosen to mimic those used to elicit withdraw responses to noxious pressure as
described above for mechanical hyperalgesia testing. Ten minutes after initiating
pressure stimulation, animals were perfused through the left ventricle with 250 ml of
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room temperature 0.1 M phosphate buffered saline (PBS) with heparin (10,000 USP
units/L) followed by 250 ml of ice-cold fixative (10% phosphate buffered formalin). The
lumbar spinal cord was removed and post-fixed overnight in 10% phosphate buffered
formalin and then cryoprotected in 30% sucrose in 0.1 M PBS for several days.
Transverse sections (30 μm) from L4-L5 were cut on a freezing microtome and collected
in 0.1 M PBS. The sections were washed three times in 0.1 M PBS and then pretreated
with blocking solution (3% normal goat serum and 0.3% Triton X-100 in 0.1 M PBS) for 1
h. Sections were then incubated in blocking solution containing the primary antibodies
rabbit anti-pERK (1:250, #4370, Cell Signaling Technology, Danvers, MA) and Alexa
Fluor 488 conjugated mouse anti-NeuN (1:200, MAB377X, EMD Millipore, Billerica, MA)
overnight at room temperature on a slow rocker in the dark. The sections were washed
three times in 0.1M PBS, and incubated in goat anti-rabbit secondary antibody (1:800,
Alexa 568, Molecular Probes, Grand Island, NY) for 90 min, washed in 0.1M PBS, 0.01M
PBS, then 0.01M PB, and non-sequentially mounted onto Superfrost Plus slides, air
dried, and cover-slipped with Prolong Gold with DAPI mounting medium (Molecular
Probes). 4-6 high quality sections were randomly selected for quantification.
All images were captured on a Nikon Eclipse TE2000-E microscope using a 10x
objective and analyzed using NIS-Elements Advanced Research software. We focused
our quantification of the number of pERK immunopositive cell profiles within lamina I-II,
where the majority of C-fibers and nociceptive peripheral afferents terminate within the
dorsal horn (Basbaum et al, 2009; Corder et al, 2010). Colabeling of pERK with NeuN is
expressed as the percentage of the total number of pERK profiles in laminae I-II also
expressing NeuN. Each spinal cord slice was analyzed by an observer blinded to
treatment. The average of n=5-6 animals per group is reported.
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4.3.6 Quantification of Methylglyoxal-Derived Advanced Glycation End-Products (MGAGEs)
MG-AGEs

were

quantified

using

a

competitive

ELISA

according

to

the

manufacturer’s instructions (STA-811, Cell BioLabs, San Diego, CA). This ELISA uses a
primary antibody that recognizes the hydroimidazolone (H1) moiety created by the
modification of protein residues by methylglyoxal (Ahmed, 2003). Whole blood taken
from the left ventricle prior to transcardial perfusions was collected in serum separator
tubes (SST™, BD Biosciences, Franklin Lakes, NJ) and allowed to clot for 30 min.
Clotted blood in SSTs was centrifuged at 5000 x g for 10 min at 4ºC and the serum was
transferred to fresh microcentrifuge tubes and stored at -80ºC until MG-H1 ELISA
analysis. Serum samples were diluted 1:2 in 0.1 M PBS to obtain concentrations in the
span of the standard curve.

4.3.7 Insulin Quantification via ELISA
Non-fasted insulin levels were quantified by ELISA according to the manufacturer’s
recommendations (EMD Millipore; EZRMI-13K; Darmstadt, Germany) from serum
obtained as described above in serum separator tubes (SST™, BD Biosciences) at time
of sacrifice.

4.3.8 Pioglitazone Incorporation into Food
Actos® (pioglitazone hydrochloride; Takeda Pharmaceuticals U.S.A., Inc., Deerfield,
IL) was obtained from the University of Kentucky pharmacy in 30 mg tablets of 25%
purity, and was incorporated into Formulab 5008 rat chow (TestDiets, Purina Mills,
Richmond, IN). Average body weight and food consumption (Saitoh et al, 2007) were
used to determine the concentration of Actos in chow required to achieve a dosing of 30
mg pioglitazone / kg body weight / day. For ZDFs the concentration of Actos in chow
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was 0.16% (catalog no. 5W01) and for ZLs the concentration was 0.207% (catalog no.
5W02). Food was provided ab libitum and consumption and body weights were
monitored in order to calculate actual dosing.

4.3.9 Experimental Design: Characterization of PDN
To determine the time course of development of pain-like behavior, we monitored ZL
and ZDF rats weekly from 4 to 18 weeks of age with n=12 per group. Weekly
measurement of pain-like behaviors occurred on Monday thru Friday in the following
order: coldplate, pressure, hotplate. Assessment of pain-like behaviors occurred prior to
determination of blood glucose and mass at 2-4pm on Fridays. Animals were not fasted
in order to minimize the potential effects of fasting on pain-like behavior. At least one day
separated coldplate and hotplate determinations to avoid cross-modality sensitization.
After behavioral and metabolic outcomes were assessed at 18 wks, the left hind paws of
control and diabetic rats were stimulated, using the same pressure device used to
determine behavioral hyperalgesia, in order to evoke pERK. Next, cardiac blood was
taken prior to transcardial perfusion and fixation, and then tissues were harvested for
subsequent assays.

4.3.10 Experimental Design: Pioglitazone Administration
Rats were divided into the following treatment groups using a 2x2 experimental
design: ZL Vehicle (n=10), ZL Pioglitazone (n=10), ZDF Vehicle (n=10), ZDF
Pioglitazone (n=9). Vehicle food was defined as unaltered Formulab 5008 chow.
Pain-like behaviors, blood glucose, and weight were measured weekly from 10 to 19
wks of age. HbA1c was measured at 12 and 19 wks. Vehicle or pioglitazone food
treatment began after assessment of behavioral and metabolic outcomes at 12 wks and
all further testing was performed by an observer blinded to drug treatment group. Food
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consumption was measured 3 times per week by calculating the mass difference
between food added to the cage and food remaining in the cage then dividing by 2, as
rats were housed in pairs, and the number of days that had lapsed between food
additions. After outcome measurements were obtained during week 19, animals were
pressure-stimulated to evoke pERK, perfused and fixed with buffered formalin for
immunohistochemical analyses of spinal cords.
One rat from the ZDF Pioglitazone group was removed from all analyses prior to
beginning pioglitazone administration due to an abnormally high baseline blood glucose
level of 514 mg/dL (more than double all other animals). Because the phenotype for
coldplate responses in ZDF was modest, we did not assess the effect of pioglitazone on
cold hypersensitivity.

4.3.11 Statistical Analysis
Mass, glucose, hotplate, pressure, coldplate, and MCS were compared using a
repeated measures two-way ANOVA followed by Holm-Sidak multiple comparison
correction. To compare ZL vs. ZDF, the outcome measures insulin, MG-AGE, HbA1c,
and area-under-the-curve (AUC; calculated via the trapezoidal method) were analyzed
using an unpaired, two-tailed t-test. To compare ZL vs. ZDF and vehicle vs. pioglitazone,
the outcomes HbA1c and AUC were analyzed via a two-way ANOVA followed by HolmSidak multiple comparison correction. Ipsilateral vs. contralateral or pioglitazone vs.
vehicle comparisons of pERK immunohistochemistry in ZL vs. ZDF were analyzed by
two-way ANOVA followed by Holm-Sidak multiple comparison correction. A value of
α=0.05 was used to determine statistical significance. All data were analyzed and
graphed using Prism 6.0 (GraphPad, La Jolla, CA) and are presented as mean ± SEM.
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4.4 Results
4.4.1 The ZDF Rat is a Model of Progressive Painful Diabetic Neuropathy
When compared to control heterozygotes or wild-types, only ZDF rats homozygous
for the fatty (fa/fa) leptin receptor mutation develop cardinal symptoms of glucoseintolerant diabetes (Clark et al, 1983) including hyperphagia (Saitoh et al, 2007; Otto et
al, 2011), hyperinsulinemia (Munoz et al, 2001; Sugimoto et al, 2008; Li et al, 2014),
obesity (Otto et al, 2011), hyperglycemia (Piercy et al, 1999; Otto et al, 2011; Vera et al,
2012), elevated HbA1c (Sugimoto et al, 2008; Li et al, 2014), and increased MG-AGE
(Shevalye et al, 2012). In the first experiment we characterized the progression of
hyperglycemia and pain-like behavior in diabetic ZDF and control ZL rats. As illustrated
in Figure 1A-C, ZDF had elevated mass [strain x time; F (14, 308) = 8.249; P < 0.0001]
from 4 to 18 wks [p < 0.01], elevated blood glucose [strain x time; F (14, 308) = 46.31; P
< 0.0001] from 8 to 18 wks [p < 0.0001], and elevated serum insulin [p = 0.0009] at 19
wks.
Advanced glycation end-products (AGEs) such as methylglyoxal (MG) derived
hydroimidazolone (MG-H1) are associated with diabetic pain in patients (Sveen et al,
2013). MG-AGEs result from the accumulation of MG (Illien-Junger et al, 2015), a
metabolite of glucose found in blood that is elevated in type 2 diabetes (Kender et al,
2014) and exacerbated in patients and mice with PDN (Bierhaus et al, 2012). Therefore
we measured MG-AGE levels and hemoglobin glycation in the form of HbA1c, an AGE
considered by clinicians to be the ‘gold standard’ diagnostic for diabetes (Sacks, 2011).
Figure 1D indicates that 19 wk old ZDFs had elevated blood levels of MG-AGE [p <
0.05]. In a separate group of subjects, Figure 1E indicates that 12 wk-old ZDFs had
elevated blood levels of HbA1c [p < 0.0001]. Thus, consistent with the literature, we
found that ZDFs exhibited: (1) obesity after weaning that persisted until the conclusion of
the study; (2) hyperglycemia beginning at 6 wks of age that progressively increased
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throughout the study; (3) hyperinsulinemia, elevated MG-AGE, and elevated HbA1c
levels at 12 wks.
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Figure 4-1. ZDF rats develop a type 2 diabetes phenotype.
(A) Body mass (n=12) and (B) blood glucose levels (n=12), serum (C) insulin (n=6)
at 19 wks, (D) methylglyoxal-derived advanced glycation end-products (MG-AGE;
n=3) at 19 weeks and (E) HbA1c at 12 weeks of age (n=10) in Zucker Diabetic Fatty
(ZDF) and Zucker Lean (ZL) controls. * p < 0.05, ZDF vs. ZL.
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To rigorously evaluate the ZDF rat as a behavioral model of PDN, we measured not
only evoked responses to noxious stimuli over an extended time course, but also signs
of affective pain. First, to assess stimulus-evoked hyperalgesia, we measured responses
to noxious mechanical and thermal stimuli. Figure 2A-B illustrates that ZDFs were
hypersensitive to a noxious hotplate [strain; F (1, 22) = 14.2; P = 0.0011] at 15, 17, and
18 weeks of age [p < 0.05], exhibiting an overall decrease in heat response threshold
from 14 to 18 wks [AUC; p < 0.05]. Figure 2C-D illustrates that ZDFs were
hyperresponsive to noxious mechanical pressure [strain x time; F (10, 220) = 6.045; P <
0.0001] from 15 to 18 wks [p < 0.001], exhibiting an overall decrease in pressure
threshold from 14 to 18 wks [AUC; p < 0.0001]. Figure 2E-F illustrates that ZDFs
exhibited more hindpaw responses in a coldplate test [strain x time; F (10, 220) = 2.372;
P = 0.0110] at 18 wks [p < 0.01], with an overall increase from 14 to 18 wks [AUC; p <
0.001].
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Figure 4-2. ZDF rats develop hyperalgesia.
Paw withdraw responses to (A-B) heat, (C-D) pressure, and (E-F) cold stimuli in ZL
and ZDF rats. Area under the curve (AUC) analyses for 14-18 wks are shown. n=12
per group. * p < 0.05, ZDF vs. ZL.

Preclinical research targeting the mechanisms of PDN primarily relies on stimulusevoked behavioral outcomes (Obrosova, 2009). However, PDN symptoms include not
just pressure and thermal hyperalgesia but also aching, paresthesia/dysesthesia, and
affective pain (Liberman et al, 2014). To our knowledge there are no reports of affective
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pain in a rodent model of type 2 diabetes (Lee-Kubli et al, 2014). To address this gap
and determine whether ZDFs possess the affective-motivational component of PDN that
is most relevant to diabetic patients, we utilized a mechanical conflict-avoidance system
(MCS) (Morrow and Harte, 2010; Donahue et al, 2012; Lau et al, 2012) as shown in
Figure 3A. Figure 3B illustrates that illustrates that during the four training trials when no
pins were present (0 mm probe height), latency to exit the light chamber was similar
between ZL and ZDF rats (p > 0.05), indicating no differences in light aversion or learned
motivation/ability to find the dark chamber. Despite contrasting results in an open field
test, where we (unpublished findings; R.B. Griggs et al, 2013) and others (JiménezAranda et al, 2013) found diminished locomotor activity in ZDF, exploration in a novel
open field environment is not equitable to behavioral training to seek the dark chamber
in MCS. Raising the probe height produced an increase in the latency to exit the light
chamber [strain x probe height; F (6, 102) = 4.262; P = 0.0007] in ZL at 4 mm (vs. 1 mm;
p = 0.0051) and in ZDF at both 3 mm (p < 0.0001) and 4 mm (p < 0.0001) heights,
indicating aversion to the mechanical stimulus in both control and diabetic rats.
Importantly, the latency to exit the light chamber was higher in ZDF compared to ZL at
both 3 mm (p = 0.0493) and 4 mm (p < 0.0001) heights, indicating that diabetes
potentiates the avoidance of a noxious mechanical stimulus.
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Figure 4-3. Diabetes increases the avoidance of mechanical probes.
(A) Diagram of the mechanical conflict avoidance system (MCS) used as a measure
of affective-motivational pain in ZL and ZDF rats. MCS behavioral testing began at
17 wks of age and consisted of three stages: familiarization (1 d), training (4 d), and
testing (3 d). Familiarization: Animals were initially placed in the light chamber and
allowed free access to explore the entire MCS apparatus. Training: Animals were
trained to move from the light chamber, through the stimulus chamber with
mechanical probes set to a height of 0 mm (i.e. no probes), and into the dark
chamber. Each animal underwent four training trials on each of the four consecutive
training days. Testing: Animals were placed in the light chamber and allowed to
cross the stimulus chamber at probe heights of 1 mm, 3 mm, and 4 mm. Each
animal was tested for 3 trials at each probe height with only one probe height tested
on each of the three testing days. (B) The latency to exit the light chamber (latency)
in ZL and ZDF rats is shown for the 4 d of training (left) and 3 d of testing (right).
The latency was similar in the absence of mechanical probes (probe height = 0 mm)
during training and at a 1 mm probe height during testing. Raising the testing probe
height increased the latency in ZL at 3 mm and ZDF at 3 and 4 mm. The latency
was greater in ZDFs compared to ZLs at the 3 and 4 mm probe height. n=9-10. * p <
0.05. † p<0.05 vs. ZL at 1mm. ‡ p<0.05 vs. ZDF at 1 mm.

Central sensitization is defined as the increased responsiveness of nociceptive
neurons in the central nervous system to their normal or subthreshold afferent input
(Woolf, 2011). As an example, expression of phosphorylated extracellular signalregulated kinase (pERK) in the dorsal horn is exacerbated by light touch stimulation after
peripheral nerve injury (Morgenweck et al, 2013) or inflammation (Gao and Ji, 2010) but
not uninjured controls, and is therefore an important marker of spinal central
sensitization (Gao and Ji, 2009). To test the hypothesis that diabetes results in central
sensitization, we evaluated noxious pressure-evoked phosphorylation of ERK (pERK) in
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dorsal horn neurons. We chose pressure as the evoking stimulus because it is a
hallmark pain modality in PDN patients (Otto et al, 2003). Figure 4A shows that unilateral
stimulation of the tibial receptive field produced unilateral pERK within the superficial
laminae of the dorsal horn. pERK was restricted to the side ipsilateral to stimulation and
was predominantly located within the medial extent of the dorsal horn, respecting
previously-described somatotopic boundaries of tibial nerve anatomy (Swett and Woolf,
1985; Corder et al, 2010). Figure 4B shows representative images indicating that pERK
predominantly colabeled with NeuN, an established immunohistochemical marker for
neurons (Kim et al, 2009). The percentage of pERK cell-profiles that colabeled with
NeuN was (mean ± SEM): ZL contralateral (81.5 ± 6.5), ZL ipsilateral (88.3 ± 3.6), ZDF
contralateral (80.5 ± 3.1), ZDF ipsilateral (92.1 ± 1.3). The degree of colocalization was
similar between ZL and ZDF at either contralateral [p = 0.93] or ipsilateral [p = 0.89]
dorsal horns. Figure 4C illustrates that pressure increased pERK in ZL [ipsilateral vs.
contralateral; p < 0.0001] and ZDF rats [p < 0.0001]. Diabetes exacerbated this increase
[ZDF vs. ZL; ipsilateral only; p = 0.001], and there was an interaction between Strain and
Stimulation [F (1, 20) = 8.051; P = 0.0102].

Figure 4-4. Diabetes exacerbates noxious pressure-induced activation of
dorsal horn neurons.
Pressure-evoked phosphorylation of ERK and colabeling with NeuN in the L4/5
dorsal horn at 18 wks of age in ZL and ZDF rats. Representative images of pERK
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(A) in the stimulated (ipsilateral) or unstimulated (contralateral) side and (B)
colabeling with the neuronal marker NeuN in the medial portion of the ipsilateral
lumbar dorsal horn after pressure stimulation. (C) Quantification of cell-like profiles
labeled with pERK in laminae I-II. n=6. † p<0.05 vs. ZL ipsilateral. ‡ p<0.05 vs. ZDF
ipsilateral. * p<0.05. Scale bars = 100 µm.

4.4.2 Chronic Administration of Oral Pioglitazone Reduces Pathological Signs of
Diabetes
Numerous reports indicate that oral administration of pioglitazone or rosiglitazone
reduces hyperglycemia in db/db mice (Takahashi et al, 2015), ZDF rats (Piercy et al,
1999), and humans (Patel et al, 1999; Aronoff et al, 2000; Xu et al, 2015) as well as
HbA1c levels in ZDF (Watanabe et al, 2015) and diet-induced type 2 diabetes (Ibrahim
et al, 2015). To confirm that pioglitazone alleviated signs of type 2 diabetes in ZDF, we
measured blood glucose and HbA1c. The average dose of pioglitazone (mg · kg-1 · d-1)
received by ZL (35.53 ± 1.94) and ZDF (32.19 ± 2.52) was similar over the 7 wk
treatment period, and was comparable to previous studies in db/db mice (4 wks of 30 mg
· kg-1 · d-1) (Takahashi et al, 2015) and ZDF rats (6 wks of 10 mg · kg-1 · d-1) (Watanabe
et al, 2015). As illustrated in Figure 5A, pioglitazone decreased blood glucose in ZDF [F
(1, 18) = 16.51; P = 0.0007] but not in ZLs [F (1, 18) = 3.51; P=0.077] from 13 to 19 wks
of age. Figure 5B illustrates that blood levels of HbA1c were elevated in ZDF rats at 19
wks of age [p < 0.0001], even greater than observed at 12 wks (Fig 1E). Pioglitazone
normalized HbA1c levels in ZDF to the level of ZL [p < 0.0001].
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Figure 4-5. Pioglitazone reduces pathological signs of type 2 diabetes.
Effect of vehicle or pioglitazone (administered in food, yellow bar) on blood levels of
(A) glucose (n=9-10) from 11 to 19 wks and (B) HbA1c (n=9-10) at 19 wks of age in
ZL and ZDF rats. ‡ p<0.05 vs. both ZL groups. † p<0.05, ZDF Pioglitazone vs. ZDF
Vehicle. * p<0.05.

4.4.3 Chronic Oral Pioglitazone Inhibits the Development of PDN and Reduces Evoked
pERK
Hyperalgesia develops in ZDF at approximately 14 wks of age (Fig 2). To test the
hypothesis that pioglitazone prevents the development of hyperalgesia, we initiated its
administration at 12 wks of age. As illustrated in Figure 6A-B, ZDF exhibited lower heat
response thresholds as compared to ZL [strain x time; F (8, 144) = 2.039; P = 0.0458]
from 13 to 19 wks. Pioglitazone temporarily normalized heat thresholds in ZDF [F (1, 17)
= 22.09; P = 0.0002] from 13 to 15 wks [p < 0.01], and then heat hypersensitivity
returned at 16 wks. Figure 6C-D illustrates that ZDF exhibited a decrease in pressure
response thresholds compared to ZL [strain x time; F (8, 144) = 2.178; P = 0.0324] from
11 to 19 wks [p < 0.05]. Pioglitazone normalized pressure thresholds in ZDF [drug; F (1,
17) = 104.9; P < 0.0001] throughout the duration of treatment, from 13 to 19 wks [p <
0.05]. Further studies are needed to investigate the differential effect of pioglitazone on
heat and noxious mechanical sensitivity. In addition, we speculate that pioglitazone
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would reduce cold hypersensitivity as we recently reported that pioglitazone reduced the
development of

63

and reversed

30

hyperresponsivitiy to acetone in the spared nerve

injury model of neuropathic pain.
Because we began pioglitazone administration prior to the development of
hyperalgesia, further intervention studies are needed to determine if the mechanism of
pioglitazone antihyperalgesia is independent from its reduction of hyperglycemia. This
may indeed be the case, since we found that a single intraperitoneal injection of
pioglitazone, given after the development of hyperalgesia in ZDF, reversed heat
hypersensitivity without changing blood glucose levels (unpublished data, R.R. Donahue
et al, 2014).
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Figure 4-6. Pioglitazone attenuates pain-like behavior.
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Effect of vehicle or pioglitazone in food (yellow bar) on the development of (A-B)
heat and (C-D) mechanical hyperalgesia (n=9-10). Pioglitazone inhibits the
development of heat and mechanical hyperalgesia in ZDF. ‡ p<0.05 ZDF Vehicle
vs. all other groups. * p<0.05.

To determine whether chronic pioglitazone treatment reduces spinal nociresponsive
neuron activation, we quantified pERK after noxious mechanical stimulation of the
hindpaw. Figure 7A-B illustrates that noxious pressure evoked greater pERK in vehicletreated ZDF as compared to ZL [p = 0.0006]. Pioglitazone but not vehicle normalized
pERK in ZDF [p = 0.011] but not ZL [p = 0.96]. There was an interaction between Strain
and Drug [F (1, 19) = 6.048; P = 0.0237].

Figure 4-7. Pioglitazone attenuates dorsal horn neuron activation.
Noxious pressure-evoked pERK in the lumbar superficial dorsal horn of ZL and ZDF
rats at 19 wks of age following a 7 wk treatment with vehicle or pioglitazone
administered in chow. (A) Representative images of pERK immunostaining. (B)
Pioglitazone reduced pERK in ZDFs to the level of ZLs. n=5-6. * p<0.05. Scale bar =
100 µm.

4.5 Discussion
4.5.1 ZDFs Develop Multiple Types of Pain-Like Behavior
Consistent with previous reports, ZDFs developed mechanical (Roane and Porter,
1986; Zhuang et al, 1997; Li et al, 2006; Brussee et al, 2008; Sugimoto et al, 2008; Otto
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et al, 2011; Rong and Ma, 2011; Vera et al, 2012; Galloway and Chattopadhyay, 2013),
heat (Roane and Porter, 1986; Li et al, 2006; Rong and Ma, 2011; Galloway and
Chattopadhyay, 2013), and cold hyperalgesia (Rong and Ma, 2011) at 14 to 18 wks of
age (Otto et al, 2011; Vera et al, 2012; Galloway and Chattopadhyay, 2013), results
which we replicated in two separate cohorts. In contrast, a comparatively small number
of ZDF studies report either mechanical hypoalgesia (Shevalye et al, 2012), heat
hypoalgesia (Sugimoto et al, 2008; Shevalye et al, 2012; Vera et al, 2012), no difference
in heat (Brussee et al, 2008) or pressure (Piercy et al, 1999) response thresholds, and/or
pressure hyperalgesia prior to hyperglycemia (Romanovsky et al, 2008). Discrepancies
in heat responses could be due to differences in the stimulus type: we used a hotplate
while other studies used an infrared beam directed at the tail (Sugimoto et al, 2008) or
hindpaw (Brussee et al, 2008; Shevalye et al, 2012; Vera et al, 2012).
A recent review of preclinical models of PDN highlights the need to establish indices
of spontaneous/affective pain (Lee-Kubli et al, 2014). One study used conditioned place
preference (CPP), an assay that has re-emerged (Sufka, 1994) as a leading preclinical
measure of tonic pain in rats (King et al, 2009) and mice (He et al, 2012), to reveal
affective pain in type 1 diabetic STZ mice in the absence of an evoking stimulus
(Wagner et al, 2014). Here, we discovered that type 2 diabetes exacerbates the
avoidance of a noxious mechanical stimulus. Unlike CPP, where presumed relief of nonevoked affective pain reinforces a chamber preference, MCS utilizes the avoidance of an
evoked stimulus as a measure of the motivational component of pain. Our results
demonstrate for the first time the existence of a motivational-affective component of PDN
in a preclinical model of type 2 diabetes.
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4.5.2 ZDFs Develop Central Sensitization in Spinal Dorsal Horn Neurons
The dorsal horn is a key site of nociceptive integration (Basbaum et al, 2009)
including central sensitization after tissue or nerve injury (Woolf, 2011). A recent
electrophysiological study in ZDF spinal cord slices indicated that non-noxious
mechanical stimulation increased afterdischarges and spontaneous activity of dorsal
horn neurons (Schuelert et al, 2015). However, the authors did not investigate pain-like
behavior and they analyzed dorsal horn neurons at 32-34 wks, after ZDF aged 26 wks
are reported to be hypoalgesic (Lee-Kubli et al, 2014). Thus, at this advanced diabetic
stage, it is unclear whether central sensitization contributed to painful diabetic
neuropathy. In our study using younger ZDF, we resolved this uncertainty by evaluating
both behavioral hypersensitivity and stimulus-evoked pERK in the same subjects.
We are the first to demonstrate both pain-like behavior and elevated spinal neuron
activation in ZDF. Both of these results were observed in response to a noxious
mechanical stimulus, and this fits with the clinical manifestations of PDN: up to 71% of
patients (Otto et al, 2003) report hyperalgesia in response to application of a similar,
static, noxious pressure stimulus (Wienemann et al, 2012) used in the current study on
ZDF. By contrast, Schuelert et al reported that spinal neurons were not sensitized to
noxious mechanical stimuli (Schuelert et al, 2015). Albeit, our results provide strong
evidence in support of the hypothesis proposed by Schuelert et al that central
sensitization contributes to hyperalgesia in type 2 diabetes (Schuelert et al, 2015). If
true, then therapies aimed at reducing central sensitization could alleviate PDN. Indeed,
spinal administration of MEK inhibitors, which prevent phosphorylation of ERK,
attenuated hyperalgesia in db/db (Xu et al, 2014) and STZ (Ciruela et al, 2003) models.
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4.5.3 Pioglitazone Reduces Pathological Signs of PDN in ZDF by Actions at PPARγ
Several lines of evidence lead us to speculate that activation of spinal peroxisome
proliferator-activated receptor gamma (PPARγ) mediated the antihyperalgesic actions of
pioglitazone reported here in ZDF. First, spinal sites are rich in PPARγ expression
(Moreno et al, 2004; Churi et al, 2008; Maeda et al, 2008) and pioglitazone crosses the
blood-brain barrier (Maeshiba et al, 1997). Second, intrathecal administration of PPARγ
antagonists inhibits the antihyperalgesic effect of both repeated systemic or single
intrathecal administration of PPARγ agonists (Churi et al, 2008; Morgenweck et al, 2013;
Griggs et al, 2015). Alternatively, non-PPARγ mechanisms can be proposed for the
antihyperalgesic effects of pioglitazone in PDN. Pioglitazone inhibits HMGB1-RAGE
signaling in spinal neurons (Wang et al, 2014) and reduces plasma RAGE (Ibrahim et al,
2015), both of which are implicated in the pathogenesis of neuropathic pain in models of
traumatic nerve injury (Feldman et al, 2012) and PDN (Ren et al, 2012; Hidmark et al,
2014). Whether pioglitazone reduces the contribution of spinal gliosis and/or HMGB1RAGE signaling to PDN remains an important direction of future studies.
Our current results suggest that pioglitazone decreases central sensitization to
reduce PDN in type 2 diabetes. In support of this idea, chronic oral pioglitazone (at the
same 30 mg · kg-1 · d-1 dose used in the current study) reduced non-noxious stimulusinduced mechanical allodynia and spinal pERK in a traumatic nerve injury model of
neuropathic pain (Morgenweck et al, 2013). Our results extend this finding by showing
that pioglitazone reduces spinal pERK following a different stimulus (noxious pressure)
and in a different neuropathic pain model that is associated with disease (type 2
diabetes).
Our studies aimed to evaluate whether ZDF exhibited hyperalgesia alongside spinal
sensitization and whether this could be reduced by a TZD, and therefore the focus was
not on peripheral mechanisms. However, several studies suggest that pioglitazone can
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inhibit peripheral mechanisms of chronic pain: 1) PPARγ is expressed in sciatic nerve
(Yamagishi et al, 2008); 2) TZDs decreased hyperalgesia, proinflammatory cytokine
expression, and macrophage infiltration in sciatic nerve after nerve injury (Maeda et al,
2008; Takahashi et al, 2011); 3) Pioglitazone reduced macrophage infiltration and pERK
in the sciatic nerve of STZ rats (Yamagishi et al, 2008); 4) Pioglitazone reduced pERK in
sciatic nerve of db/db mice (Dasu et al, 2009); and 5) Rosiglitazone and resolvin D1
coadministration to the site of hindpaw incision in db/db mice promotes a M2
macrophage phenotype and reduces mechanical hypersensitivity (Saito et al, 2015).
Future studies in preclinical models of type 2 PDN could investigate the effect of local
TZD administration to the peripheral nerve (Takahashi et al, 2011; Hasegawa-Moriyama
et al, 2012) on: macrophage polarization (Hasegawa-Moriyama et al, 2012); TNFα,
which is elevated in patients with PDN (Uceyler et al, 2007; Purwata, 2011); nerve
conduction velocity, which is decreased in type 2 diabetes (Brussee et al, 2008); and
pain-like behaviors.

4.5.4 Pioglitazone Reduces PDN Independent of its Anti-Hyperglycemic Action
Although we found that hyperglycemia preceded pain-like behavior as it does in type
2 diabetic patients (Abbott et al, 2011), we propose that pioglitazone reduces PDN
independent of its simultaneous reduction of blood glucose. This is based on several
lines of evidence. First, pioglitazone and other PPARγ agonists reduce neuropathic painlike behavior in normoglycemic animals after various routes of administration including:
repeated oral (Maeda et al, 2008; Morgenweck et al, 2013) or intraperitoneal (Maeda et
al, 2008; Takahashi et al, 2011; Hasegawa-Moriyama et al, 2012; Morgenweck et al,
2013); local injection to the injured sciatic nerve (Takahashi et al, 2011) or incised paw
(Hasegawa-Moriyama et al, 2012); or a single spinal (Park et al, 2007; Churi et al, 2008;
Morgenweck et al, 2010; Griggs et al, 2015) or brain (Morgenweck et al, 2010) injection.
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Second, numerous drugs can reduce PDN without reducing hyperglycemia in patients
with PDN, including tapentadol (Schwartz et al, 2011) or the FDA-approved PDN
medications duloxetine and pregabalin (Mendell and Sahenk, 2003; Smith and Argoff,
2011). Furthermore, the antioxidant taurine (Li et al, 2006), aldose reductase inhibitors
(Calcutt et al, 2004; Ramos et al, 2007; Obrosova, 2009), insulin growth factor (Zhuang
et al, 1996; Zhuang et al, 1997), or poly-ADP-ribose inhibitors (Obrosova et al, 2005;
Obrosova et al, 2008; Drel et al, 2010) reduce hyperalgesia in animal models of PDN
without inhibiting hyperglycemia. Consistent with these findings, pioglitazone normalized
peripheral nerve conduction velocities without affecting hyperglycemia in the STZ model
(Yamagishi et al, 2008). Third, mechanical hyperalgesia that is not associated with
hyperglycemia has been reported in ZDFs, which suggests that hyperalgesia can be
independent from blood glucose levels (Romanovsky et al, 2008). Finally, it is important
to note that normalization of blood glucose alone cannot reverse the neurotoxic effects
resulting from long-term hyperglycemia (Tomlinson and Gardiner, 2008) that contribute
to PDN (Vincent et al, 2011).
The results from this pretreatment study are clinically important as they suggest that
pre-diabetic patients could benefit from adjuvant treatment with pioglitazone or an
alternative PPARγ agonist in addition to recommended lifestyle changes such as diet
and exercise. This is supported by preclinical studies indicating that TZD treatment prior
to or coinciding with peripheral nerve injury are quite effective at reducing hyperalgesia
(Maeda et al, 2008; Takahashi et al, 2011; Morgenweck et al, 2013). Further study is
needed to definitively dissociate the antihyperglycemic and antihyperalgesic effects of
targeting PPARγ with pioglitazone. For example, alternative agonists such as 15d-PGJ2
that alleviate neuropathic pain (Churi et al, 2008) without alteration of glucose or HbA1c
could be tested in ZDF. Also, we could test a “control” drug that normalizes glucose
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metabolism without affecting hyperalgesia or investigate whether administration of
glucose to pioglitazone-treated ZDF could reinstate hyperalgesia.

4.5.5 Conclusions and Future Directions
The current results are the first to demonstrate in a preclinical model of type 2
diabetes that pioglitazone prevents the development of not only pain-like behavior but
also noxious stimulation-evoked central sensitization – within the same subjects. We go
beyond the use of non-noxious von Frey hairs to evaluate spinal sensitization in ZDF
(Schuelert et al, 2015) or nerve injury (Morgenweck et al, 2013) by evoking spinal pERK
and hyperalgesia using a clinically relevant pressure stimulus (Otto et al, 2003). Our
results extend the potential efficacy of pioglitazone from resolving neuropathic pain after
traumatic nerve injury to the growing problem of PDN.
Alternative strategies using other TZDs or related therapies may bypass the human
safety risks of pioglitazone (Lewis et al, 2011). First, the non-TZD PPARγ agonists
FK614 (Minoura et al, 2007), MBX-102 (Chandalia et al, 2009; Gregoire et al, 2009), or
MDG548 (Lecca et al, 2015) reduce insulin insensitivity, hyperglycemia, and
inflammation and are neuroprotective (Lecca et al, 2015). Second, TZDs (Geldenhuys et
al, 2010; Yonutas and Sullivan, 2013) or the novel ligand TT01001 (Takahashi et al,
2015) reduce diabetic mitochondrial dysfunction by targeting the mitochondrial protein
mitoNEET, which is thought to alleviate other neurological diseases (Feinstein et al,
2005; Yonutas and Sullivan, 2013). Finally, a multiple drug strategy, such as
coadministration of pioglitazone with canagliflozin (Watanabe et al, 2015) or geraniol
(Ibrahim et al, 2015) might reduce diabetes without the adverse effects of adipocyte
differentiation, fat deposition, and weight gain associated with pioglitazone-only
treatment. PDN patients may also benefit from other diabetic drugs such as metformin,
which reduces peripheral neuropathic pain (Mao-Ying et al, 2014) and PDN in STZ rats

115

(Byrne et al, 2015; Ma et al, 2015), as well as decreases hyperglycemia, HbA1c, and
MG in patients with type 2 diabetes (Kender et al, 2014). Future clinical studies could
investigate whether the above treatments or other PPARγ-directed therapies alleviate
both hyperglycemia and neuropathic pain, as simultaneous inhibition is necessary to
maximize quality of life in type 2 diabetic patients.

4.6 Supplemental Data & Discussion
4.6.1 Pioglitazone produces weight gain and hyperphagia.
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Figure 4-8. Pioglitazone increases food consumption and weight in both ZL
and ZDF.
Both (A) mass and (B) food consumption were increased within one week of
beginning pioglitazone administration.

In Figure 4-8 we illustrate that chronic oral administration of pioglitazone produced
an increase in food consumption that presumably led to exacerbated weight gain in both
ZL and ZDF. Hyperphagia and obesity did not change the average dose received by ZL
and ZDF during the period of administration (see 0). Weight gain and edema are
consistent with the known side effects of TZDs. Figure 4-9 illustrates that the same dose
of pioglitazone (30 mg/kg/d) modestly increased weight gain in nerve injured SpragueDawley rats. It appears that the increase in weight gain is exacerbated by type 2
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diabetes, as 7 wks of pioglitazone treatment resulted in SNI animals weighing roughly
450 g while ZDF were almost 700 g. These results indicate that weight gain should be
monitored during long-term pioglitazone treatment and that future studies could
investigate ways to reduce TZD-associated weight gain.
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Figure 4-9. Pioglitazone effect on weight gain in Sprague-Dawley rats after
traumatic nerve injury.
Data courtesy of Renee Donahue.
Pioglitazone administration in food began 7 d prior to spared nerve injury (SNI). (A)
Pioglitazone modestly increased weight gain at 6-7 weeks after beginning
administration at the same dose (30 mg/kg/d) used to treat PDN in ZDF. (B)
However, pioglitazone did not increase the weight when analyzed using area-underthe-curve calculation for 0 to 42 d after SNI. * p<0.05 Pio 30 vs. Vehicle. † p<0.05
Pio 30 and Pio 3 vs. Vehicle.

4.6.2 Exploratory locomotor behavior in ZDF decreases as PDN develops
In order to measure the effect of diabetes on sedentary behavior we measured
locomotor activity using an open field photo beam array. Rearing number, rearing
duration, distance travelled, total beam breaks, and active/resting duration were
quantified in control ZL and diabetic ZDF rats at 6, 12, and 18 weeks of age. Figure 4-10
shows that there are no significant differences in any of the activity measures at 6 or 12
wks but by 18 wks diabetic animals showed decreased activity levels in all measures
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tested. These results are consistent with decreased locomotor activity in ZDF rats
(Jiménez-Aranda et al, 2013) and db/db mice (Sharma et al, 2010) at similar stages of
type 2 diabetes. Five weeks of rosiglitazone treatment (20 mg/kg/d orally) at a similar
dose to the 30 mg/kg/d of pioglitazone in the current studies did not attenuate
hypolocomotive behavior in db/db mice. Rosiglitazone did however attenuate
hyperglycemia (Sharma et al, 2012). These results indicate that alleviating type 2
diabetes in rodents is not sufficient to reduce the hypolocomotion that may reflect
affective components of animal behavior.

4.6.3 Mechanisms of PDN
Other mechanisms in addition to neuronal central sensitization might drive PDN in
type 2 diabetes. First, increased expression of NGF (Cheng et al, 2009), pp38 (Cheng et
al, 2010; Galloway and Chattopadhyay, 2013), Nav1.6 (Ren et al, 2012), Nav1.7
(Galloway and Chattopadhyay, 2013), TNFα (Cheng et al, 2010; Galloway and
Chattopadhyay, 2013), and IL-1β (Galloway and Chattopadhyay, 2013) in the lumbar
DRG of db/db mice and ZDF rats with PDN suggests peripheral pain sensitization.
Further supporting expressional studies, administration of anti-NGF (Cheng et al, 2009)
or a p38 kinase antagonist (Cheng et al, 2010) reduced mechanical allodynia in 8 wk old
db/db mice. Second, PDN is associated with an increase in spinal expression of markers
of astrocyte (GFAP) (Liao et al, 2011; Dauch et al, 2012; Ren et al, 2012; Xu et al, 2014)
but not microglia (Ox42) (Liao et al, 2011; Xu et al, 2014) gliosis. Indeed, the astrocyte
toxin LAA but not the microglial inhibitor minocycline reversed mechanical hyperalgesia
in db/db mice (Liao et al, 2011). However, our preliminary results in ZDF contrast with
previous reports indicating upregulation of glial markers in the spinal cord in PDN. Figure
4-11 illustrates that the expression of microglial and astrocyte activation markers is
similar in ZL and ZDF at 18 wks of age. Given that this is the first study to investigate
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glial activation in the spinal cord in ZDF, it is possible that species differences between
db/db mice and ZDF rats contribute to the lack of upregulation in Iba1 or GFAP in the
current study. In the future, assessment of functional markers for glial activation could be
performed to investigate the interplay between neurons and glia in peripheral, spinal,
and brain areas and to evaluate their contribution to PDN.
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Figure 4-10. Locomotor activity decreases with age in ZDF.
General exploratory behavior in an open field activity box was measured in 5 min
bins for 45 min at 6, 12, and 18 wks of age in ZL and ZDF. The number of rearing
events, rearing duration, total beam breaks, distance travelled, active duration, and
resting duration are shown. * p<0.05 ZDF vs. ZL.

Figure 4-11. Immunohistochemical quantification of microglial and astrocyte
markers.
(A) Representative images of the ipsilateral dorsal horn in ZL and ZDF rats aged 18
wks from the first experiment characterizing the development of PDN. Quantification
of (B) the microglial marker Iba1 and (C) the astrocyte marker GFAP revealed no
significant differences in the expression of gliosis markers in the spinal cord.
Integrated density was determined by thresholding the images using the default
algorithm within NIS Elements to reduce background and include positively stained
cells. Integrated density of the region of interest (ROI) is equal to the product of ROI
area and mean intensity value. The mean intensity value represents the sum of the
intensity values for all pixels above the threshold in the ROI divided by the number
of pixels above threshold within the ROI. This method controls for differences in
fluorescence background levels between slices and subjects.

We offer several explanations for our result that pioglitazone did not significantly
reduce blood insulin levels in diabetic ZDFs: (1) Hyperinsulinemia in ZDFs occurs at an
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earlier age (Gregoire et al, 2009; Ibrahim et al, 2015; Watanabe et al, 2015) and
therefore insulin production in diabetic ZDFs may already be diminished in the vehicle
group; (2) Pioglitazone treatment produces a modest increase in insulin production as
evidenced by our control ZDFs; or (3) Pioglitazone did not reduce insulin in similarly
aged diabetic ZDFs (Watanabe et al, 2015); (4) The duration of pioglitazone treatment
was not long enough to reduce the overcompensation of pancreatic beta cell insulin
production, although insulin sensitivity was enhanced as evidenced by the reduction in
hyperglycemia. However, this finding does rule out an alternative mechanism of
pioglitazone analgesia providing support to the conclusion that antihyperalgesia is
independent of the metabolic benefits of pioglitazone.
Pioglitazone may decrease PDN by reducing diabetes-associated inflammation. In
humans, TNF-α plasma levels and macrophage TNF-α expression are positively
correlated with diabetic neuropathy-associated pain (Purwata, 2011). TZDs reduce
proinflammatory factors such as: (1) blood TNF-α in a long-term model of diabetes
(Qiang et al, 1998) or after methylglyoxal treatment (Hsu et al, 2013); (2) adipose TNF-α
in ZDFs (Minoura et al, 2007); (3) in vitro production of TNF-α in activated macrophages
(Jiang et al, 1998); (4) proinflammatory cytokine release in TLR-activated human
monocytes and db/db mice (Dasu et al, 2009); (5) pioglitazone reduces diabetesassociated elevations in urinary (Ye et al, 2010) and monocyte (Dasu et al, 2009)
expression of the chemokine MCP-1/CCL2; (6) glucose induction of TNF-α and MCP-1
release from rat microglia (Quan et al, 2011) may be diminished by pioglitazone
reduction of hyperglycemia; and (7) molecules implicated in the generation of pain such
as proinflammatory cytokines, Nav1.7, and pp38 are elevated in the DRG from diabetic
ZDF (Galloway and Chattopadhyay, 2013). We speculate that chronic pioglitazone
treatment decreases the neuroinflammatory state produced by type 2 diabetes, thereby
reducing PDN.
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Separating improvements in hyperglycemia and insulin resistance from analgesic
effects of PDN treatments is non-trivial. Several lines of evidence make it unclear as to
whether the correction of hyperglycemia (by treating the underlying insulin resistance in
type 2 diabetes or by insulin infusion in type 1) results in decreased pain. (1) Localized
hyperglycemia in the sciatic nerve or DRG induces pain-like behavior and was reversed
by an aldose reductase inhibitor. This suggests that production of reactive oxygen
species (ROS), the endpoint of the glucose-polyol pathway, is responsible for pain-like
hypersensitivity (Dobretsov et al, 2003) rather than the direct neurotoxic effect of glucose
(Tomlinson and Gardiner, 2008). (2) Taurine, an antioxidant, improves nerve conduction
velocity and attenuates mechanical and thermal hyperalgesia without affecting
hyperglycemia (Li et al, 2006). (3) Markers for oxidative or nitrosative stress, which can
lead to pain, are reduced by Poly(ADP)-ribose polymerase inhibition without eliminating
hyperglycemia (Obrosova et al, 2005). (4) Hyperglycemia persists when pain-like
behavior is reduced in STZ (Ramos et al, 2007) and ZDF (Piercy et al, 1999) rats after
treatment with IGF (Zhuang et al, 1996), IGF-II (Zhuang et al, 1997), or aldose reductase
inhibitors (Ramos et al, 2007). (5) Pain behavior can persist even after correction of
hyperglycemia (Lee and McCarty, 1992). Contrasting with the above, studies indicate
that acute exposure to glucose can produce hyperalgesia (Dobretsov et al, 2001;
Dobretsov et al, 2003) and glycemic control correlates with pain relief in diabetic patients
(Oyibo et al, 2002). Nevertheless, treatments such as TZDs and metformin that reduce
both hyperglycemia and pain-like behavior in preclinical models need further clinical
investigation.

123

CHAPTER 5: Methylglyoxal produces pain in type 2 diabetes via sensitization of
TRPA1 and AC1

Manuscript in preparation.
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Bradley K. Taylor1*
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Department of Physiology, College of Medicine, University of Kentucky Medical Center,
Lexington, KY 40536.

5.1 Abstract
Type 2 diabetic pain remains difficult to treat, in part because the mechanisms that
lead to painful diabetic neuropathy (PDN) are poorly understood. Metabolic
dysregulation in diabetes produces an increase in the glucose metabolite methylglyoxal
(MG) and blood levels of MG correlate with PDN in patients. The current literature led to
our hypothesis that elevated MG contributes to pain in type 2 diabetes by sensitizing
peripheral and/or spinal nociceptive neurons via activation of TRPA1 and AC1.
We confirmed that methylglyoxal is increased in the db/db mouse model of type 2
PDN. Intraplantar injection of MG produced multiple types of pain-like behaviors,
including spontaneous nociceptive responses, mechanical and heat hypersensitivity, and
conditioned place aversion, a measure of affective pain in preclinical studies. MG also
triggered spinal nociceptive transmission, as it evoked phosphorylation of ERK and
increased intracellular calcium in superficial dorsal horn neurons. Pharmacological and
genetic disruption of TRPA1 attenuated pERK and pain-like behavioral responses to MG
administration as well as reversed hyperalgesia in db/db mice. Knockout of AC1
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abolished MG-induced hyperalgesia but not nociceptive responses while the AC1
inhibitor NB001 attenuated hyperalgesia in db/db mice. Finally, the novel MG
scavenging peptide GERP10 attenuated hyperalgesia in db/db mice without altering
hyperglycemia or elevated HbA1c. We conclude that elevated MG in type 2 diabetes
contributes to PDN through a TRPA1-AC1 dependent pathway.

5.2 Introduction
Painful diabetic neuropathy (PDN) is associated with accumulation of methylglyoxal
(MG), a major metabolite of glycolysis, in the blood in both patients and rodent models
(Bierhaus et al, 2012). For example, in healthy control subjects blood MG levels are 150300 nM (McLellan et al, 1992; Bierhaus et al, 2012) and ~600 nM in diabetic patients,
though levels are greatly exacerbated in diabetic patients reporting pain (~900 nM). This
suggests a potential role for MG in the production of pain associated with diabetes.
Previous studies indicate that acute administration of MG produces spontaneous
nociception (Andersson et al, 2013) and evoked heat hypersensitivity in mice (Bierhaus
et al, 2012). Data from knockout mice suggest activation of transient receptor potential,
ankyrin subtype 1 (TRPA1) as a mechanism of these effects in primary afferents.
However, additional measures of evoked and affective pain-like behavior beyond MGinduced nociception and the use of additional pharmacological and genetic tools in
preclinical models are needed to assess the contribution of MG and TRPA1 to ongoing
PDN in type 2 diabetes.
A majority of PDN studies focus on the streptozotocin (STZ) model of type 1 diabetes
(Calcutt et al, 2009). Indeed, using the STZ model or administration of exogenous MG,
Bierhaus et al showed that MG scavenging compounds (e.g. ALT-711, aminoguanidine)
or an arginine-rich peptide (i.e. GERP10) reduced MG-associated hypersensitivity
(Bierhaus et al, 2012). Here we focus on db/db mice (Kodama et al, 1994), a model of
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type 2 diabetes that is ideal because: (1) type 2 diabetes represents the majority (90%)
of diabetic patients (World Health Organization) and has a greater incidence of PDN
compared to type 1 (Van Acker et al, 2009; Abbott et al, 2011); (2) pain mechanisms in
type 1 versus type 2 likely differ (Schmidt et al, 2003; Schmidt et al, 2004; Kamiya et al,
2005; Schuelert et al, 2015); (3) it is unknown whether administration of the MG
scavenger GERP10 will alleviate type 2 PDN as it does in STZ (Bierhaus et al, 2012);
and (4) STZ may activate TRPA1 to produce peripheral neuropathy and pain prior to the
development of diabetic hyperglycemia (Andersson et al, 2015) thereby confounding
conclusions from previous STZ studies investigating the role of TRPA1 in development
of PDN (Wei et al, 2009; Wei et al, 2010; Koivisto et al, 2012).
Several lines of evidence suggest that sensitization of nociceptive neurons in the
spinal dorsal horn of primary afferents may contribute to painful type 2 diabetes (aka
PDN) through a TRPA1 mechanism. First, increased phosphorylation of extracellular
signal-regulated kinase (pERK), a marker for nociresponsive spinal neuron activation (Ji
et al, 1999; Gao and Ji, 2009), is associated with pain-like hypersensitivity in type 2
diabetic rats (see Chapter 4: ). Second, inhibition of spinal ERK phosphorylation in db/db
mice reversed pain-like hypersensitivity (Xu et al, 2014). Third, MG-evoked nociception
and calcium mobilization in DRG neurons was abolished in TRPA1 knockout mice
(Eberhardt et al, 2012; Andersson et al, 2013). Fourth, MG-evoked activation of SHSY5Y cells was prevented by NMDA receptor inhibition (de Arriba et al, 2006). Along
these lines, we hypothesized that: (1) MG activation of peripheral TRPA1-positive
nociceptors induces spinal phosphorylation of ERK (pERK) that is dependent on
peripheral and/or spinal TRPA1; and (2) elevated MG in type 2 diabetes produces
painful spinal sensitization as evidenced by exacerbated glutamate- and/or MG-evoked
calcium responses in spinal slices and dissociated DRG neurons from wild-type and
db/db mice.
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Calcium activated adenylyl cyclase 1 (AC1) (Xia and Storm, 1997) is a key modulator
of pain plasticity in the central nervous system (Zhuo, 2012). For example, AC1
mediates spinal LTP and ERK activation induced by capsaicin or glutamate in mice (Wei
et al, 2006) as well as NMDA-induced pain reinstatement after injury (Corder et al,
2013). As glutamate and NMDA receptors play a role in both normal and sensitized pain
transmission, and activation of TRPA1 leads to a rise in intracellular calcium (Eberhardt
et al, 2012; Ohkawara et al, 2012), we tested the hypothesis that AC1 mediates pain-like
responses after MG administration and in db/db mice with PDN.

5.3 Materials and Methods
5.3.1 Subjects
Experiments were carried out in accordance with the Institutional Animal Care and
Use Committee at the University of Kentucky (Approved Protocol # 2009-0486). All
efforts were made to minimize animal suffering, to reduce the number of animals used,
and to utilize alternatives to in vivo techniques, in accordance with the International
Association for the Study of Pain (Zimmermann, 1983) and the National Institutes of
Health Office of Laboratory Animal Welfare Guide for the Care and Use of Laboratory
Animals.
Animals were housed in a temperature and humidity controlled room on a 12 hour
light – 12 hour dark cycle with lights on from 07:00 to 19:00. Animals were provided
water and chow ad libitum. All rats and mice used were male. Male Sprague-Dawley rats
(CD-IGS, Charles River Laboratories, Inc., Wilmington, MA) weighing 300-450g at the
time of behavioral procedures were used. TRPA1 knockout (-/-) and wild-type littermates
(+/+) mice were graciously provided by Dr. Gregory Frolenkov (Department of
Physiology, University of Kentucky, Lexington, KY), courtesy of Drs. Kelvin Kwan and
David Corey (Harvard University, Cambridge, MA), and were used to setup a TRPA1
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knockout colony. AC1-/- and AC1+/+ mice were graciously provided by Dr. Daniel Storm
(Washington University, Seattle, WA, USA) and were used to setup an AC1 knockout
colony. Both congenic knockout mouse lines were maintained using a heterozygote
breeding strategy onto a C57BL/6J (000664, JAX Mice, The Jackson Laboratory, Bar
Harbor, ME) background. Genotypes were confirmed by PCR. Control (C57BLKS/J;
BKS) and diabetic (Leprdb; db/db) mice (The Jackson Laboratory, Bar Harbor, ME; Stock
No. 000642) were aged 6-14 wks. Mice aged 8-12 wks were used for all non-db/db
studies with C57BL/6J serving as congenic controls.

5.3.2 Drugs & Injections
Methylglyoxal (M0252, Sigma-Aldrich, St. Louis, MO) was diluted in 0.9% sterile
saline for intraplantar injections (0-1000 µg) or aCSF (0-10 mM) for calcium imaging
studies. NB001 (SML0060, Sigma-Aldrich) was diluted in water for intrathecal injections.
GEAP10 and GERP10 were graciously provided by Drs. Thomas Fleming and Peter
Nawroth (University Hospital Heidelberg, Heidelberg, Germany) and diluted in 0.9%
saline for intraperitoneal injections. For intrathecal (5-10 μL), intraperitoneal (100 µL),
and intraplantar (5-25 µL) injections un-anaesthetized mice were lightly restrained and a
30Ga½“ needle attached to a Hamilton microsyringe was used to administer drug
solutions. Intrathecal injections were performed by puncturing the dura between the
L5/L6 vertebrae and confirmed by presence of reflexive tail or hindpaw flick as
previously described (Fairbanks, 2003).
Stock solutions of methylglyoxal contain <1% of impurities such as formalin, which is
known to be an agonist for TRPA1 (McNamara et al, 2007). However, concern that
contaminates in the Sigma-Aldrich solution used in this study could confound our
conclusions is mitigated by the finding that electrophysiological results using MG from
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Sigma-Aldrich and synthesized pure MG were identical in a previous CNS study (Distler
et al, 2012).

5.3.3 Pain-like Behavior
Fluctuations in noise, vibrations, temperature, and other distractors in the behavioral
testing room were minimized to optimize reliable measurements between cohorts of
animals tested on different days. Animals were acclimated to the different testing
apparatuses prior to commencing behavioral studies and for 30-60 min on the day(s) of
testing.
Nociceptive responses were measured by placing the animals within an acrylic
enclosure immediately following intraplantar injection of saline or methylglyoxal. A mirror
was positioned below the enclosure to facilitate quantification of spontaneous
licking/lifting (s) or flinching (#) of the injected hindpaw for five minutes. The seconds of
licking/lifting and the number of flinches were added together to obtain a combined
number of nociceptive responses, where one second of licking/lifting or one flinch were
equated to one nociceptive response.
Heat hypersensitivity was assessed by placing the animals on a heated surface (52.5
± 1 °C) within an acrylic enclosure (Hotplate; Columbus Instruments, Columbus, OH).
The time until a hindpaw withdraw response (e.g. jumping, licking, flicking) occurred was
recorded. The animal was immediately removed after the withdraw response or at a
cutoff of 30 s to avoid tissue injury. Three trials were averaged for each timepoint.
Mechanical hypersensitivity was assessed by placing animals within a rectangular
acrylic box (15x4x4 cm; 3 white opaque walls and 1 clear wall) and stimulating the
ventral-medial hindpaw plantar surface with an incremental series of 8 von Frey
monofilaments (Stoelting, Inc., Wooddale, IL) of logarithmic stiffness using a modified
up-down method (Dixon, 1980; Chaplan et al, 1994). Testing began by applying an
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intermediate von Frey monofilament (number 4.31, exerts 2.0 g of force) perpendicular
to the glabrous skin, causing a slight bending. In the case of a positive response
(withdraw of the paw) a filament exerting less force was applied. In the case of a
negative response, a filament exerting greater force was applied. The calculated 50%
withdraw threshold is reported.
Conditioned place aversion (CPA) testing was completed using a three-chambered
acrylic enclosure with manual doors and the time spent in each chamber was quantified
using a 4 x 16 photobeam array (Place Preference, San Diego Instruments, San Diego,
CA; http://www.sandiegoinstruments.com/place-preference/). Printed paper was used to
cover the outside of the clear box so that the middle chamber was grey and the end
chambers had either vertical or horizontal black and white stripes that were ¾” wide.
Mice were acclimated to the CPA box on d1-2 and then preconditioning preferences
were assessed on d3. During conditioning on d4, intraplantar saline injection-pairing in
the morning was followed by methylglyoxal (300µg) injection-pairing to the opposite
chamber in the afternoon. On d5, the same conditioning procedure was repeated with
methylglyoxal injected into the hindpaw that received saline on d4. Drug pairings and the
hindpaw initially receiving methylglyoxal were counterbalanced. On d6, postconditioning
preferences were assessed in the absence of any injections.

5.3.4 pERK quantification via immunohistochemistry
Animals were injected intraplantar with saline or methylglyoxal, nociceptive
responses were quantified, and then mice were anesthetized with isoflurane (5%
induction, 2% maintenance). Ten minutes after intraplantar injection, animals were
perfused through the left ventricle with room temperature 0.1 M phosphate buffered
saline (PBS) with heparin (10,000 USP units/L) followed by ice-cold fixative (10%
phosphate buffered formalin). The lumbar spinal cord was removed and post-fixed
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overnight in 10% phosphate buffered formalin and then cryoprotected in 30% sucrose in
0.1 M PBS for several days. Transverse sections (30 μm) from L3-L4 were cut on a
freezing microtome and collected in 0.1 M PBS. The sections were washed three times
in 0.1 M PBS and then pretreated with blocking solution (3% normal goat serum and
0.3% Triton X-100 in 0.1 M PBS) for 1 h. Sections were then incubated in blocking
solution containing the primary antibody rabbit anti-pERK (1:250, #4370, Cell Signaling
Technology, Danvers, MA) overnight at room temperature on a slow rocker. The
sections were washed three times in 0.1M PBS, and incubated goat anti-rabbit
secondary antibody (1:800, Alexa 568, Molecular Probes, Grand Island, NY) for 90 min,
washed in 0.1M PBS, 0.01M PBS, then 0.01M PB, and non-sequentially mounted onto
Superfrost Plus slides, air dried, and cover-slipped with Prolong Gold with DAPI
mounting medium (Molecular Probes).
All images were captured on a Nikon Eclipse TE2000-E microscope using a 10x
objective and analyzed using NIS-Elements Advanced Research software. We focused
our quantification of the number of pERK immunopositive cell profiles within lamina I-II,
where the majority of C-fibers and nociceptive peripheral afferents terminate within the
dorsal horn (Basbaum et al, 2009; Corder et al, 2010). Each spinal cord slice was
analyzed by an observer blinded to treatment. 4-6 high quality sections were randomly
selected for quantification.

5.3.5 Calcium imaging
Preparation of adult mouse spinal cord slices. Mice were anesthetized with 5%
isoflurane and quickly perfused transcardially with 10 ml of ice-cold sucrose-containing
artificial cerebrospinal fluid (aCSF) (sucrose-aCSF) that contained (in mM): NaCl 95, KCl
1.8, KH2PO4 1.2, CaCl2 0.5, MgSO4 7, NaHCO3 26, glucose 15, sucrose 50, kynurenic
acid 1, oxygenated with 95% O2, 5% CO2; pH 7.4. The lumbar spinal cord was rapidly
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isolated by laminectomy from the cervical enlargement to the cauda equina, placed in
oxygenated ice-cold sucrose-aCSF, cleaned of dura mater and ventral roots, and superglued vertically to a block of 4% agar (Fisher Scientific, Pittsburgh, PA) on the stage of a
Campden 5000mz vibratome (Lafayette, IN). Transverse slices (450 µm) from lumbar
segments L3/L4 were cut in ice-cold sucrose-aCSF.
Fluorometric Ca2+ measurements. Slices were incubated for 30 min with Fura-2 AM
(10 μM), pluronic acid (0.1%) in oxygenated aCSF containing (in mM): NaCl 127, KCl
1.8, KH2PO4 1.2, CaCl2 2.4, MgSO4 1.3, NaHCO3 26, glucose 15 at 37ᵒ C, followed by a
20 min de-esterification period in normal aCSF. Prior to recording, slices were kept at RT
in a chamber containing approximately 150 ml of oxygenated aCSF. Slices were
perfused at 1-2 ml/min with normal aCSF in an RC-25 recording chamber (Warner
Instruments, Hamden, CT) mounted on a Nikon FN-1 upright microscope fitted with a
79000 ET FURA2 Hybrid filter set (Nikon Instruments, Melville, NY) and a Photometrics
CoolSNAP HQ2 camera (Tucson, AZ). Relative intracellular Ca2+ levels were determined
by measuring the change in ratio of fluorescence emission at 510 nm in response to
excitation at 340 and 380 nm (200 ms exposure). Paired images were collected at 1-1.5
seconds/frame. Relative changes in Ca2+ levels were evaluated using Nikon Elements
software by creating a region of interest over the cell body and calculating the peak
change in ratio. The peak magnitude of Ca2+ response to 90 s exposure to MG was
normalized to the Ca2+ response to 1 mM glutamate (10 s). Only cells that displayed a
consistent response to 1 mM glutamate at the beginning and end of the experiment
(showing a less than 40% decrease in glutamate-evoked Ca2+ transients) were included
in this study.
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5.3.6 Quantification of Methylglyoxal-derived advanced glycation end-products (MGAGEs)
MG-AGEs

were

quantified

using

a

competitive

ELISA

according

to

the

manufacturer’s instructions (STA-811, Cell BioLabs, San Diego, CA). This ELISA uses a
primary antibody that recognizes the hydroimidazolone (H1) moiety created by the
modification of protein residues by methylglyoxal (Ahmed, 2003). Whole blood taken
from the left ventricle prior to transcardial perfusions was collected in serum separator
tubes (SST™, BD, Franklin Lakes, NJ) and allowed to clot for 30 min. Clotted blood in
SSTs was centrifuged at 5000 x g for 10 min at 4ºC and the serum was transferred to
fresh microcentrifuge tubes and stored at -80ºC until MG-H1 ELISA analysis. Serum
samples were diluted in 0.1M PBS to obtain values in the span of the standard curve.

5.3.7 Measurement of blood glucose & HbA1c
Mice were lightly restrained in a towel and the distal tail wiped with an alcohol swab.
A small nick was made at the distal tip of the tail using a #11 scalpel blade. Initial
bleeding was wiped clean with gauze and subsequent drops of blood were either loaded
into a room temperature HbA1c cartridge and analyzed using a DCA Vantage Analyzer
(Siemens, Munich, Germany), or placed on a glucose test strip in duplicate and inserted
into a glucose monitor (TrueTrack, Walgreens, Deerfield, IL). To avoid perturbations in
pain-like behavior elicited by fasting or exogenous glucose administration (Dobretsov et
al, 2001; Dobretsov et al, 2003), non-fasted blood glucose was measured. A random
blood glucose level greater than 200 mg/dL (11.1 mmol/L) was defined as
hyperglycemia (Capes et al, 2000; Sacks, 2011).
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5.3.8 Data analysis and statistics
Nociceptive behavior and calcium responses in wild-type rats and mice were
analyzed using a one-way ANOVA followed by Holm-Sidak multiple comparison
correction. Nociceptive behavior, pERK immunohistochemistry, blood glucose, and
HbA1c in wild-type, TRPA1-/-, AC1-/-, and db/db mice were analyzed using a two-way
ANOVA followed by Holm-Sidak multiple comparison correction. Nociceptive behavior,
mechanical hypersensitivity, heat hypersensitivity, conditioned place aversion, and blood
glucose in wild-type, TRPA1-/-, AC1-/-, and db/db mice were analyzed using a repeated
measures two-way ANOVA followed by a Holm-Sidak multiple comparison correction.
An alpha value of α=0.05 was used to determine statistical significance. All data were
analyzed and graphed using Prism 6.0 (GraphPad, La Jolla, CA) and are presented as
mean ± SEM.

5.4 Results
5.4.1 Methylglyoxal produces pain-like behavior
First we determined whether exogenous intraplantar administration of methylglyoxal
into the hindpaw is sufficient to produce pain-like behaviors. As illustrated in Figure 1AC, methylglyoxal produced dose-dependent nociceptive responses in rats [F(2,9) = 6.87;
P = 0.015] and mice [F(7,41) = 88.2; p < 0.0001], with 1000 μg of MG producing
nociceptive responses that lasted for one hour [drug x time; F(15,90) = 3.4; p = 0.0002].
As illustrated in Figure 1D-E, methylglyoxal produced hypersensitivity to mechanical
[drug x time; F(5,85) = 3.54; p = 0.0059] and heat [dose x time; F(15,100) = 5.0; p <
0.0001] stimuli.
To determine an aspect of affective pain we tested whether methylglyoxal produced
conditioned place aversion. Baseline preconditioning time spent in the saline-paired
(mean ± SEM; 334.7 s ± 38.9) or methylglyoxal-paired (354.2 s ± 42.35) chambers was
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similar

[p

=

0.75],

indicating

our

injection

pairings

were

counterbalanced.

Postconditioning time spent in the methylglyoxal-paired chamber (273.9 s ± 38.6) was
less than time spent in the saline-paired chamber (489.6 s ± 49.9) [p = 0.0026],
indicating avoidance of methylglyoxal administration. As illustrated in Figure 1E, the
difference scores for saline and methylglyoxal were significantly different [p = 0.021],
indicating conditioned place aversion to injection of methylglyoxal.
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Figure 5-1. Exogenous methylglyoxal produces spontaneous, evoked, and
affective pain-like behavior.
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Nociceptive behavioral responses in (A) rats (n=3-5) and (B-C) mice (n=3-14) as
well as evoked (D) mechanical (n=9-10) and (E) heat (n=4-12) thresholds after
intraplantar (i.pl.) injection of methylglyoxal (MG). (E) Difference scores (post minus
pre conditioning) for conditioned place aversion testing using two days of i.pl. MG
(300 μg) injections in mice (n=8). ★ p<0.05 vs. Saline. # p<0.05, MG 10 μg vs.
Saline. † p<0.05, MG 30 μg vs. Saline. ‡ p<0.05 MG 100 μg vs. Saline.

5.4.2 Methylglyoxal activates spinal neurons to produce PDN
Previous studies indicate methylglyoxal activates dorsal root ganglia neurons via
TRPA1 to produce nociception (Eberhardt et al, 2012; Andersson et al, 2013). However,
whether elevated methylglyoxal in type 2 diabetes sensitizes spinal neurons remains
unknown. Therefore we tested the hypothesis methylglyoxal activates nociresponsive
neurons in the spinal cord dorsal horn. Figure 2A illustrates that intrathecal injection of
methylglyoxal produces hindpaw mechanical hypersensitivity at 30-120 min [p < 0.05]
with a significant Drug by Time interaction [F(6,36) = 4.712; p = 0.0012].

Figure 5-2. Methylglyoxal activates nociceptive neurons in the spinal cord
dorsal horn to produce pain-like behavior.
Data courtesy of Renee Donahue. I formulated the hypothesis, designed the
experiment, and analyzed the data.
(A) Mechanical sensitivity before and after intrathecal (i.t.) injection of MG (n=4). ★
p<0.05 vs. Saline.
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5.4.3 TRPA1 mediates spinal sensitization and pain in type 2 diabetes
Phosphorylated extracellular signal-regulated kinase (pERK) in the spinal cord dorsal
horn (Ji et al, 1999; Zhuang et al, 2005) is a marker of nociresponsive neuron activation
(Gao and Ji, 2009) and stimulus-evoked central sensitization (Morgenweck et al,
2013)(Griggs et al, 2015, under review at Journal of Pain), which is defined as the
increased responsiveness of nociceptive neurons in the central nervous system to their
normal or subthreshold afferent input (Woolf, 2011). To evaluate methylglyoxal-induced
spinal sensitization we measured the number of cell profiles displaying pERK in the
superficial dorsal horn after MG hindpaw administration. To determine the contribution of
peripheral and/or spinal TRPA1 we administered MG in wild-type and TRPA1 knockout
(-/-) mice, or after administration of intrathecal vehicle or HC030031, a TRPA1 inhibitor,
to wild-type mice.
Figure 3A-B shows that MG injection increased pERK in wild type [p < 0.0001], but
not TRPA1-/- [p = 0.95] mice [drug x strain; F(1,11) = 48.41; p < 0.0001] as well as in
wild-type mice with intrathecal (i.t.) vehicle [p < 0.0001] but not HC [p = 0.088]
administration [drug x drug; F(1,12) = 67.02; p < 0.0001]. As illustrated in Figure 3C,
methylglyoxal produced nociception in wild-type [vs. saline; p < 0.0001] but not TRPA1-/[p = 0.77] mice [F(1,14) = 44.66; p < 0.0001] as well as in wild-type mice with i.t. vehicle
[p < 0.0001] administration [drug x drug; F(1,19) = 29.57; p < 0.0001]. Importantly,
although MG produced modest nociceptive behavior in HC-treated mice [vs. HC Saline;
p = 0.0026], nociceptive response was significantly less than that in vehicle-MG mice [p
< 0.0001]. Figure 3D illustrates that, compared to saline, methylglyoxal decreased
withdraw latency to heat in wild-type but not TRPA1-/- mice [strain x time; F(5,45) =
10.67; p < 0.0001]. Compared to TRPA1-/-, methylglyoxal produced heat hypersensitivity
in wild-types at 30 min [p < 0.0001]. As illustrated in Figure 3E, intrathecal administration
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of HC030031 reversed heat hypersensitivity in diabetic db/db but not control BKS mice
[F(5,30) = 7.088; p = 0.0002] from 15-45 min [p < 0.05].
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Figure 5-3. TRPA1 mediates methylglyoxal-induced spinal nociceptive neuron
activation and hyperalgesia in painful diabetic neuropathy.
To determine whether activation of spinal neurons is dependent upon TRPA1 we
injected methylglyoxal (MG; i.pl.) in wild-type mice alongside intrathecal (i.t.)
HC030031 (HC) or in TRPA1 knockouts and measured phosphorylated ERK
(pERK), a marker of nociceptive neuron activation, in the L4-L5 spinal cord. (A)
Representative dorsal horn images ipsilateral to injection of saline or MG.
Quantification of (B) pERK+ cells, (C) nociceptive responses, or (D) hotplate
behavior after i.pl. saline or MG injection in animals treated with with i.t. vehicle or
HC (10 μg), or in wild-type (+/+) or TRPA1 knockout (-/-) mice. pERK, nociceptive
responses, and heat hyperalgesia were abolished after pharmacological or genetic
inhibition of TRPA1. (E) Heat thresholds in control BKS and diabetic db/db mice
after i.t. injection of the TRPA1 antagonist (10 μg) at 10 wks of age. ★ p<0.05 vs. all
other groups. # p<0.05 vs. db/db Vehicle.

5.4.4 AC1 facilitates methylglyoxal-induced hypersensitivity
Our finding that activation of TRPA1 by methylglyoxal resulted in subsequent heat
hypersensitivity is puzzling, considering TRPA1 primarily responds to cold (Story et al,
2003), mechanical (Kwan et al, 2009), or chemical (Bautista et al, 2005; McNamara et
al, 2007; Trevisani et al, 2007; Eberhardt et al, 2012) stimuli. However, previous studies
suggest a functional link between TRPA1 and TRPV1 containing primary afferents
(Fischer et al, 2014; Spahn et al, 2014; Weng et al, 2015), a phenomena that might be
mediated by AC1 (Spahn et al, 2014). Therefore we tested the hypothesis that AC1
mediates pain-related behaviors in wild-type (WT) and AC1 knockout (AC1-/-; KO) mice
after methylglyoxal administration, as well as in BKS and db/db mice with pretreatment
with the AC1 inhibitor NB001.
Figure 4A illustrates that, compared to saline, methylglyoxal produced nociceptive
responses [drug; F(1,14) = 193.6; p < 0.0001] in wild-type [vs. saline; p < 0.0001] and
AC1-/- [p < 0.0001] mice. Saline or methylglyoxal-induced responses were similar in
wild-type and AC1-/- mice [p = 0.99]. As illustrated in Figure 4B, compared to saline
injection methylglyoxal produced heat hypersensitivity in wild-type mice [drug in WT;
F(5,30) = 8.72; p < 0.0001] at 30-60 min [p < 0.001] but not in AC1-/- [drug in KO;
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F(5,30) = 1.12; p = 0.37]. Compared to AC1-/-, methylglyoxal produced heat
hyperalgesia in wild-types at 30 min [p = 0.03]. As illustrated in Figure 4C, intraplantar
methylglyoxal injection had no effect on mechanical thresholds in AC1-/- at any timepoint
measured [F(5,35) = 0.575; p = 0.72]. As illustrated in Figure 4D, intrathecal injection of
the AC1 inhibitor NB001 had no effect on heat thresholds in control BKS mice [F(1,6) =
0.05; p = 0.83]. However, NB001 significantly attenuated heat hyperalgesia in db/db
mice overall [F(1,6) = 7.35; p = 0.035] and at 45 min [p = 0.044].
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Figure 5-4. AC1 mediates methylglyoxal-induced hyperalgesia in painful
diabetic neuropathy.
(A) Nociceptive, (B) hotplate, and (C) mechanical behavioral responses after
intraplantar injection of saline or methylglyoxal in wild-type C57BL6J (+/+) or AC1
knockout (-/-) littermates. (D) Heat thresholds after intrathecal (i.t.) injection of the
AC1 inhibitor NB001 (1.5 μg) in BKS and db/db mice at 13 wks of age. # p<0.05 as
shown. ★ p<0.05 vs. all other groups.

5.4.5 Methylglyoxal scavenging reduces pain-like behavior in type 2 diabetes
We reasoned that if methylglyoxal is producing pain in type 2 diabetes, then
strategies that reduce elevated methylglyoxal in diabetic subjects would alleviate painlike behavior. Recently, the novel peptide GERP10 and its control GEAP10 were
administered to methylglyoxal or streptozotocin treated mice. GERP10 peptide, which
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contains ten repeats of the amino acid arginine that favors formation of MG-H1 residues
(Allaman et al, 2015), but not GEAP10 (instead containing non-reactive alanine) was
shown to reduce hyperalgesia and serum methylglyoxal levels (Bierhaus et al, 2012).
Here we extended this experiment to the db/db model of type 2 diabetes, which
progressively develop mechanical (Liao et al, 2011; Ren et al, 2012; Xu et al, 2014) and
thermal (Xu et al, 2014) hypersensitivity as well as elevated blood MG (Bierhaus et al,
2012). As illustrated in Figure 5A, db/db mice developed heat hyperalgesia [F(4,112) =
11.49; p < 0.0001] at 7-10 wks of age [p < 0.0001] but were not hyperalgesic at 6 wks [p
= 0.60]. As illustrated in Figure 5B-C, db/db mice had elevated blood glucose [F(4,112) =
9.092; p < 0.0001] at 6-10 wks [p < 0.0001] and increased MG-H1 AGE at 10 wks [p =
0.03]. As illustrated in Figure 5D, a single intraperitoneal injection of GERP10 but not
GEAP10 increased heat thresholds in db/db mice [F(1,13) = 7.49; p = 0.02] without
altering thresholds in BKS controls [F(1,13) = 0.134; p = 0.72]. GERP10 attenuation of
heat hyperalgesia in db/db mice lasted for several days. As illustrated in Figure 5E-F,
blood glucose [p < 0.0001] and HbA1c [p < 0.0001] were elevated in db/db compared to
BKS mice 7 d after injection of the control peptide GEAP10. GERP10 did not alter blood
glucose [F(1,12) = 0.1; p = 0.76] or HbA1c [F(1,8) = 1.49; p = 0.26] levels.
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Figure 5-5. The methylglyoxal scavenger GERP10 reduces painful diabetic
neuropathy.
Measurement of (A) heat thresholds, (B) blood glucose, and (C) serum
methylglyoxal (11 wks of age) in BKS and db/db mice. (D) Heat thresholds, (E)
blood glucose, and (F) blood HbA1c levels after a single intraperitoneal (i.p.)
injection of the methylglyoxal scavenging peptide GERP10 (1 mg) or its control
GEAP10 (1 mg) in BKS or db/db mice at 10-11 wks of age. ★ p<0.05 vs. all other
groups.

5.5 Discussion
5.5.1 Methylglyoxal contributes to painful type 2 diabetes
Our current results are the first to show a number of related findings with regard to
the spinal contribution of methylglyoxal to pain in diabetes. First, i.pl. administration of
exogenous MG produces spontaneous nociceptive behavior in both mice and rats.
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Second, MG produced transient, stimulus-evoked mechanical and heat hypersensitivity
and negative affect as evidenced by conditioned place aversion. Third, we show that
administration of MG to the spinal cord produces behavioral hypersensitivity, suggesting
that spinal sites of action are involved in diabetic pain. Fourth, activation of spinal
neurons and behavioral hypersensitivity depends upon both TRPA1 and AC1. Fifth,
inhibition of spinal TRPA1 or AC1 attenuates pain-like behavior in db/db mice. Finally,
scavenging of systemic methylglyoxal by GERP10 alleviates pain in a model of type 2
diabetes.
We provide evidence that the nociceptive response to MG is dose-dependent, occurs
in rats, and persists for one hour at the highest dose tested (1000 µg). The level of
nociceptive responses in mice were comparable to a previously used dose (18 µg; i.pl. )
(Andersson et al, 2013). Nociception occurs rapidly, within several seconds, suggesting
direct modulation (i.e. activation/depolarization) of primary afferent nociceptors. Indeed,
MG produced a calcium response in cell culture (after transfection with human TRPA1)
(Eberhardt et al, 2012; Ohkawara et al, 2012; Andersson et al, 2013) and mouse
peripheral DRG neurons (Eberhardt et al, 2012; Andersson et al, 2013). This is in
contrast to the notion that MG sensitizes nociceptors through a process mediated by
keratinocytes, that could result in evoked hypersensitivity (Kwan et al, 2009).
Hindpaw administration of MG produced peripheral sensitization to further
mechanical or heat stimulation that lasted for approximately one hour. Evoked
hypersensitivity followed the initial chemical-induced spontaneous nociceptive responses
and was maintained beyond the period of spontaneous pain-like responses. One
explanation is suggested by previous findings, where MG mobilized calcium in isolated
DRG neurons (Eberhardt et al, 2012; Andersson et al, 2013) to activate a substantial
portion of polymodal nociceptors (Eberhardt et al, 2012), presumably contributing to the
mechanical and heat hypersensitivity indicated by the current results. Evoked
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hypersensitivity also occurs after hindpaw administration of the TRPV1 agonist
capsaicin, both in humans (Simone et al, 1987; Simone et al, 1989) and rodents
(Gilchrist et al, 1996). With capsaicin, initial spontaneous responses are mediated
peripherally while the longer-lasting stimulus-dependent sensitization is due to a spinal
mechanism (Zhang et al, 2006; Willis, 2009). These results taken together suggest that
MG produces pain-like behavioral sensitization at least through a peripheral, if not also
spinal, mechanism akin to activation of TRPV1 afferents. This hypothesis is further
supported by our finding that intrathecal MG administration produced long-lasting
mechanical hypersensitivity.
Strategies to block the effects of endogenous MG reveal its role in maintaining painlike behavior in type 2 diabetes. It is clear that increases in circulating MG are
associated with diabetes (Bierhaus et al, 2012; Kong et al, 2014). Further increases in
circulating MG are associated with PDN (Bierhaus et al, 2012) and raising the
intracellular MG concentration in freshly isolated DRG neurons from 1.5 µM to 2.2 µM
(after 90 s application of 3 mM MG) induces neuronal activation (Eberhardt et al, 2012).
Although these are examples of the effects of free (unbound) MG, MG-derived advanced
glycation end-products (AGE), such as the formation of methylglyoxal-hydroimidazolone
(MG-H1) moiety created by the modification of reactive protein residues by
methylglyoxal (Ahmed, 2003), also contribute to painful neuropathy. AGEs such as MGderived hydroimidazolone (MG-H1) are associated with diabetic pain in patients (Sveen
et al, 2013) and result from the accumulation of free MG (Illien-Junger et al, 2015).
These results suggest that even modest increases in global or local MG could contribute
to painful sensitization.
Here we demonstrate that a single systemic administration of the free MG
scavenging peptide GERP10 attenuates painful type 2 diabetes in db/db mice. We
contribute to the growing body of work indicating that inhibition of MG, after exogenous
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MG administration, in the STZ type 1 diabetes model (Bierhaus et al, 2012), and in type
2 diabetic db/db mice (current results) reduces pain-like behavior. This is in line with
other methods of blocking MG, including administration of aminoguanidine or ALT-711
(Bierhaus et al, 2012), or by systemic overexpression of GLO1 (Bierhaus et al, 2012).
Future studies are needed to determine whether GERP10 could alleviate painful
diabetes in humans.
The major metabolic enzyme for MG, glyoxalase 1 (GLO1), plays a role in generating
painful diabetes. For example, reduced GLO1 expression and activity is associated with
pain in type 1 and type 2 patients (Skapare et al, 2013) as well as mice injected with MG
or STZ (Jack et al, 2011; Bierhaus et al, 2012; Jack et al, 2012). Alternatively,
administration of the GLO1 inhibitor Sr-p-Bromobenzylglutathionecyclopentyl diester
(every 2nd day for 2 weeks, i.p. 50 mg/kg) resulted in hot, cold, pressure, and light-touch
hypersensitivity (Andersson et al, 2013). Pain-like hypersensitivity presumably occurred
via pharmacologically increasing endogenous MG, but elevated MG was not confirmed
(Andersson et al, 2013). Finally, overexpression of GLO1 reduced painful diabetes in
STZ (Bierhaus et al, 2012) and prevented MG-derived AGE formation (Berner et al,
2012). These results suggest that decreased GLO1 activity alone is sufficient to produce
pain and that restoration of GLO1 activity could be beneficial for reducing the
contribution of free MG and MG-AGEs to painful diabetes.

5.5.2 Methylglyoxal requires TRPA1 to produce painful diabetes
MG activates human (Eberhardt et al, 2012; Ohkawara et al, 2012), rat (Eberhardt et
al, 2012), and mouse TRPA1 in both heterologous cell culture (Eberhardt et al, 2012;
Ohkawara et al, 2012) and sensory neurons isolated from rodent DRGs (Eberhardt et al,
2012; Koivisto et al, 2012; Andersson et al, 2013). For the first time we report that either
pharmacological inhibition or genetic knockout of TRPA1 abolished pain-related
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responses (spontaneous nociceptive behavior and spinal pERK) and subsequent
evoked behavioral hypersensitivity (hotplate). Along these lines, calcium influx or
nociceptive behavior is abolished in cells (Eberhardt et al, 2012) or mice (Andersson et
al, 2013) lacking TRPA1, respectively. Furthermore, the pain-like behavior that occurs
after pharmacologically raising MG levels by repeated administration of the GLO1
inhibitor BrBz in wild-type mice is absent in TRPA1 knockouts (Andersson et al, 2013).
These results taken together provide strong evidence that MG activates TRPA1 to
produce pain.
There are many lines of evidence that support the hypothesis that tonic activation of
TRPA1 contributes to neuropathic pain in diabetes. (1) Intrathecal Chembridge-5861528
(TRPA1 antagonist; CHEM) attenuates pain-like hypersensitivity in STZ rats (Wei et al,
2010). (2) Inhibition of TRPA1 prevents the loss of intraepidermal nerve fibers that
occurs after STZ-induced diabetes (Koivisto et al, 2012). (3) Activation of spinal TRPA1
by cinnemaldehyde (Wei et al, 2011) or methylglyoxal (current results) produces
hindpaw hypersensitivity. (4) Spinal administration of CHEM reduces secondary
hyperalgesia produced by intraplantar formalin or capsaicin (Wei et al, 2011). (5)
Intrathecal TRPA1 inhibition reduces hypersensitivity after spinal nerve ligation, an
alternative model of painful neuropathy (Wei et al, 2011). (6) TRPA1 modulates dorsal
horn neuron responsivity in naïve wild-type rats (Kosugi et al, 2007). It is clear that both
peripheral and spinal TRPA1 contribute to pain-like behavior in multiple pain models.
In the current study, we provide two additional experimental results that support the
hypothesis that tonic MG produces painful diabetes through spinal TRPA1. First,
blockade of spinal TRPA1 with HC reduces both nociceptive behavior and spinal pERK
in response to peripheral MG administration. We suggest that activation of TRPA1
afferents by MG produces release of endogenous TPRA1 agonists in the spinal cord that
induce subsequent evoked hypersensitivity in a feed forward process, probably through
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sensitization of spinal nociresponsive neurons. We favor this over the alternative
explanation that MG activates TRPA1 located in spinal dorsal horn neurons, as there is
no convincing evidence from the literature that suggests TRPA1 is expressed in dorsal
horn neurons. This idea is supported by studies showing spinal release of reactive
oxygen species or arachidonic acid derivatives such as 4-hydroxynonenal that drive pain
through TRPA1 (Koivisto et al, 2013). Second, spinal inhibition of TRPA1 attenuated
heat hypersensitivity in db/db mice. This further suggests that endogenous activation
and/or sensitization of TRPA1 mediates painful diabetes. Future studies could
investigate whether spinal inhibition of MG, or overexpression of the MG detoxification
enzyme glyoxalase 1 (GLO1), would also alleviate PDN.
The above findings indicate that sustained activation of spinal and/or peripheral
TRPA1 contributes to painful diabetes. However, our enthusiasm for this mechanism is
tempered by two studies that the STZ model in studies of diabetic pain is an
inappropriate model for studying the role of TRPA1. First, there is a dissociation between
the reduction of evoked hypersensitivity and the lack of conditioned place preference, a
measure of the reward associated with pain relief, produced by spinal TRPA1
antagonism in STZ or SNI (Wei et al, 2013). Second, STZ directly activates TRPA1 to
cause peripheral neuropathy that precedes STZ-induced type 1 diabetes (Andersson et
al, 2015). Behavioral hypersensitivity produced by STZ was delayed in TRPA1
knockouts, suggesting that TRPA1 mediates rapid sensitization and degeneration of
peripheral afferents following STZ administration. This confounds TRPA1 antagonist
studies in STZ, because now these results could be interpreted as the antagonist is
blocking STZ-evoked hypersensitivity and neuropathy rather than MG-evoked painful
diabetes.
The mode of activation of TRPA1 by MG is covalent and produces long-lasting
sensitization TRPA1-containing neurons. MG reacts with lysine and arginine residues to
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form H1 residues, as well as facilitating the formation of disulfide bonds between
reactive cysteines. Cys 621, Cys 641, and Cys 665 have been identified by site-directed
mutagenesis to be critical for MG activation of TRPA1 (Eberhardt et al, 2012), as
mutation of these residues abolished MG-induced calcium responses. Another study
provided somewhat conflicting results, whereas mutation of these same cysteine
residues to serines inhibited responses to AITC but not MG (Andersson et al, 2013).
However, MG-evoked calcium responses are diminished by the disulfide bond breaker
DTT (Eberhardt et al, 2012), indicating indeed reactive cysteines are involved. We
hypothesize that the cell type of heterologous expression may explain the discrepancy.
In any case, the publication of the crystal structure of TRPA1 indicated that TRPA1
channel function could be regulated by these same three critical cysteine residues (621,
641, 665) (Paulsen et al, 2015). In addition to cysteines, MG forms adducts with lysine
and arginine residues. Indeed, mutation of lysine 710 to glutamine reduced MG-evoked
responses (Andersson et al, 2013). Modification of proteins in this manner is also
referred to as advanced glycation end products (AGEs), which, along with their cognate
receptor RAGE, are implicated in the pathogenesis of painful diabetes (Toth et al, 2008;
Yao and Brownlee, 2010). In addition to sensitization of TRPA1, MG may contribute to
PDN through AGE-RAGE signaling, as RAGE specifically recognizes MG-derived AGEs
(Xue et al, 2014), but this remains a future direction.

5.5.3 MG induces cross-modality sensitization to heat via a TRPA1-AC1 pathway
TRPA1 is activated by cold (Story et al, 2003), mechanical (Kwan et al, 2009), and
chemical (Bautista et al, 2005; McNamara et al, 2007; Trevisani et al, 2007; Eberhardt
et al, 2012) stimuli. Here, activation of TRPA1 by MG led to hypersensitivity, an effect
that was abolished by TRPA1 knockout. In mice, TRPA1 is expressed in small, mostly
unmyelinated,

peptidergic

peripheral DRG neurons
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(C/Aδ)

and predominantly

colocalizes with TRPV1 (Story et al, 2003; Bautista et al, 2005; Kobayashi et al, 2005;
Garcia-Anoveros and Duggan, 2007). Functional studies indicated that MG produced a
calcium response in 72% of capsaicin (prototypical TRPV1 agonist) responsive DRG
neurons (Andersson et al, 2013), suggesting that 72% of TRPV1 fibers also express
TRPA1. Furthermore, sensitization of TRPA1 in peripheral neurons is suggested to fine
tune mechanical sensitivity (Kwan et al, 2009; Brierley et al, 2011). Considering these
lines of evidence, it is not surprising that TRPA1-dependent activation of a substantial
portion of C-mechanoheat sensitive afferents by MG (Eberhardt et al, 2012) would result
in sensitization to subsequent mechanical or heat stimulation.
At least three possible scenarios may explain this TRPA1-TRPV1 sensitization: (1) It
is indirect, where sensitization occurs via TRPA1-dependent depolarization of
nociceptors lowering the activation/response threshold; (2) It is mediated by direct
interaction of TRPA1 and TRPV1 (Fischer et al, 2014) or through a scaffolding protein
such as Tmem100 that was previously implicated in persistent pain (Weng et al, 2015);
or (3) Sensitization is produced by stimulation of secondary messengers such as AC1,
as cAMP activation of PKA can result in phosphorylation-dependent sensitization of
TRPV1 (Spahn et al, 2014). Here we present evidence that AC1 plays a critical role in
mechanoheat sensitization after MG administration, but not in the spontaneous
responses produced by direct activation of TRPA1 nociceptors.
We are the first to implicate AC1 and its sensitization by an MG-TRPA1 mechanism
in diabetic pain. We suggest that AC1 mediates spinal sensitization, because intrathecal
administration of NB001 attenuated heat hypersensitivity in db/db mice. However,
nociceptive responses evoked by peripheral MG administration in the current results,
pERK induced by application of capsaicin or glutamate to spinal slices (Wei et al, 2006),
and pERK after peripheral injection of formalin (Wei et al, 2006) were similar in wild-type
and AC1 knockout mice. This suggests that AC1 is not necessary for acute activation of
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nociceptive neurons, even after activation of TRPA1 with an alternative agonist such as
formalin. We can conclude, however, that AC1 is required for subsequent
hypersensitivity to both non-noxious mechanical and noxious heat stimuli as well as
painful spinal sensitization in type 2 diabetes. If indeed AC1 activity is upregulated in
painful diabetes, then a future study could investigate whether intrathecal forskolininduced cAMP production is exacerbated in db/db mice compared to their non-diabetic
controls.

5.5.4 Conclusions toward treatments for painful diabetes
Our results are the first study to implicate AC1 in the maintenance of painful type 2
diabetes. Furthermore, we confirm that TRPA1 mediates MG-induced nociception and
extend these results to indicate MG evokes both hypersensitivity and affective pain.
Finally, we provide further evidence that strategies aiming to inhibit the MG-related effect
on painful neuropathy in diabetes, such as GERP10, are effective at reducing type 2
diabetic pain-like behavior.
Our results suggest that blocking TRPA1 in peripheral and spinal nociceptive
neurons could be a strategy for alleviating painful diabetes. To this end several groups
are developing new TRPA1 antagonists. Glenmark pharmaceuticals (Mumbai, India)
holds several U.S. patents on various molecules that act as TRPA1 antagonists.
Although the structure has not been revealed, one such molecule presumably covered
by a Glenmark patent, GRC-17536, underwent a Phase 2a clinical trial with sites in
India, Germany, Czech Republish, and United Kingdom in patients with painful diabetic
neuropathy. GRC reduced average pain intensity and was determined safe, although the
complete

results

have

not

yet

been

released

(https://clinicaltrials.gov/ct2/show/study/NCT01726413). Preclinical studies presented in
abstract form that preceded this clinical trial indicated GRC to be a potent and selective
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TRPA1 antagonist (Anupindi et al, 2010), but we were unable to find peer-reviewed
publications on this molecule. In addition, new compounds that block TRPA1 activity are
being developed by rational drug design using structure-activity relationships based on
the prototypical TRPA1 antagonist discovered in 2007, HC030031 (Preti et al, 2015),
which we used to block TRPA1 in the current studies.
Thus, approaches that minimize availability of MG to produce sensitization
(Andersson et al, 2013), MG-AGEs (Sveen et al, 2013), or directly activate TRPA1
(Eberhardt et al, 2012; Ohkawara et al, 2012) or Nav1.8 (Bierhaus et al, 2012) could
benefit patients with painful diabetes. For example, the type 2 diabetes drug metformin
reduces plasma MG and increases GLO1 activity in peripheral blood mononuclear cells
from type 2 diabetic patients (Kender et al, 2014); however, whether metformin reduces
diabetic pain in humans as it does in STZ rats (Byrne et al, 2015; Ma et al, 2015)
remains unknown. Our manuscript under review at Journal of Pain indicates that the
PPARγ agonist pioglitazone reduced PDN and spinal sensitization in type 2 diabetic rats
that exhibited increased MG-AGEs. A future direction of our lab is to determine whether
pioglitazone could reduce the MG-AGE formation, TRPA1 sensitization, and pain.
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CHAPTER 6: Overall Discussion and Supplemental Data

6.1 Summary
The results discussed herein suggest multiple ways of targeting methylglyoxal or
PPARγ to alleviate the neuropathic pain associated with type 2 diabetes. I began by
discussing the background information that is necessary to understand preclinical pain
research and the growing problem of painful type 2 diabetes. Next I showed published
evidence in Chapter 2: that gabapentin produces conditioned place preference in rats
with traumatic nerve injury, an important finding indicating that: 1) systemic injection of
an analgesic drug is sufficient to produce conditioned place preference in rodents
suggesting rapid alleviation of pain; and 2) I validated the use of conditioned place
preference (or aversion as shown in section 5.4.1 ) to assess an aspect of motivationalaffective pain in rodents. Below I propose several additional studies to utilize novel
assays to assess motivational-affective pain in preclinical type 2 diabetes.
I presented another publication indicating that PPARγ agonists rapidly reduce
nociceptive and neuropathic pain-like behaviors through a non-genomic, astrocyterelated mechanism in Chapter 3: . In addition to rapid analgesia, my manuscript under
review at the Journal of Pain shows that genomic PPARγ mechanisms also mediate
inhibition of type 2 diabetic neuropathic pain and associated sensitization of spinal
nociresponsive neurons. These results, along with unpublished studies shown below,
indicate a differential effect of acute versus chronic administration of PPARγ agonists
such as pioglitazone on Fos and/or pERK markers of painful central sensitization in the
setting of nerve injury or type 2 diabetes. Furthermore, data below suggest that
pioglitazone is sufficient to both prevent and reverse pain associated with type 2
diabetes, independent of its glucose lowering effect. Below I speculate on how
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pioglitazone, through a PPARγ-dependent or independent mechanism, may alleviate
neuropathic pain.
Finally, in Chapter 5: I implicated methylglyoxal in the generation and maintenance of
pain associated with type 2 diabetes. I showed that methylglyoxal is sufficient to produce
nociceptive, evoked, and affective pain-like behavior. The production of pain evoked by
methylglyoxal requires TRPA1 and AC1, as knockout of these proteins in normal, nondiabetic mice or administration of their pharmacological inhibitors to db/db mice
alleviated pain-like behaviors. Several lines of investigation pointed toward a spinal
mode of action, whereby activation of dorsal horn nociresponsive neurons produces
pain-like behavior. I showed that inhibition of methylglyoxal using the scavenging peptide
GERP10 alleviated hypersensitivity in diabetic db/db mice. Future directions outlined
below propose to target glyoxalase 1, the catabolic enzyme for methylglyoxal, in order to
reduce the contribution of methylglyoxal to neuropathic pain in type 2 diabetes.

6.2 How does type 2 diabetes lead to painful neuropathy?
I propose that pre-diabetic conditions in type 2 diabetes lead to peripheral insulin
resistance feeding forward to an increase in blood glucose that results in chronic glucose
neurotoxicity. This causes permanent changes in somatosensory processing that cannot
be reversed by glucose management alone. I also believe the mechanisms of PDN differ
in type 1 versus type 2 models of diabetes and this is supported by simultaneous studies
of type 1 and type 2 diabetic models (Schmidt et al, 2003; Schmidt et al, 2004; Kamiya
et al, 2005; Schuelert et al, 2015). Although there has been extensive research into the
streptozotocin-induced type 1 diabetic model in both mice and rats this method fails to
investigate mechanisms of pain in type 2 diabetes, and type 2 diabetes has greater
prevalence in the human diabetic patient population. The greater number of publications
studying pain in STZ compared to ZDF or db/db is disproportionate to the prevalence of
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type 1 diabetes (just 10%) and is inappropriate with the recent publication indicating that
STZ activates nociceptors through agonist action at TRPA1 (Andersson et al, 2015).
Therefore more work is needed to replicate studies in STZ models using models specific
to painful type 2 diabetes.

6.2.1 Motivational-affective pain in models of painful type 2 diabetes
We are the first to show negative affect in type 2 diabetes using MCS. We also
provide evidence using CPP that gabapentin, a common treatment for PDN (Wodarski et
al, 2009; Rauck et al, 2013), alleviates affective pain in SNI, an alternate model of
neuropathic pain. Therefore we propose to investigate in a reverse translation study
whether administration of gabapentin reverses affective pain in type 2 diabetes. This
could be accomplished in several models including MG-induced CPA in wild-type mice,
MCS in ZDF, or CPP in db/db or ZDF. As we are the first to measure negative affect in a
model of type 2 diabetes using MCS, we attempted to extend this finding to an
alternative model of type 2 diabetes using a complementary assay. We began to test the
hypothesis that systemic gabapentin would produce conditioned place preference in
diabetic db/db mice.
Figure 6-1 illustrations preliminary results (n=8) indicating baseline preconditioning
preferences in db/db mice. As shown, db/db spent the majority of time in the center (C)
grey neutral chamber, as opposed to exploration of the pairing chambers on the left (L)
and right (R) of the center chamber. This is in contrast to the normal preconditioning
preferences in non-diabetic sham or SNI rats (see Figure 2-3), where the majority of the
time is spent in the white or black pairing chambers. Because diabetic animals at this
stage of diabetes exhibit decreased exploratory locomotor activity (see Figure 4-10) and
the mice were initially placed in the center chamber to assess initial preferences, it is not
surprising that the majority of time was spent in the neutral start chamber. CPP could be
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performed at an earlier age, when locomotor activity is not diminished, however this is
unadvisable because db/db mice do not exhibit behavioral hyperalgesia until several
weeks after hyperglycemia begins. Therefore an alternative approach to assess affective
pain in type 2 diabetes would be to use a two-chamber CPP apparatus, the MCS assay,
or test the hypothesis that gabapentin administration reverses MG-induced CPA in wildtype mice.

d b /d b m ic e

B a s e lin e t im e in c h a m b e r ( s )
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Figure 6-1. Preliminary preconditioning results in db/db mice using CPP.
Time spent in the left (L), center (C), and right (R) chambers in a conditioned place
preference assay using a three-chamber box. Mice were placed into the center,
neutral chamber to begin assessment of preconditioning baseline. The db/db mice
failed to explore the left and right drug-pairing chambers during preconditioning.

6.2.2 Inhibition of TRPA1 to reduce painful type 2 diabetes
Our current results implicate spinal TRPA1 in the mediation of pain-like behavior
associated with type 2 diabetes. Therefore we propose several strategies of inhibiting
TRPA1 in order to reduce painful diabetes. First, reduction of endogenous activation of
TRPA1 by methylglyoxal in type 2 diabetes could be achieved by masking agonist
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binding sites using antibodies. This was demonstrated in a previous study where a
TRPA1 antibody blocked calcium mobilization induced by AITC (Lee et al, 2014). This
could prevent the tonic activation of TRPA1 by compounds such as methylglyoxal and 4HNE that are endogenously generated in diabetes (Koivisto et al, 2012). Second, we
could prevent the TRPA1-dependent sensitization of TRPV1 in nociceptors by blocking
their interaction through modulation of the peptide Tmem100. A recent study showed
that the Tmem100 mediates an optimal interaction of TRPA1 with TRPV1 that
contributes to pain after injury. The authors developed a mutant peptide, Tmem100-Q3
that facilitates a strong interaction between TRPA1 and TRPV1 thereby inhibiting pain.
Strikingly, a cell permeable peptide mimicking the 3Q region of Tmem100-3Q had a
similar effect of reducing pain sensitization in vivo (Weng et al, 2015). Therefore we
hypothesize that administration of this Tmem100-Q3 peptide derivative would alleviate
painful type 2 diabetes by blocking the cross-sensitization between TRPA1 and TRPV1
in peripheral nociceptors.
Previous studies show a dissociation between evoked and non-evoked pain
measures. The TRPA1 antagonist HC reduced evoked hypersensitivity, but failed to
produce conditioned place preference in STZ or SNI after spinal administration (Wei et
al, 2013) or in CFA after systemic administration (Okun et al, 2011). As affective pain is
mediated by CNS and PNS mechanisms, it is possible that reducing TRPA1 activity
peripherally is necessary to produce CPP, similar to studies showing peripheral lidocaine
induces CPP in inflammatory (Okun et al, 2011) or incisional (Navratilova et al, 2012)
models. Therefore we propose a future study to test the hypothesis that peripheral nerve
block inhibits CPA to intraplantar methylglyoxal administration. Alternatively, the ability of
TRPA1 antagonists to produce CPP or reduce MCS-related pain behavior could be
tested in ZDF or db/db. This experiment could inform whether activation of nociceptors
by MG is sufficient to produce negative affect.
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Increased methylglyoxal in diabetes is known to sensitize sensory neurons through
TPRA1 (Wei et al, 2009; Koivisto et al, 2012; Wei et al, 2013). Similarly, in the
streptozotocin model of type 1 diabetes, drugs such as HC-030031 and Chembridge586152 inhibit stimulus-dependent pain-like behavior (Wei et al, 2010; Koivisto et al,
2012) but not ongoing aversion in the CPP paradigm (Wei et al, 2013). Therefore we
wanted to test the hypothesis that TRPA1-dependent activation of peripheral sensory
neurons in the dorsal root ganglia is potentiated by type 2 diabetes. Figure 6-2 illustrates
that AITC (TRPA1 agonist; 100μM) stimulation produced DRG neuron responses in both
ZL and ZDF as evidenced by ratiometric Fura-2 calcium imaging. Neuronal cells were
identified by their response to K+ and capsaicin (100μM) (data not shown). The
percentage of the DRG neurons that responded to AITC, and therefore were peripheral
neurons putatively containing TRPA1, was 35-38%. This is in line with previous
functional expression studies (Kobayashi et al, 2005; Hjerling-Leffler et al, 2007). The
response in ZL and ZDF was similar, indicating that painful type 2 diabetes did not alter
TRPA1-dependent activation of peripheral nociceptors. This suggests that TRPA1
sensitization in peripheral neurons may not mediate the pain associated with type 2
diabetes.
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Figure 6-2. TRPA1-dependent calcium response in DRG neurons from ZL and
ZDF.
Data courtesy of Suzanne Doolen. I formulated the hypotheses, designed the
experiments, and analyzed the data.
Neurons were dissociated from L4/5 dorsal root ganglia harvested from control (ZL)
and diabetic (ZDF) rats. Quantification of (A) peak height, (B) peak height as a % of
the response to potassium, and (C) percentage of the cells analyzed that responded
to AITC. There was no difference between ZL and ZDF responses in any of the
parameters measured.

Next we tested the hypothesis that MG would produce an exacerbated pain
response when administered to diabetic db/db mice. Figure 6-3 illustrates that
intraplantar methylglyoxal produces equal nociceptive response in control BKS and
diabetic db/db. An alternative approach to this result revealing an absence of peripheral
TRPA1 sensitization in painful type 2 diabetes is to further investigate the role of spinal
TRPA1 in naïve animals. As such, we propose to test the hypothesis that the activation
of spinal neurons by MG is attenuated by TRPA1 inhibition. This is based upon several
results: (1) MG-induced nociceptive behavior and pERK in the dorsal horn was inhibited
by intrathecal HC and TRPA1 genetic knockout; (2) spinal administration of HC reduced
painful type 2 diabetes in db/db mice; and (3) MG activation of DRGs is absent in
TRPA1-/- mice (Eberhardt et al, 2012).
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Figure 6-3. Nociceptive behavior after MG administration in type 2 diabetic
mice.
Nociceptive response after intraplantar methylglyoxal (MG; 3 μg) administration in
control BKS and type 2 diabetic db/db mice at age 11 wks. There was no difference
in BKs and db/db mice in nociceptive response evoked by i.pl. MG.

Several possible results exist for the proposed experiment that TRPA1 inhibition
reduces MG-evoked spinal neuron activation. The TRPA1 antagonist HC030031 could
reduce the MG-induced response indicating that TRPA1 plays a role in spinal neuron
activation. Alternatively, the results could indicate that inhibition of presumably
presynaptic TRPA1 in the dorsal horn is not sufficient to reduce MG-evoked calcium
responses. This provides for the possibility that MG activates post-synaptic neurons
directly, independent of its effects on TRPA1. A clue comes from previous work, where
MG was shown to activate Nav1.8 in primary afferents (Bierhaus et al, 2012). Care must
be taken in the experimental design so that spinal neurons are not exposed to MG more
than once, as MG covalently binds to lysine, arginine, or cysteine residues within TRPA1
and therefore it is reasonable to suspect that this produces long-lasting sensitization that
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could alter the efficacy of the HC antagonist during future MG stimulation (see 5.5.2 ).
This is supported by a study showing the calcium response to a low dose of MG is
biphasic, suggesting sustained sensitization of TRPA1 (Koivisto et al, 2012). These
studies could be performed using dorsal root stimulation (DRS) to begin to separate pre
versus post synaptic activation of neurons by MG. A possible expected result is that MG
activates post synaptic neurons independent of TRPA1, while pre synaptic effects are
indeed regulated, at least in part, by TRPA1. DRS studies could test this idea.

6.2.3 AC1 and mechanisms of spinal sensitization
In addition to the pERK evidence presented herein, studies are needed to further
investigate functional spinal sensitization in models of type 2 diabetic pain. One
approach is to test the hypothesis that glutamate evoked neuron activation, by using a
combination of calcium imaging and electrophysiological studies, is exacerbated in the
spinal cord dorsal horn from ZDF or db/db. A similar approach is to use methylglyoxal as
the activation stimulus. We predict that spinal neuron responses would be greater in
ZDF or db/db compared to their respective controls, which would be consistent with
previous results from our colleagues in inflammatory and nerve injury models (Doolen et
al, 2012; Corder et al, 2013). Follow-up studies could test whether GERP10, HC,
pioglitazone, or NB001 inhibits glutamate- or methylglyoxal-evoked spinal sensitization.
Another approach is to bypass the downstream targets of methylglyoxal in diabetes
by testing whether spinal inhibition of MG directly could reduce painful type 2 diabetes.
As spinal inhibition of TRPA1 attenuated heat hypersensitivity in db/db mice, but not
calcium mobilization induced by TRPA1 activation ex vivo, one method to clarify the role
of spinal MG in PDN would be to test whether inhibition of MG in the spinal cord would
reduce painful diabetes. Our results suggest that endogenous activation and/or
sensitization of TRPA1 in the spinal cord, presumably on presynaptic terminals,
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facilitates evoked hypersensitivity. Therefore if elevated MG is contributing to this
process, then intrathecal administration of GERP10 (or other MG scavenging
compound) would reduce behavioral hypersensitivity in db/db mice.
Contrary to the results above that suggests that sensitization of peripheral TRPA1
does not mediate PDN, we show pain-like behavior is reduced by spinal inhibition of
both TRPA1 and AC1 in db/db mice and in AC1-/- after MG administration. This leads us
to speculate that there is an upregulation of AC1 activity, or the AC1 system is primed
and that endogenous activation of TRPA1 by MG produces pain through revealing this
calcium-dependent AC1 sensitization. Along this line of thinking, there would be no
difference between control and diabetic animals in the calcium response mediated by
artificial activation of DRG neurons with AITC (as above). However, we would speculate
that the production of cAMP would be greater in diabetic animals after TRPA1 activation,
indicating a primed AC1 system. Since we suspect that activation of TRPA1 produces
sensitization of AC1, and that this sensitization leads to a potentiated cAMP, one
possible mechanism of the generation of heat hypersensitivity in type 2 diabetes is PKAdependent phosphorylation/sensitization of TRPV1 (Spahn et al, 2013). To test this we
could stimulate DRG neurons with MG or saline followed by capsaicin in the presence or
absence of NB001 pretreatment. Several results are possible in this experiment. First,
we predict that initially stimulating the DRGs with MG (as opposed to saline) would
potentiate the response to capsaicin, revealing a functional link between TRPA1 and
TRPV1. Second, we predict that inhibition of AC1 with NB001 would reduce the
capsaicin-evoked calcium response subsequent to MG stimulation, indicating that MG
sensitizes TRPV1 through AC1.
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6.3 Methylglyoxal and glyoxalase 1 in painful type 2 diabetes
6.3.1 Developing a chronic model of MG-induced PDN
To test the hypothesis that methylglyoxal is sufficient to produce diabetic-like pain a
chronic administration model is needed. Several reports indicate that a diabetic-like
phenotype develops after repeated or chronic administration of MG to rodents, but painlike behavior in these models has not been tested. A recent review of modeling type 2
diabetes in rodents suggested that a major culprit of diabetic dysfunction is MG, and
suggested chronic MG administration as a suitable model for type 2 diabetes (Dornadula
et al, 2015). A chronic MG model may better model the type 2 diabetic condition when
compared to intraplantar MG administration, because MG is elevated in the plasma
rather than at local sites such as at subcutaneous nociceptors in the dermis or
epidermis. Therefore we summarize a few chronic MG studies as a basis for future
experimentation.
Intraperitoneal administration of methylglyoxal (17.25 mg/kg) produced a modest
increase in tissue MG concentrations 3 h after administration and increased plasma MG
within 5-15 min (Dhar et al, 2010). Coadministration with the MG scavenging compound
Alagebrium (100 mg/kg) attenuated increases in MG. Both i.p. and i.v. (50 mg/kg)
administration of

MG acutely resulted in decreased glucose tolerance. MG

administration decreased the levels of GSH and increased D-Lactate, indicating that the
glyoxalase system was activated by exogenous MG administration (see Figure 1-2).
Plasma MG levels remained elevated two fold at 2 h after administration, although
further timepoints were not assessed. This result suggests that repeated (e.g. twice
daily) i.p. injection of MG could be sufficient to increase circulating and tissue
concentrations of MG and possibly induce a pain-like phenotype.
Chronic MG treatment by addition to the drinking water (50-75 mg/kg/d) in Wistar
(control, W) and Goto-Kakizaki (nonobese type 2 diabetes, GK) aged 6 months (young,
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control, C) or 14 months (aged, A) resulted in impaired glucose tolerance and increased
MG (Rodrigues et al, 2014). Results are shown in the figure below adapted from the
manuscript. Kidney immunohistochemical expression of AGEs and RAGE appeared
greater in the GKC and in the W and GK rats that were aged or treated with MG,
indicating that MG induces the AGE-RAGE system.
Chronic minipump infusion (60 mg/kg/d) for 28 d in Sprague-Dawley rats resulted in
changes in fasting plasma glucose (33% increase), insulin (60% decrease), and GSH
(50% decrease). Glucose and GSH were also lowered in pancreatic, skeletal muscle,
and adipose tissues. Impaired oral glucose tolerance and fasting measures were
alleviated by the MG scavenger and AGE breaker Alagebrium (Dhar et al, 2011).
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Figure 6-4. Diabetic measures after chronic administration of methylglyoxal.
Adapted from (Rodrigues et al, 2014).
Methylglyoxal (MG) is elevated in a type 2 diabetes model (GK), in aged (A) rats, or
after administration of exogenous MG in drinking water. [KEY: Wistar (W), GotoKakizaki (GK), young Control (C), Aged (A), methylglyoxal administered (MG)].
Blood glucose in (A) fasted or (B) at 2 h in an oral glucose tolerance test. (C) Serum
methylglyoxal levels are shown.
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Based on the above findings, we attempted to test the hypothesis that chronic
administration of MG using Alzet minipumps would produce pain-like mechanical and/or
heat hypersensitivity. Figure 6-5 illustrates the effect of MG minipump administration on
blood glucose, weight, and behavioral hypersensitivity. After 7 d of MG administration we
found no difference in mechanical or heat thresholds. It should be noted that all mice in
the high dose (100 mg/kg/d) had removed their minipumps by the second week of the
experiment. By the third week almost all the mice subjected to MG administration had
removed their minipumps. All of the minipumps in the saline mice remained implanted at
week 3. We speculate that chronic release of MG in the subcutaneous space along the
lumbar dorsal region cause an irritation or hypersensitivity that resulted in scratching and
eventual removal of the minipumps. Minipump MG administration by Dhar et al as
described was also subcutaneous, but at a lower dose of 60 mg/kg/d using a larger
minipump (2ML4) and the experiment was performed in rats over a 28 d administration
period. The authors anecdotally reported no inflammatory response associated with the
minipump implant (Dhar et al, 2011), but it is unclear whether any minipumps had been
removed during the experiment. We suspect that species or dose differences could
explain the aversive effect of MG minipumps in our study. It remains a future direction for
us to develop a chronic model of MG-induced pain through minipump, daily injections, or
drinking water administration of MG in mice and rats.
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Figure 6-5. Pain-like sensitivity is unchanged by MG minipump administration.
Alzet minipumps (#2004) were implanted subcutaneously in the dorsal-lumbar
region. Concentrations in the minipump were calculated to deliver 0 (saline vehicle),
1, 30, or 100 mg/kg/d of methylglyoxal (MG). (A) Blood glucose was measured
immediately following implant. (B) Weight, (C) mechanical, and (D) heat
hypersensitivity were monitored before (BL; baseline) and at several timepoints
following minipump implant. Chronic administration of MG for one week did not
affect weight gain or evoked pain-like behaviors. (n=8)

6.3.2 Manipulating GLO1 expression/function to reduce painful diabetes
Several lines of evidence suggest that the activity and/or expression of GLO1
regulates the contribution of MG to painful diabetes. (1) Both type 1 and type 2 diabetic
patients whose neuropathy symptom score was rated as severe, compared to moderate
or mild ratings, exhibited decreased blood Glo1 activity (Skapare et al, 2013). (2) Aging
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impairs GLO1 expression and function and impairs wound healing, which can be
restored by administration of aminoguanidine (Fleming et al, 2013). (3) Strain differences
in the copy number variants of Glo1 results in protection from STZ-induced diabetic
neuropathy in BALB/cByJ mice compared to BALB/cJ mice, in which GLO1 expression
is decreased tenfold (Jack et al, 2012). (4) GLO1 polymorphisms regulate GLO1 activity
(Peculis et al, 2013), but a link between SNPs and diabetic pain risk has not been
established. (5) Repeated administration of BrBz resulted in behavioral hypersensitivity
to mechanical, heat, and cold stimulation (Andersson et al, 2013). (6) GLO1
overexpression reduced STZ-mediated hypersensitivity (Bierhaus et al, 2012). The
above findings indicate that strategies aiming to increase GLO1 activity in type 2
diabetes could potentially alleviate pain.
We propose several methods to overexpress GLO1 by both systemic and targeted
vectors. (1) Somatic gene transfer using the pCMV-Neo overexpression vector for GLO1
(i.p. injection in db/db mice) provided to us by our colleagues Thomas Fleming and Peter
Nawroth. (2) AAV overexpression of GLO1 by insertion of the pCMV-Neo
overexpression cassette into an AAC serotype. Local injections to the spinal cord, brain,
or peripheral nerve could be used to determine the site of MG-related hyperalgesia
and/or affective pain. For example, we hypothesize that overexpression of GLO1
peripherally would reduce hyperalgesia and affective pain, as negative pain affect
requires both the central and peripheral nervous systems (Qu et al, 2011). (3) Cross
BAC-GLO1-transgenic mice (Distler and Palmer, 2012; Distler et al, 2012; Distler et al,
2013) with a transgenic mouse that has neuronal promoter-driven CRE to specifically
overexpress GLO1 in neurons.
A method alternative to overexpression of GLO1 could be promoting degradation of
methylglyoxal using substances in addition to already known MG scavengers and AGE
breakers. For example, we hypothesize that administration of glutathione would facilitate
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MG degradation, even in type 2 diabetes where GLO1 activity is low, by providing a
surplus of the required cofactor for GLO1. Glutathione has antioxidant properties and
could also act to scavenge ROS, prevent MG-AGE formation, and ameliorate
mitochondrial dysfunction, all mechanisms that contribute to PDN.

6.4 Mechanisms of PPARγ-related analgesia
6.4.1 The rapid effects on pain by PPARγ agonists
Three of our findings led us to conclude that PPARγ agonists exhibit non-genomic,
possibly receptor-independent effects on pain-like behavior. First, we found that both
rosiglitazone and pioglitazone attenuate mechanical hyperalgesia in rats with nerve
injury within five to ten minutes of intrathecal administration. Second, the rapid
antihyperalgesic effect was unchanged by the translation inhibitor anisomycin, whereas
the antihyperalgesic effects at sixty to ninety minutes were reduced by anisomycin.
Third, pioglitazone attenuated heat hyperalgesia in ZDF and db/db mice within one hour
of administration. We suspect that PPARγ mediates this rapid effect as the PPARγ
antagonist GW9662 inhibited pioglitazone antihyperalgesia in SNI within thirty minutes of
administration. However, several of these timepoints are in the ambiguous time frame
between anisomycin insensitive (10 min) and sensitive (60 min) periods, so future
studies could seek to determine the antihyperalgesic effect of pioglitazone at rapid
timepoints in alternative pain models or in transgenic animals where PPARγ has been
temporally and/or spatially eliminated.
The exact mechanism by which pioglitazone rapidly reduces pain in nociceptive
(intraplantar capsaicin and methylglyoxal administration), diabetic (ZDF and db/db
models), or nerve injury conditions still remains unknown. We provide correlative
evidence that pioglitazone reduces markers of central sensitization. Acute pioglitazone
administration reduces astrocyte activation within one hour (section 3.4.9 ). Chronic
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administration of pioglitazone reduces both activation of glia in SNI (Morgenweck et al,
2013) as well as inhibits spinal neuron sensitization to noxious pressure in painful type 2
diabetes (section 4.4.3 ) and non-noxious light-touch in SNI (see Figure 6-6 below). But,
these latter findings were in chronic administration scenarios, and new data below
reveals that acute administration of pioglitazone does not alter stimulus-evoked markers
of neuronal sensitization in the spinal cord (as evidenced by light-touch evoked Fos and
pERK).
A growing body of evidence suggests that the mechanisms of pioglitazone analgesia
are different between acute (rapid) and chronic (sustained) administration. For example,
acute administration of pioglitazone did not reduce light-touch evoked pERK or Fos in
SNI (Figure 6-7 below), even though chronic administration in both diabetic and nerve
injury models reduced stimulus-evoked pERK. Similarly, pioglitazone did not reduce
spinal Fos expression associated with capsaicin injection (see Figure 3-6). Furthermore,
although

acute

intrathecal

pioglitazone

rapidly

reduced

evoked

mechanical

hypersensitivity, it failed to produce CPP in SNI rats (Figure 6-8 below). In fact, we found
that sham rats exhibited CPP to intrathecal pioglitazone while preferences in SNI rats
were unchanged by pioglitazone conditioning. This finding that uninjured animals
perceived pioglitazone as rewarding is puzzling because we see no effect of pioglitazone
on sensory thresholds in sham or naïve animals. However, it could be that the activation
of reward pathways in sham animals by pioglitazone is diminished after peripheral nerve
injury, although this is unfounded speculation.
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Figure 6-6. Chronic pioglitazone administration reduces light touch-evoked
pERK.
Adapted from (Morgenweck et al, 2013).
Representative images of phosphorylated ERK (p-ERK) in spared nerve injury rats
that were administered (A) saline or (B) pioglitazone for seven weeks. (C)
Pioglitazone reduced p-ERK in the dorsal horn evoked by light touch stimulation of
the sural receptive field of the injured hindpaw using a cotton swab.  significantly
different from “0” (unpaired). n = 5-8.
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Figure 6-7. Acute pioglitazone does not reduce evoked spinal pERK or Fos in
SNI rats.
Two weeks after SNI surgery rats were injected i.p. with either saline vehicle or
pioglitazone (100 mg/kg) one hour prior to stimulation of the injured hindpaw as
described
above.
Rats
were
perfusion-fixated
and
processed
for
immunohistochemical staining of phosphorylated ERK (pERK) and expression of
Fos in the lumbar dorsal horn. (A) Quantification of ipsilateral and contralateral
pERK in vehicle animals. (B) Quantification of ipsilateral pERK in vehicle or
pioglitazone animals (n=3-4). (C-F) Representative images of pERK in the indicated
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groups. (G) Quantification of ipsilateral and contralateral Fos in vehicle animals. (H)
Quantification of ipsilateral Fos expression in vehicle or pioglitazone animals (n=8).
(I-L) Representative images of Fos expression in the indicated groups. Light-touch
stimulation of the injured hindpaw in SNI rats produced an increase in pERK and
expression of Fos in the spinal dorsal horn ipsilateral to stimulation. Pretreatment
with pioglitazone prior to stimulation did not change evoked pERK or expression of
Fos.  p<0.05 vs. ipsilateral.
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Figure 6-8. Pioglitazone produces conditioned place preference in sham but
not SNI rats.
(A) Mechanical withdraw thresholds in sham and SNI rats before injury (BL), before
the CPP preconditioning (PRE), and after CPP postconditioning (POST). (B)
Preconditioning and postconditioning time spent in the saline or pioglitazone paired
chamber. (C) Difference scores (preconditioning time spent in chamber minus
postconditioning time spent in chamber) for sham and SNI rats are shown.  p<0.05
vs. preconditioning in B or vs. sham saline in C. n=6-8.

6.4.1.1 pERK and Fos
Evidence from our pioglitazone studies indicate that pERK and Fos markers of spinal
sensitization are differentially affected by acute versus chronic administration. With
regard to these pERK and Fos studies, we did not perform colabeling with neuronal or
glial markers. The cell type where pERK and Fos are labeled via immunohistochemistry
is unclear as is the excitatory or inhibitory nature these cells. Therefore it is possible that
pioglitazone produced activation of inhibitory neurons or increased the phosphorylation
of ERK (pERK) or expression of Fos in glial cells, even though those glial cells may have
been contributing to the anti-hypersensitive effect of pioglitazone. pERK has previously
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been shown to be expressed in glial cells (Gao and Ji, 2010), along with activitydependent phosphorylation of other MAPK in nerve injury (Tsuda et al, 2004; Ji et al,
2009) or diabetes (Daulhac et al, 2006). ERK activation is suggested to facilitate pain (Ji,
Gereau et al. 2009) and several studies suggest that PPARγ agonists may inhibit ERK
phosphorylation. For example, activated PPARγ prevents MEK, the MAPK kinase
upstream of ERK, from phosphorylating ERK (Burgermeister, Chuderland et al. 2007,
Burgermeister and Seger 2007), although contrary to the finding that increased pERK is
associated with decreased PPARγ expression in a microbial sepsis model (Kaplan et al,
2010). PPARγ reduces ERK phosphorylation after TNFα or IFNγ stimulation (Lombardi,
Cantini et al. 2008, Lombardi, Cantini et al. 2009) and administration of these cytokines
in vivo can directly mediate hyperalgesia (Tsuda, Masuda et al. 2009, GruberSchoffnegger, Drdla-Schutting et al. 2013). Taken together, our results and the literature
indicate a direct interaction between PPARγ and the MAPK pathway (Gardner et al,
2005).

6.4.1.2 Cytokines and chemokines
Rapid analgesia after pioglitazone administration may result from decreased
chemokine/cytokine release. For example, reduction of neuropathic pain is associated
with a decrease in MCP1/CCL2 (Gao, Zhang et al. 2009) or TNFα (Ohtori, Takahashi et
al. 2004), which can contribute to astrocyte pain sensitization (Zhang, Berta et al. 2011)
and spinal LTP (Gruber-Schoffnegger, Drdla-Schutting et al. 2013). Repeated PPARγ
activation reduces TNFα in the spinal cord and DRG after nerve injury (Maeda, Kiguchi
et al. 2008) and decreases astrocyte TNFα release after inflammatory activation in vitro
(Storer, Xu et al. 2005). Furthermore, pioglitazone rapidly decreases astrocyte TNFα
release in vitro (Gurley, Nichols et al. 2008). As cytokines can directly and quickly
modulate the responsivity of nociceptive neurons, reduction of their release by TZDs is

173

one possible mechanism of rapid analgesia. Furthermore, increased TNFα is associated
with pain in diabetic patients (Purwata, 2011).

6.4.1.3 mitoNEET
Receptor-independent functions of PPARγ agonists at mitochondria was first
proposed ten years ago by Feinstein and colleagues (Feinstein et al, 2005).
Mitochondrial dysfunction resulting in alterations in calcium homeostasis contributes to
hyperactivity of sensory processing (Flatters, 2015), painful neuropathy (Fernyhough
and Calcutt, 2010; Barrière et al, 2012; Verkhratsky and Fernyhough, 2014), and
neurodegenerative disease (Feinstein et al, 2005; Geldenhuys et al, 2010; Yonutas and
Sullivan, 2013). TZDs (Geldenhuys et al, 2010; Yonutas and Sullivan, 2013) or
exogenous ligands such as TT01001 (Takahashi et al, 2015) reduce diabetic
mitochondrial dysfunction by targeting the mitochondrial protein mitoNEET. Functional
and expressional evidence indicate that pioglitazone binds to and stabilizes mitoNEET
within the outer mitochondrial membrane (Bolten et al, 2007; Paddock et al, 2007),
making mitoNEET a potential target for the rapid antihyperalgesic effect of TZDs.
Therefore we hypothesize that pioglitazone or other TZDs act at mitoNEET to rapidly
restore calcium homeostasis in PDN (Latham et al, 2009; Cao et al, 2011; Todorovic and
Jevtovic-Todorovic, 2014; Verkhratsky and Fernyhough, 2014) or after experimental
traumatic nerve injury and that this could be a mechanism of acute PPARγ agonist
analgesia.

6.4.1.4 GPR40
The rapid effects of pioglitazone could be mediated by “off-target” effects at GPR40,
a G-protein coupled receptor recently implicated in the regulation of hyperalgesia
associated with formalin, CFA, SNL, and stroke (Nakamoto et al, 2012; Nakamoto et al,
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2013; Harada et al, 2014; Karki et al, 2015; Nakamoto et al, 2015). Activation of GPR40
by endogenous (e.g. DHA, polyunsaturated fatty acids) and exogenous (GW9508)
ligands reduces inflammatory (Nakamoto et al, 2012; Nakamoto et al, 2013),
neuropathic (Karki et al, 2015), and post-stroke (Harada et al, 2014) pain. Analgesic
effects were inhibited by the GPR40 antagonist GW1100. GPR40 is expressed in POMC
and β-endorphin neurons in the hypothalamus (Nakamoto et al, 2013), serotonergic and
noradrenergic neurons in the RVM and LC (Nakamoto et al, 2015), and neurons but not
glia in the spinal cord (Karki et al, 2015). Therefore both functional and expressional
evidence implicate GPR40 in various pain models. Furthermore, calcium mobilization
produced by rosiglitazone is abolished by siRNA knockdown of GPR40, suggesting that
TZDs may also activate GPR40 (Gras et al, 2009). This is intriguing, given the notion
that GPR40 functions to facilitate descending inhibition (Harada et al, 2014; Karki et al,
2015; Nakamoto et al, 2015), that TZDs may activate GPR40, and TZDs rapidly inhibit
hypersensitivity. Both inflammatory (carrageenan and CFA) and nerve injury (SNL)
models increase the expression of GRP40 in the spinal cord (Karki et al, 2015). There’s
even evidence that activation of GPR40 by GW9508 increases the expression of Fos
after injury even with simultaneous reduction of formalin nociception (Nakamoto et al,
2013; Nakamoto et al, 2015), which would explain the lack of effect of pioglitazone on
Fos expression in capsaicin and SNI models – pioglitazone decreased Fos in
nociceptive neurons while simultaneously increasing Fos in inhibitory neurons resulting
in no net change in Fos expression. Finally, hyperalgesia after injury and decreased
endogenous activity of GPR40 in the descending inhibitory system, either through
decreased expression of GPR40 or lesser availability of endogenous PUFA agonists, is
associated with changes in GFAP (Harada et al, 2014) further supporting the interplay of
pioglitazone, GPR40, and astrocytes. Thus GPR40 is an intriguing candidate for the
regulation of rapid analgesia produced by TZDs.
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6.4.1.5 TRP channels
PPARγ agonists may reduce hypersensitivity via interactions with TRP channels.
15d-PGJ2 activates TRPA1 by covalent modification of reactive cysteine residues (CruzOrengo et al, 2008; Takahashi et al, 2008; Weng et al, 2012). Peripheral administration
of 15d-PGJ2 results in immediate nociceptive behavior and calcium mobilization in
TRPA1 containing DRG neurons. Paradoxically, although 15d-PGJ2 activates TRPA1 to
produce immediate nociception, we and others have shown that 15d-PGJ2 reduces
evoked hypersensitivity in an inflammatory pain model (Morgenweck et al, 2010; Alves
et al, 2011). These antihyperalgesic effects are thought to be mediated by PPARγ, as
they are blocked by a PPARγ antagonist. However, a possible mechanism of the rapid
analgesic effects of PPARγ agonists such as 15d-PGJ2 is through the acute
desensitization of TRPA1 (Weng et al, 2012). Indeed, rosiglitazone is suggested to
directly inhibit TRP channels (Majeed et al, 2011), suggesting a possible mechanism for
the rapid inhibition of pain produced by TZDs. A future direction is to test the hypothesis
that the antihyperalgesic effect of pioglitazone is abolished in TRPA1 or TRPV1
knockouts, which would suggest that TRP channels play a role in the rapid analgesic
effect of both endogenous and exogenous PPARγ agonists.

6.4.2 How does pioglitazone reduce painful type 2 diabetes?
Therapeutic management of hyperglycemia does not always reverse PDN (Calcutt,
2002), indicating the need for dual therapies that treat both the hyperglycemia and
insulin desensitization as well as the neuronal mechanisms that contribute to pain. Here
we show that chronic oral administration of pioglitazone reduced both hyperglycemia
and hypersensitivity in ZDF. One could conclude that the mechanism of analgesia is
mediated by normalizing blood glucose and therefore reducing the neurotoxic effects of
hyperglycemia on nociceptive processing. However, Figure 6-9 illustrations that acute
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administration of pioglitazone rapidly increased heat response thresholds (within one
hour) in both db/db mice and ZDF rats but not in their respective normoglycemic
controls. Furthermore, pioglitazone reduced hypersensitivity without changing blood
glucose. This result provides strong evidence that the reduction of PDN by pioglitazone
is not mediated through its role as an insulin-sensitizer, but likely facilitated by one of the
rapid action mechanisms described above.
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Figure 6-9. Effect of acute systemic pioglitazone on heat hyperalgesia and
blood glucose in type 2 diabetes models.
Data courtesy of Renee Donahue and Tommaso Iannitti.
Pain-like heat withdraw latencies and blood glucose were measured before and
after intraperitoneal (i.p.) injection of saline or pioglitazone (Pio) in rat and mouse
models of type 2 diabetes. Heat sensitivity is shown in (A) control ZL and (B)
diabetic ZDF rats (n=4-5) as well (C) control BKS and (D) diabetic db/db mice (n=816). Glucose levels are shown in (E) control ZL and (F) diabetic ZDF rats (n=4-5) as
well (G) control BKS and (H) diabetic db/db mice (n=8-16). Acute administration of
pioglitazone attenuated heat hypersensitivity without changing blood glucose levels
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within 2 hrs of administration.  high, † high and medium, ‡ high, medium, low dose
Pio significantly different (p<0.05) from Saline.

We provide evidence that pioglitazone may alleviate painful type 2 diabetes through
a methylglyoxal mechanism. Not only did acute administration of pioglitazone rapidly
attenuate heat hyperalgesia in type 2 diabetic mice and rats, but it also acutely reduced
MG-evoked nociception and hyperalgesia. Figure 6-10 illustrates that systemic or spinal
administration of pioglitazone reduced MG-evoked nociceptive behavior. These data
indicate that spinal administration of pioglitazone is more effective than systemic
administration at reducing peripherally evoked nociception. We conclude that
pioglitazone reduced the contribution of MG to pain-like behavior in type 2 diabetes
through a spinal mechanism. I speculate that chronic administration of pioglitazone could
act as an AGE breaker (Rahbar et al, 2000) to reduce PDN in ZDF.
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Figure 6-10. Pioglitazone reduces MG-evoked pain-like behavior.
Data in Panels A, C, D courtesy of Renee Donahue. I formulated the hypotheses,
designed the experiments, and analyzed the data.
(A) Intraperitoneal (100 mg/kg; mice) or (B) intrathecal (300 μg; rats) administration
of pioglitazone but not saline vehicle 30 min prior to intraplantar methylglyoxal (100
μg) reduced nociceptive responses in wild-type animals (n=3-4). Nociceptive licking,
lifting, and flinching were quantified for the first five minutes after intraplantar
administration of methylglyoxal (MG). Intraperitoneal administration of pioglitazone
(100 mg/kg; mice) reduced (C) mechanical and (D) heat hyperalgesia.  p<0.05, #
p<0.05 vs. Veh-Saline, $ p<0.05 vs. i.p. pioglitazone + i.pl. methylglyoxal.
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Enough evidence exists for us to speculate that pioglitazone inhibits the development
of tolerance to the endogenous opioid system that normally acts to inhibit pain after
injury. Corder et al established that behavioral hypersensitivity after inflammatory, nerve,
or incisional injury recovers due to the body’s endogenous opioid system. They showed
that endogenous mu opioid receptors mediate the restoration of normal sensory
thresholds (Corder et al, 2013) by administration of opioid receptor antagonists. In the
setting of type 2 diabetes, ZDF rats became hyposensitive to morphine after a prolonged
period of behavioral hypersensitivity, suggesting that the ability of the body to recover
from injury in diabetes is impaired, possibly due to impaired G-protein coupling of the mu
opioid receptor (Otto et al, 2011). Therefore strategies that mitigate changes in the
endogenous opioid system could be beneficial pain therapies. To this end, a recent
study showed that pioglitazone delayed the behavioral tolerance that develops after
repeated morphine administration (de Guglielmo et al, 2014; Ghavimi et al, 2014). This
effect was reduced by GW9662 inhibition of PPARγ or by Cre recombinase knockout of
PPARγ in nestin-positive neurons. reduced the effect of pioglitazone on delaying
tolerance to morphine (de Guglielmo et al, 2014). Therefore we suggest that pain in type
2 diabetes occurs by desensitization of and/or tolerance to the body’s endogenous pain
inhibitory system, and speculate that chronic oral administration of pioglitazone reduced
the development of hyperalgesia by mitigating (in the case of mechanical pressure
hyperalgesia) or delaying (in the case of heat hyperalgesia) endogenous opioid
tolerance. This hypothesis could help explain why pressure hyperalgesia was completely
prevented by pioglitazone, while the onset of heat hyperalgesia was delayed several
weeks but not abolished.
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6.5 Conclusions
Figure 6-11 summarizes this work. My working model is that hyperglycemia and
decreased GLO1 activity in type 2 diabetes leads to accumulation of methylglyoxal.
Methylglyoxal tonically activates TRPA1 in vivo, priming the AC1 system resulting in
peripheral and spinal sensitization through a yet to be determined mechanism, but I
speculate that cAMP/PKA and TRPV1 as well as spinal plasticity mechanisms are
involved. This proposed pathway of pain in type 2 diabetes can be altered at many
different junctions to reduce pain sensitization. MG is inhibited by GERP10 and by
pioglitazone, probably through activation of PPARγ activation, although PPARγindependent mechanisms could be involved in TZD analgesia. Inhibition of TRPA1 and
AC1 activity through pharmacologic and genetic methods reduced spinal sensitization
and pain. I propose a multitude of future studies to further investigate this overall
mechanism. (1) Overexpression and inhibition of GLO1 activity as well as chronic MG
administration as tools to manipulate MG levels either systemically or within specific
tissues such as the spinal cord dorsal horn. (2) Inhibition of MG by alternative
scavenging compounds such as ALT-711, AG, and GSH. (3) CHEM inhibition of TRPA1
or using dorsal root stimulation, Tmem100 cell permeable peptide, blocking antibodies,
and TRPV1 knockouts (-/-) to investigate the interplay between TRPA1 and TRPV1. (4)
Investigate the mechanism of rapid pioglitazone antihyperalgesia through TRP channels,
mitoNEET, or GPR40. (5) Use electrophysiology and CPP to uncover the mechanisms
of MG-dependent spinal sensitization and affective pain, respectively.
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Figure 6-11. Overall schematic of the current results and future directions.
Working model of the contribution of methylglyoxal to pain in type 2 diabetes and
inhibition of such pain mechanisms by pioglitazone. KEY: Line Arrows
activation/production; Line Dots inhibition; Dark Blue drugs/interventions/tools;
Black proteins/molecules/processes; Light Blue models/assays; Purple future
studies; Red conditions. Abbreviations can be found in the Appendix.

Type 2 diabetes is a growing problem in the United States and throughout the world.
Pain associated with type 2 diabetes is a complex process involving both peripheral and
central sensitization. My results in combination with the literature provide evidence that
this pain cannot be reversed by management of blood glucose and insulin dysfunction
alone. Therefore I reasoned that the known antihyperalgesic and antihyperglycemic
effects of TZDs could be combined to reduce painful type 2 diabetes. I provide the first
preclinical evidence that pioglitazone reduces hyperglycemia and pain-like behavior
associated with type 2 diabetes. The antihyperalgesic influence of pioglitazone in type 2
diabetes is independent of its glucose lowering effect because acute administration of
pioglitazone reversed hypersensitivity without changing blood glucose. I show that acute
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pioglitazone rapidly reduces astrocyte gliosis but not markers of neuronal activation, and
therefore provide insight into future studies determining the exact mechanisms by which
pioglitazone rapidly reduces neuropathic pain, a phenomena we showed in several
models including nociception induced by capsaicin and methylglyoxal, traumatic nerve
injury, and type 2 diabetes. Drugs such as pioglitazone and other TZDs that inhibit
glucose neurotoxicity, are anti-inflammatory, reduce gliosis, improve insulin signaling
and glucose metabolism, and reduce pain are likely to provide a greater benefit to
patients than treating the symptoms of pain or hyperglycemia independently.
In preclinical pain studies it is important to include measures of negative affect. This
work highlights the importance of measuring “pain” in rodents using mechanical conflict
avoidance and conditioned place preference/aversion assays, in addition to stimulusevoked measures of hypersensitivity. For the first time we show negative affect in a
model of type 2 diabetes and implicate methylglyoxal in the generation of this
motivational-affective pain in diabetes.

Measurement of evoked and non-evoked,

affective pain in preclinical studies will be essential to enhance the translation of new
analgesic drugs.
We extend previous studies investigating the effects of methylglyoxal on peripheral
nociceptors and in the STZ model of type 1 diabetes by showing methylglyoxal induces
spinal sensitization and pain-like behavior that is dependent upon TRPA1 in painful type
2 diabetes. We identified a new target in painful type 2 diabetes, AC1, and suggest
future studies aiming to reduce the methylglyoxal-TRPA1-AC1 sensitization pathway.
We show for the first time that blocking methylglyoxal by administering GERP10 has
long-lasting antihyperalgesia after a single dose. Finally, we indicate that pioglitazone
reduces methylglyoxal-evoked pain and suggest future studies to investigate this
mechanism. We conclude that both PPARγ and methylglyoxal represent promising
targets for reducing the pain associated with type 2 diabetes.
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APPENDIX

Description of abbreviations used.
Abbreviation

Description

15d

15d-PGJ2, endogenous prostaglandin PPARγ agonist

AC1

adenylyl cyclase 1, calcium activated enzyme that produces cAMP

AG

aminoguanidine, methylglyoxal scavenger and AGE breaker

AGE

advanced glycation end-product

ALT-711

alagebrium, methylglyoxal scavenger and AGE breaker

ANOVA

analysis of variance, statistical test

BKS

C57BLK6S, mouse strain that is a control for db/db mice

BrBz

S-p-bromobenzylglutathioine cyclopentyl diester, GLO1 inhibitor

cAMP

cyclic adenosine monophosphate

CHEM

Chembridge-5861528, TRPA1 antagonist derived from HC

CIG

ciglitazone, PPARγ agonist

CPA

conditioned place aversion

CPP

conditioned place preference

db/db

Lepr-/- mouse model of type 2 diabetes

DH

dorsal horn

DRG

dorsal root ganglia sensory neuron

DRS

dorsal root stimulation

DTT

dithiothreitol, disulfide bond reducing agent

GEAP

control peptide containing 10 repeats of G,E,A,P amino acids

GERP

MG scavenging peptide containing 10 repeats of G,E,A,P amino acids

GFAP

glial fibrillary acidic protein, an astrocyte marker

GLO1

glyoxalase 1, primary enzyme involved in MG detoxification

GLO2

glyoxalase 2, secondary enzyme involved in MG detoxification

GSH

glutathione, GLO1 cofactor

H1

hydroimidazolone residue

i.p.

intraperitoneal
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i.pl.

intraplantar

i.t.

intrathecal

IASP

International Association for the Study of Pain

Iba1

ionized calcium-binding adapter molecule 1, a microglia marker

MCS

mechanical conflict avoidance system

MG

methylglyoxal

MG-AGE

methylglyoxal-derived advanced glycation end-product

PDN

painful diabetic neuropathy

pERK

phosphorylated extracellular signal-regulated kinase

Pio

pioglitazone, TZD PPARγ agonist

PKA

protein kinase A, activated by cAMP

PPARγ

peroxisome proliferator-activated receptor gamma

PUFA

polyunsaturated fatty acids

Rosi

rosiglitazone, TZD PPARγ agonist

s.c.

subcutaneous

SEM

standard error of the mean

STZ

streptozotocin model of type 1 diabetes

TRPA1

Transient Receptor Potential cation channel A1

TRPV1

Transient Receptor Potential cation channel V1

TZD

thiazolidinedione, structural class of PPARγ agonists

vF

von Frey, method of determining mechanical sensitivity

ZDF

Zucker Diabetic Fatty rat (fa/fa) model of type 2 diabetes
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IASP definitions of terms used to describe pain phenomena.
TERM

DEFINITON

Allodynia

Pain due to a stimulus that does not normally provoke pain.

Hyperalgesia

Increased pain from a stimulus that normally provokes pain.

Hypoalgesia

Diminished pain from a stimulus that normally provokes pain.

Paresthesia

An abnormal sensation, whether spontaneous or evoked.

Dysesthesia

An unpleasant abnormal sensation, whether spontaneous or
evoked.

Hyperesthesia

Increased sensitivity to stimulation, excluding the special senses.

Hypoesthesia

Decreased sensitivity to stimulation, excluding the special senses.

Neuropathic Pain Pain caused by a lesion or disease of the somatosensory nervous
system.
Neuropathy

A disturbance of function or pathological change in a nerve: in one
nerve, mononeuropathy; in several nerves, mononeuropathy
multiplex; if diffuse and bilateral, polyneuropathy.

Nociception

The neural process of encoding noxious stimuli.

Nociceptive

A central or peripheral neuron of the somatosensory nervous

Neuron

system that is capable of encoding noxious stimuli.

Nociceptive Pain

Pain that arises from actual or threatened damage to non-neural
tissue and is due to the activation of nociceptors.

Nociceptive

An actually or potentially tissue-damaging event transduced and

Stimulus

encoded by nociceptors.

Nociceptor

A high-threshold sensory receptor of the peripheral somatosensory
nervous system that is capable of transducing and encoding
noxious stimuli.

Noxious

A stimulus that is damaging or threatens damage to normal tissues.

Stimulus
Central

Increased responsiveness of nociceptive neurons in the central

Sensitization

nervous system to their normal or subthreshold afferent input.

Peripheral

Increased responsiveness and reduced threshold of nociceptive

Sensitization

neurons in the periphery to the stimulation of their receptive fields.
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(2015) March, 56(3):469-82. PMID: 25599238

2013

PPARγ activation blocks development and reduces established
neuropathic pain in rats. J. Morgenweck, R.B. Griggs, R.R. Donahue,
J.E. Zadina, B.K. Taylor. Neuropharmacology. (2013) July, 70:236-46.
PMID: 23415633
247

GRANTS
2013 – 2015 F31 Individual Fellowship – NIH NINDS NS083292
Methylglyoxal and TRPA1 contribution to neuropathic pain in type 2
diabetes
2012 – 2013 T32 Institutional Fellowship – NIH NINDS NS077889
Neurobiology of CNS Injury & Repair
ORAL PRESENTATIONS AS INVITED SPEAKER
2012

Society for Neuroscience 42nd Annual Meeting – Nanosymposium.
Neuropathic Pain: Mechanisms and Models (Organizer: Dr. Michael
Iadarola; NIDCR) Behavioral signs of painful diabetic neuropathy and
stimulus-induced spinal pERK expression in the ZDF rat model of Type 2
diabetes. R.B. Griggs, R.R. Donahue, B.K. Taylor

MENTORSHIP
Graduate Students
Weisi Fu (PhD Candidate, 2011-2015); Lilian Goncalves Custodio, MD
(PhD Student, 2014-2015); Maks Gold (MD Student, 2014-2015); Stuart
Cowley (MD Candidate, 2014); Clayton Bright (MS, 2011-2012)
Undergraduate Students
Josh Bose (2012, 2014); Braxton Adkins (2011-2013); Jennifer Grasch
(2011, 2013); Justin Pinson (2012-2013); Amanda Sutton (2011-2012);
Katelyn McNamara (2009-2011)
TEACHING EXPERIENCE
2015

Graduate Certificate in Teaching Physiology
University of Kentucky – Department of Physiology

2014 – 2015 Concepts of Biology Laboratory I: Cell & Molecular (BIO 151L)
General Biology Laboratory I (BIO 101L)
Adjunct Faculty, University of Dayton – Department of Biology
2012 – 2013 Human Anatomy & Physiology Lab (BIO 137) – Instructor
Bluegrass Community and Technical College – Natural Sciences
Critical Scientific Readings (IBS 610) – Senior Student Leader
University of Kentucky – Integrated Biomedical Sciences
Human Physiology (PGY 206 / PGY 412G / PGY 502) – Tutor
University of Kentucky – Department of Physiology
2011 – 2012 Elementary Human Physiology Recitation (PGY 207) – Instructor
University of Kentucky – Biological Sciences
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FINANCIAL AWARDS EARNED
2014

Conference Travel Award (UK), $800
Competitive Financial Aid (IASP), $900
15th World Congress on Pain, Buenos Aires, Argentina

2013

Graduate Student Incentive Program (UK Graduate School), $1100
Conference Travel Award (UK), $400
Society for Neuroscience Annual Meeting, San Diego, USA

2012

Competitive Financial Aid (IASP), 800€
14th World Congress on Pain, Milan, Italy
Conference Travel Award (UK), $400
American Pain Society Annual Meeting, New Orleans, USA

2011

Conference Travel Award (UK), $400
Society for Neuroscience Annual Meeting, Washington D.C., USA

2010

Conference Travel Award (UK), $800
13th World Congress on Pain, Montreal, Canada

JOURNAL PEER-REVIEWING
2014
2014
2013
2012

Current Topics in Behavioral Neuroscience
Frontiers in Cellular Neuroscience
PLOS One
Journal of Neuroscience

LEADERSHIP, SERVICE, OUTREACH
2014

Neuroscience Researcher visit to Career Fair – Outreach Coordinator
Lori Vogel, Northern Elementary (Grades 2-5) in Lexington, KY

2012 – 2013 Graduate Student Department Representative (Peer Elected)
University of Kentucky – Department of Physiology
2011 – 2013 TEAM Student Leader and Organizer (Peer Elected)
Department of Physiology – Teaching Education And Mentoring Group
2011 – 2012 Science Explorers – Neuroscience Coordinator and Volunteer
Katherine Bullock, Living Arts and Sciences Center in Lexington, KY
2010 – 2014 BGSFN Neuroscience Outreach – Coordinator and Volunteer
Fayette County Public School Annual Science Fair in Lexington, KY
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MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS
International Association for the Study of Pain (IASP)
Society for Neuroscience (SFN)
American Pain Society (APS)
Bluegrass Society for Neuroscience (BGSFN)
University of Kentucky Department of Physiology Teaching, Educating,
and Mentoring (TEAM)
CONFERENCE PRESENTATIONS
2015

American Pain Society Annual Meeting (Palm Springs, CA)
Early Career Forum – Invited Panel Member (Hosted By: Jennifer
Rabbitts, M.B.,Ch.B)

2014

IASP 15th World Congress on Pain (Buenos Aires, Argentina)
Methylglyoxal produces pain and activates spinal neurons via TRPA1
9th Annual CCTS & 30th Annual BGSFN Spring Neuroscience Day
Elevated methylglyoxal in diabetes produces nociception via spinal
TRPA1 activation.
R.B. Griggs, S. Doolen, W. Fu, R.R. Donahue, B.K. Taylor.

2013

Society for Neuroscience 43rd Annual Meeting (San Diego, CA)
Pioglitazone reduces pain and spinal dorsal horn sensitization in the ZDF
rat model of type 2 diabetes. R.B. Griggs, R.R. Donahue, B.K. Taylor.
Midwest Regional Pain Interest Group Meeting (Cincinnati, OH)
Acute spinal PPARγ analgesia is not dependent on genomic, ERK, or Fos
activity. R.B. Griggs, J. Morgenweck, A.C. New, R.R. Donahue, B.K.
Taylor.
3rd Annual Barnstable Brown Obesity & Diabetes Research Day
8th Annual CCTS & 29th Annual BGSFN Spring Neuroscience Day
(Lexington, KY)
19th Annual KSCHIRT Symposium (Louisville, KY)
Oral pioglitazone attenuates painful diabetic neuropathy in the Zucker
Diabetic Fatty rat model of type 2 diabetes. R.B. Griggs, S. Doolen, B.
Adkins, K. Anderson, C. DeMoll, R.R. Donahue, O. Thibault, B.K. Taylor.

2012

Society for Neuroscience 42nd Annual Meeting (New Orleans, LA)
Behavioral signs of painful diabetic neuropathy and stimulus-induced
spinal pERK expression in the ZDF rat model of Type 2 diabetes.
R.B. Griggs, R.R. Donahue, B.K. Taylor.
IASP 14th World Congress on Pain (Milan, Italy)
Sex differences observed in pain symptoms induced by experimental
autoimmune encephalomyelitis. E.J. Rahn, R.B. Griggs, C.R. Bright, K.C.
McNamara, R.R. Donahue, B.K. Taylor.
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CONFERENCE PRESENTATIONS (continued)
2012

2nd Annual Barnstable Brown Obesity & Diabetes Research Day
(Lexington, KY)
Type 2 diabetes is associated with spinal neuronal sensitization and painlike behavior in the zucker diabetic fatty rat.
R.B. Griggs, A.D. Sutton, B.K. Taylor.
7th Annual CCTS & 28th Annual BGSFN Spring Neuroscience Day
(Lexington, KY)
Spinal neuronal sensitization in the zucker diabetic fatty rat model of type
2 diabetes contributes to pain-like behavior. R.B. Griggs, A.D. Sutton,
B.K. Taylor.

2011

Midwest Regional Pain Interest Group Meeting (Chicago, IL)
PPARγ regulates nociception and spinal glial activation associated with
nerve and tissue injury. R.B. Griggs, R.R. Donahue, B.K. Taylor.

2010

IASP 13th World Congress on Pain (Montreal, Canada)
PPARγ contributes to the rapid effects of low- and high-dose 15d-PGJ2 on
Ca2+ influx in DRG cultures. S. Doolen, R.B. Griggs, I. Parikh, B.K.
Taylor.
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